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(ii) Abstract 
Chronic complications of diabetes mellitus are a pathological consequence of unregulated 
levels of blood glucose leading to disorders of the vascular system. When investigating the 
vascular complications the changes in the endothelium are of particular significance as they 
are central to vascular function. The endothelium actively regulates vascular function by 
regulating permeability, vascular tone and inflammatory responses. Certain endothelium-
derived molecules, such as nitric oxide, act as vasodilators as well as exhibiting anti-platelet, 
anti-proliferative, permeability decreasing and anti-inflammatory properties (Kawashima el 
aZ. 2004). Changes to the molecular processes or injury to the endothelium lead to 
endothelial dysfunction and the initiation and progression of certain diseases such as the 
development of atherosclerosis as well as micro and macro-angiopathy (De Caterina el aZ. 
2000). In the present study, we examine the effect of glucose and oxygen on endothelial 
DNA damage derived within 24h of incubation and the cytoprotective effect of the flavonoid 
antioxidant, silymarin, and two of its constituents, taxifolin and silibinin. 
Results show a significant increase in endothelial DNA damage in response to glucose and 
hypoxia which appears to be additive. These findings are supported by a significant rise in 
mitochondrial ractive oxygen species (ROS) production within 6h of exposure, while 
mitochondrial number, morphology and HUVEC size stay the same. A change in superoxide 
radical production in hypoxic conditions alone emphasises the important contribution of 
hypoxia in the pathogenesis of endothelial damage. Further investigation reveals a role for 
HIF-la in the development of endothelial DNA damage which is hypoxia-dependent. 
Attempts to counteract the observed cytotoxicity to endothelial cells using the flavonoid 
antioxidant, silymarin, revealed that silymarin is a potent cytoprotective agent for hypoxia-
induced DNA damage. This appears to be due to its strong mitochondrial radical scavenging 
activity. Further analysis into the mechanism ofsilymarin reveals that the impurity, taxifolin, 
2 
possesses more potent cytoprotective activity than the formerly known active component 
silibinin. 
Taken together, the results strongly emphasise the important contribution of hypoxia in the 
early development of endothelial changes, which have the potential to accumulate to 
vascular complications in diabetes since its cytotoxic effect appears to be additive to that of 
glucose. Flavonoid antioxidants, such as silymarin and taxifolin, show promising potential to 
prevent or slow the progression of these changes. 
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CHAPTER ONE: Introduction 
9 
1.1. Diabetes Mellitus 
Diabetes mellitus is a chronic metabolic disorder which is characterised by high blood 
glucose levels (hyperglycaemia) and is the fifth leading cause of death in most developed 
countries (International Diabetes Federation; IDF, 2006). Type 1 diabetes results from 
cellular-mediated autoimmune destruction of pancreatic islet beta-cells causing the loss of 
insulin production and Type 2 diabetes is characterized by insulin resistance and relative 
insulin deficiency (IDF, 2006). Currently 171 million people worldwide have been 
diagnosed with diabetes but many more are believed to remain undiagnosed. These figures 
published by the World Health Organisation (WHO) have risen from only 30 million in the 
year 1995 and are thought likely to more than double to an estimated of 366 million in the 
subsequent 25 years. There are strong signs for diabetes mellitus to become a global 
pandemic, accounting for approximately 9% of the global death toll (Wild el al. 2004). 
In the United Kingdom, t.7 million people are currently suffering from diabetes mellitus 
(World Health Organisation 2004), accounting for approximately 5% of total NHS 
expenditure. In December 200 I, the Department of Health published the National Service 
Framework for Diabetes which sets the national standards for diabetes treatment and care 
(Department of Health, 2007). In addition to highlighting important building blocks of 
diabetes care, one of the main aims of this document is to identify diabetes as early as 
possible and thus prevent complications to improve the patient's quality of life (NHS 
Scotland, 2002). In October 2002, the Department of Health published a review of the 
current and future research on diabetes which identifies research questions still to be 
addressed. Emphasis is given to the understanding of molecular events involved in the 
pathogenesis of diabetes and diabetic complications (Department of Health, 2002). 
10 
1.2. Vascular complications of diabetes 
Chronic complications of diabetes mellitus are a pathological consequence of unregulated 
levels of blood glucose leading to disorders of the vascular system. Not only are these 
complications a much greater burden on both diabetic patients and overall medical costs than 
diabetes itself (McMillan et al. 1997), they are also the major cause of morbidity and 
mortality in the diabetic population. 
During the 1990s, two landmark trials, the Diabetes Control and Complications Trial 
(DCCT) (The Diabetes Control and Complications Trial Research Group, 1993) and the UK 
Prospective Diabetes Study (UKPDS); (UK Prospective Diabetes Study Group, 1998) 
investigated the effect of blood glucose control on the development of diabetic vascular 
complications. While the DCCT monitored the disease progression of 1,441 type 1 diabetes 
patients over the course of 10 years in the United States and Canada, the UKPDS study 
tracked the development of type 2 diabetes in 5, I 02 volunteers across England, Wales, 
Northern Ireland and Scotland. Both studies published evidence that intensive blood glucose 
control considerably slows the onset and progression of diabetic complications. Not only did 
they record a 44% reduction in the incidence of stroke (UKPDS), a 76% reduction in the 
development of diabetic eye disease and up to 60% reduction in kidney disease (DCCT), 
they also found a 32% reduction in the incidence of overal diabetes-related deaths (UKPDS). 
Although these findings still form the basis of modem diabetes treatment, to date the 
processes which led to the development of these debilitating vascular complications are not 
yet fully understood. 
In general, diabetic vascular complications are classified into macro- and microvascular 
complications. 
11 
1.2.1. Macrovascular complications 
Macrovascular complications are characterised by the fonnation of atherosclerotic plaques in 
arteries of diabetic patients. This is seen as the most serious complication of diabetes 
mellitus due to its high mortality rate (McMillan et af. 1997, Kammersgaard et af. 2006). 
Thus, cardiovascular (CV) disease is the most common cause of death for individuals with 
type 2 diabetes, accounting for approximately 80% of diabetes-related deaths (Williams et 
af. 1999). It is also responsible for an increase in mortality of patients with type 1 diabetes 
(Department of Health, 2002). 
Hyperglycaemia is a major risk factor for the development of CV disease (Kannel et af. 
1979) with other factors such as smoking, hypercholesterolaemia, duration of diabetes and 
age adding to the risk (Gray et af. 1997). Atherosclerosis can lead to myocardial infarction 
(MI), stroke, hypertension and leg/artery disease, requiring lower limb amputation in many 
cases. The development of atherosclerotic lesions is strongly associated with age while the 
duration of diabetes is of little significance (McMillan et af. 1997). Pathological changes in 
diabetes leading to atherosclerosis include the inactivation of nitric oxide (NO) (an 
endogenous vasodilator) (Giugliano et af. 1996), arterial wall thickening (Mohamed et af. 
1999), plasma lipid disturbances, oxidation of low density lipid (LDL) cholesterol 
(Guillausseau et af. 1994, Gray et af. 1997) raised fibrinogen levels (McMillan et af. 1997, 
Gries et al. 1995) and haemodynamic changes (Gray et al.1997). There is also evidence to 
show an association between inflammation and its associated inflammatory markers and the 
pathogenesis of atherosclerosis (Gries et af. 1995). 
1.2.2. Microvascular complications 
Microvascular complications primarily affect the eyes, kidneys and the nervous system 
leading to highly disabling conditions such as blindness, renal failure and neuropathy. 
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1.2.2.1. Diabetic Retinopathy 
Diabetic retinopathy is the leading cause of blindness in the Western world and requires 
continuous screening of diabetic patients (Cooper et al. 1997). Early abnormalities of the 
retinal vasculature include an increase in permeability, a thickening of the basement 
membrane, a reduction in blood flow and the loss of retinal pericytes (Mandarino et al. 
1992). Basement membrane thickening and leucocyte activation lead to a reduction of 
perfusion through the vasculature, resulting in areas of hypoxia. As part of the body's repair 
mechanism, it is thought that new vessel growth attempts to revascularise the hypoxic areas. 
If these attempts are aborted because of an imbalance between pro- and anti-angiogenic 
factors, microaneurysms may result (Grant et al. 2004). Depending on the severity of the 
retinopathic changes microaneurysms (abortive neovascularization), cotton-wool spots 
(retinal infarcts) or severe haemorrhage, leading to retinal detachment and complete loss of 
vision, can be seen. Changes in the basement membrane structure and increased vascular 
permeability lead to cellular swelling and the formation of macular oedema (either focal or 
diffuse). These may lead to cell death and irreversible visual impairment (Forrester et al. 
1997). 
1.2.2.2. Diabetic Neuropathy 
Diabetic neuropathy can affect many different neuropathic areas. The severity is related to 
the duration of diabetes and the degree of blood glucose control. Diabetic neuropathy is 
classified into acute mononeuropathy (reversible, affecting single nerves), diffuse, 
symmetrical neuropathy (progressive and irreversible), and pressure palsies (Ward et al. 
1997). As with all diabetic vascular complications, a multitude of factors contribute to the 
pathogenesis of neuropathy. These include axonal loss, demyelination and regeneration, a 
reduction in nerve conduction velocity, basement membrane thickening, haematological 
changes, and decreased oxygen tension (Tesfaye et al. 2002), frequently leading to the 
development of severe ulceration and, in some cases, limb amputations (Vinik et af. 2006). 
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1.2.2.3. Diabetic Nephropathy 
Diabetic nephropathy is a result of glomerular enlargement resulting in an increase in kidney 
volume and progressive loss of function. Diabetic nephropathy is the single most common 
cause of end-stage renal failure in the UK affecting 25% of all diabetic patients (Department 
of Health, 2004). Again, there is substantial evidence to suggest that the risk of developing 
nephropathy is related to the extent and duration of hyperglycaemia. Other causative factors 
include advanced glycated end products (AGE), impairing protein structures through the 
formation of protein cross links (Lehamn et al. 200 I). Direct alteration of cell and cell 
component growth, activation of protein kinase C (PKC) enhancing the vascular 
permeability, haemodynamic disturbances and the activation of the "polyol pathway" 
(Trevisan et al. 1997); (Section 1.6.1). 
1.3. Endotbelial cell function and glucose uptake 
When investigating vascular complications, changes in the endothelium are of particular 
importance as they present the first point of contact with the elevated concentrations of blood 
glucose. The response of the endothelium to adverse conditions is therefore important in 
understanding subsequent damage. Endothelial cells line the lumen of all vessels and act as a 
physical barrier between the blood and the tissue. Glucose is transported across the 
endothelial plasma membrane via membrane associated carrier proteins, also known as 
facilitative glucose transporters (GLUTs); (Bell et al. 1990). Once inside the cell, glucose is 
metabolised by glycolysis which drives oxidative phosphorylation in the mitochondria and 
subsequent generation of ATP (Fig. 1.1). Very often, glucose analogues such as 2-deoxy-D-
glucose (200) and 3-ortho-methyl (30M) are used to determine the relative importance of 
D-glucose transport into the cell and its further metabolism by glycolysis and oxidative 
phosphorylation (Wood et al. 2007; Litherland et al. 2007; Cavallo-Perin et al.1985). 2-
deoxy-D-glucose (2DG) has the 2-hydroxyl group replaced by hydrogen. Once inside the 
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cell the molecule is phosphorylated by hexokinases giving rise to 2-D-glucose-6-phosphate 
(2-DG-6P) during the first step of the glycolysis reaction. Because of its structure the 
phosphorylated molecule (2-DG-6P) cannot be metabolized further or diffuse outside the cell 
leading to the inhibition of glycolysis and the accumulation of the metabolised by-product 
(2-DG-6P) inside the cell. In contrast, 3-ortho-methyl glucose (30M) is not metabolised at 
all and simply enters and leaves the cell. To date a family of thirteen related facilitative 
glucose transporters (GLUTs) has been identified all of which have a distinct tissue 
distribution and biochemical properties (Barnes el al. 1997); (Table 1.1). 
GLUT-l was the first glucose transporter to be isolated and is widely distributed throughout 
the body, with the highest levels found in erythrocytes and endothelial cells (Pardridge el al. 
1990). Although GLUT-2 is found in pancreatic (3-cells, where it acts as a glucose sensor 
(Chen et al. 1990), GLUT -4 is responsible for insulin-regulated glucose metabolism and is 
expressed in insulin-sensitive tissues (Olson et al. 1996). GLUT -4 is stored in specialized 
vesicles which, in the absence of insulin, move along a microtubule network below the 
plasma membrane. Once insulin binds to its receptor on the cell surface exterior, these 
vesicles are halted and fuse with the plasma membrane, where they release GLUT -4 which 
facilitates glucose transport into the cell (Lizunov et al. 2005). 
Glucose transport into the cell is dependent on the Michelis Menten Constant (Km) of the 
glucose tans porter, which inversely reflects the tissue affinity for glucose (Kahn et al. 1992). 
A low Km (e.g. GLUT-l - 2mmol/l) will lead to saturation of glucose transport at 
physiological levels, whilst a high Km (e.g. GLUT-2 - 66mmol/l) will prevent saturation and 
ensure that glucose flux is directly proportional to the plasma glucose concentration. 
Therefore, the Km of the glucose transporter is the rate-limiting step for glucose uptake into 
tissues (Resh et al. 1983; Olson et al. 1996) and is likely to be associated with the 
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accumulation of glucose in these tissues including the endothelium, and therefore the 
development of complications (Hirsch et al. 1999). 
Glucose transporter isoform 
GLUT-I 
GLUT-2 
GLUT-3 
GLUT-4 
Class II - fructose transporter 
Class III 
Tissue distribution 
erythrocytes, endothelial cells, blood brain barrier, 
blood retina-barrier 
islet beta cells, hepatocytes, intestine 
neurons, placenta, heart 
adipose tissue, skeletal muscle, cardiac muscle 
GLUT-5, 7,9 & 11 
GLUT - 6,8, I 0, 12 and the H+/myoinositol transporter 
Table 1.1: Facilitative glucose transporters and their characteristic tissue distribution. 
Apart from glucose uptake, the above mentioned barrier function of endothelial cells is 
crucial in maintaining cellular homeostasis, and the provision of a balance between opposing 
physiological and molecular effects (Calles-Escandon et al. 200 I). These include essential 
control of vascular tone through nitric oxide (NO)-mediated vasodilation and angiotensin-II 
(ANG-I1) mediated vasoconstriction, maintenance of blood flow through activation of the 
proteolytic enzyme thrombin and the natural substrate fibrinogen, differentiation of VSMC 
through production of PGF and ANG-II and the regulation of inflammatory processes 
(Calles-Escandon et al. 2001, Crane et al. 2005; Shaw et al. 2005). 
Endothelial dysfunction in type 1 diabetes is usually characterised by an increase in 
plasminogen inhibitors leading to an increase in blood clotting, inflammatory markers such 
as endothelial intercellular adhesion molecule I (cICAM-I) and vascular cell adhesion 
16 
molecule I (cVCAM-I), protein kinase C (PKC), fibronectin and von Willebrand Factor 
(vWF), a marker for endothelial dysfunction (Calles-Escandon et al. 2001), as well as a 
reduction in NO and NO-mediated vasodilation (Rodrigues-Nanas et al. 2003). Vascular 
changes and their detection seem more complex for type 2 diabetes as markers for 
endothelial dysfunction are usually present long before any damage occurs (Evans et al. 
2002). 
1.4. Cellular responses to byperglycaemia 
Since diabetes is characterized by abnormally high levels of circulating blood glucose, it 
follows that increased amounts of glucose enters the cell which results in more substrate 
being available for glycolysis and subsequent oxidative phosphorylation by the mitochondria 
(Fig. 1.1). 
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Fig. 1.1: Schematic diagram showing basic mitochondrial function and mitochondrial ROS generation . Electrons are removed from electron donors such 
as NADH and F ADH2 and passed down the mitochondrial electron transport chain (ETC) via a series of redox reactions. The energy generated is used to 
pump protons from the mitochondrial matrix into the inter membrane space, generating an electrochemical potential referred to as the mitochondrial 
membrane potential (~lJlm) . This gradient drives A TP synthesis via the re-uptake of protons into the mitochondrial matrix. 
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1.4.1. Mitochondrial morphology and function 
Mitochondria are remnants of a bacterial endosymbiont which are thought to have resided in 
a host cell over 1,500 million years ago (Margulis et a/. 1986). They play essential and 
diverse roles in the metabolism and physiology of eukaryotic cells and provide energy 
through oxidative phosphorylation. Mitochondria are sub-cellular compartments for 
numerous essential metabolic reactions such as glycolysis, ROS detoxification, fatty acid 
transport and oxygenation and play central roles in apoptosis and aging (Scheffler et a/. 
2001). 
The cellular function of mitochondria is reflected in their structure, which varies according 
to cell type, cell cycle stage and intracellular metabolic state (Westermann et al. 2002). The 
establishment and maintenance of an intracellular mitochondrial continuum by continuous 
membrane fusion and fission events is thought to be important for the distribution of energy 
in the cell (Westermann et a/. 2002). Fusion of mitochondria serves to mix and unify 
mitochondrial compartments (Chan el a/. 2006) important for the inheritance and 
maintenance of the mitochondrial genome encoding several polypeptides required for 
respiratory function and multiple cell signalling cascades. Proteins such as GTPases, kinases 
and phosphatases are involved in bi-directional communication between the mitochondrial 
reticulum and the rest of the cell, linking mitochondrial function and dynamics to the 
regulation of metabolism, cell-cycle control, development, antiviral responses and cell death 
(Neuspiel et al. 2005, McBride et al. 2006, Wang et al. 2006). 
It has been proposed that mitochondrial fusion counteracts the manifestation of 
mitochondrial DNA (mtDNA)-linked diseases (Nakada et a/. 2001) and cellular ageing 
(Chan el a/. 2006). Mitochondrial DNA is highly susceptible to ROS-mediated damage, as it 
is subjected to a much higher level of free radicals compared to nuclear DNA (Kang el al. 
2005). Multiple mitochondrial DNA deletions can be caused by an increased in ROS 
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(Wallace et al. 2002) and are thought to be associated with genetic disorders (Maassen et al. 
2004). Research aimed at elucidating the role of mitochondria in cell death has become one 
of the fastest growing disciplines in biomedicine (Kim et al. 2007). 
1.4.2. Mitochondrial regulation in hyperglycaemia and hypoxia 
Calcium (Ca2+) homeostasis is vital to the function and survival of cells and plays an 
essential role in mitochondrial regulation (Kannan el al. 2000). It helps to regulate the 
tricarboxylic acid cycle involved in fuel molecule catabolism and A TP production (Duchen 
et al. 2004) and mitochondrial membrane potential (~'I'm); (Richter et al. 1998). There is a 
close relationship between Ca2+ concentration and cell death, with the disruption of Ca2+ 
homeostasis being responsible for most endothelial dysfunction associated with oxidative 
stress (Dreher et al. 1995). 
Under normal physiological conditions, the ~'I'm drives Ca2+ accumulation in the 
mitochondria through its passive diffusion through the ruthenium red-sensitive uniporter 
(Jomot et al. 1999). A sharp increase in Ca2+, oxidants and inorganic phosphate levels occurs 
as a result of hyperglycaemia and an increase in oxidative stress stimulates Ca2+ release 
(Richter el al. 1998) via the mitochondrial membrane permeability transition pore (mPTP) 
(Duchen et al. 2004). This results in a loss of ~'I'm' leakage of the mitochondrial membrane, 
inhibition of ATP synthesis, mitochondrial damage and cell death (Fig.I.I). 
Under hypoxic conditions, there is a reduction in mitochondrial respiration due to the lack of 
available molecular oxygen. This results in a reduction in cellular Ca2+ cycling (Gnaiger et 
al. 2000). In effect, a much slower rise in intracellular Ca2+, a reduction in mitochondrial 
ROS production and subsequent closing of the mPTP, resulting in a reduced rate of 
mitochondrial depolarisation. One paper even suggests a functional switch of mitochondrial 
NO synthase (mtNOS) in endothelial cells from a NO generating enzyme under normoxic 
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conditions to a superoxide radical (02-.) generating enzyme under hypoxic conditions (Du et 
al. 1999). Since the intracellular Ca2+ concentration is known to regulate eNOS activity 
(Droge et al. 2002) it is important to also consider the role of NO in the responses to 
hyperglycaemia-induced mitochondrial dysfunction. 
It has been shown on many occasions that NO can combine with O2-. to form highly reactive 
peroxynitrite (ONOO-); (Green el al. 2004) (Fig. 1.1). The formation of peroxynitrite is 
thought to be a critical step in the apoptotic process in endothelial cells in response to 
hyperglycaemia (Du el al. 1999). Some of the cytotoxic and pro-apoptotic downstream 
effects of peroxynitrite include: mitochondrial membrane depolarisation, activation of 
caspases 9 and 8, inactivation of ATP synthase, aconitase and creatine kinase (Waldorf el al. 
2004), lipid peroxidation, oxidation of protein sulphydryls, nitration of tyrosines and DNA 
damage (Du el al. 2003). Therefore, peroxynitrite is a critical effector of apoptosis. Once 
formed, peroxynitrite inhibits NADH: ubiquinone reductase activity (complex J) and the 
ATP synthetase (complex V); (Waldorf el al. 2004). This will not only alter the permeability 
transition of the mitochondrial membrane but also the redox balance of the cell. 
Despite contradictory reports about the oxidant properties of NO (Liu el al. 2001, Matsunaga 
el al. 2004, Brown el al. 2007), more recent studies have suggested that NO modulates the 
expression of the peroxisome proliferators-activated receptor (PPAR) gamma coactivator 1-
alpha (PGC-lalpha), thereby regulating the mitochondrial ROS detoxification system (Valle 
et al. 2005, Borinquel el al. 2006). Interestingly, Wu el al. (2006) has identified the 
transducer of regulated CREB (cAMP response element-binding protein) binding protein 
(TORC) I, as an upstream regulator of PGC-l alpha, the master regulator of the ROS 
detoxification system (Wu el al. 2006). TORCs have been shown to be essential upstream 
regulators of CREB activity in beta cells (Conkright el al. 2003) and are thought of as 
promising new therapeutic targets for the treatment of diabetes mellitus (PatH el al. 2005). 
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1.4.3. Oxidative stress, DNA damage and repair 
Oxidative stress was first recognised by Conger and Fairchild in 1952 (Conger et al. 1952) 
and is now thought to be an integral component of the development of vascular 
complications in diabetes mellitus (McMillan et al. 1997). There is evidence to suggest that 
an increase in plasma free-radical concentration impairs insulin action, which in tum 
contributes to the development of hyperglycaemia and further production of free radicals 
(Ceriello el al. 2000). This observation of a continued cycle of metabolic stress and free-
radical production leads to the hypothesis that oxidative stress represents a pathway linking 
hyperglycaemia to reduced insulin action (Baynes et al. 1991, Giugliano el al. 1996, Ceriello 
el al. 2000). Further, increased production of reactive oxygen species in response to 
hyperglycaemia is closely linked to an increase in oxidative DNA damage (Dandona et al. 
1996). Oxygen and ROS have been shown to induce many different types of DNA damage, 
including single- and double-strand DNA breaks, base and sugar modifications and DNA 
protein cross links. If left un-repaired these mutations may have disastrous consequences for 
the organism (Tsuzuki el al. 2007). 
DNA repair is a hierarchical process which is initiated by signalling proteins. Two enzymes 
governing serine-threonine kinases which regulate the response to DNA damage, thereby 
acting as cell cycle checkpoints (Rehman et al. 1999), are ataxia telangiectasia (A TM), 
mutated A TM and Rad3-related (A TR). These protein kinases respond to distinct types of 
DNA damage such as single or double strand breaks (Walworth et al. 2000). To date, the 
highly selective processes by which cells detect DNA damage, signal its presence and recruit 
the correct cellular mechanisms to effect its repair are not fully understood (Jackson et al. 
200t). What is known is that once expressed these signalling proteins activate a number of 
DNA repair enzymes, such as DNA polymerase enzymes which catalyze the polymerization 
of deoxyribonucleotides alongside a DNA strand through the addition and subsequent 
elongation of free nucleotides to the 3' end of the newly forming strand. DNA polymerases 
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continuously scan the DNA for damage and on detection will initiate an appropriate repair 
pathway. Single strand breaks are mainly repaired via base excision repair (BER), in which 
the altered base is removed by the enzyme DNA glycosylase and the resulting sugar 
phosphate excised (Walworth et al. 2000). Double strand breaks are potentially more 
dangerous lesions as they leave no template for repair and if left unattended may lead to the 
breakdown of chromosomes. Double strand repair takes place mainly during non 
homologous end-joining (also known as DNA mismatch repair; MMR) and homologous 
end-joining (double-strand break repair; DSB (Walworth et af. 2000). During non-
homologous end-joining, the broken ends of the double helix structure are juxtaposed and 
rejoined by DNA ligation, thus allowing for the complete DNA sequence to be restored. In 
order to facilitate DNA repair, cellular progression through the cell cycle is delayed until 
DNA repair is complete to avoid cell death or the formation of cellular mutations during 
replication (Barzilai et af. 2004; Alberts et af. 200 I). 
To prevent attacks from ROS and other free radicals, living cells employ a number of 
defences including low molecular weight compounds and antioxidants such as vitamin C and 
E which scavenge free radicals. More complex systems such as the enzymes superoxide 
dismutase (SOD), catalase and glutathione peroxidase have also evolved to limit the damage 
induced by ROS. The ROS that causes oxidative damage can be divided into two categories: 
free radicals (01I, NO & .02") and non-radical ROS (l-h02); (Shackelford elol. 2000). 
Free radicals induce DNA lesions by attacking at the 8'position of guanine since it is the 
most oxidisable base (Rehman el af. 1999). The hydroxyl radical first reacts with guanine to 
form a C8-0H adduct followed by the loss of an electron and proton to generate 8-oxo-d-
guanine (8-oHdG) (Slupphaug et al. 2003). Unless repaired prior to DNA replication, 8-
oHdG residues can result in GC to T A transversion, which may ultimately lead to 
mutagenesis (Griffiths et af. 2002). The detection of 8-oHdG has been shown to be a suitable 
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biomarker for the detection of DNA damage in response to oxidative stress (Peoples et al. 
2005) and is being used for the detection of oxidative DNA damage in diabetic patients 
(Leinonen et al. 1997, Park et al. 2001) using chromatographic methods such as HPLC and 
GC-MS. However, 8-oHdG is an unstable molecule which is further hydrolyzed to 8-oHG 
resulting in the analysis being marred by the risk of auto-oxidation during sample 
preparation and manual induction of false positive background readings (Gedik et al. 2002). 
Although suggested improvements in the method aim at eliminating the oxidation of guanine 
during handling, the measurement of the more stable hydrolyzed form 8-0110 has been 
proposed (Gedik et al. 2002). 
Since the first results directly associating an increase in ROS with an increase in DNA 
damage in type 1 and type 2 diabetic patients (Dandona et al. 1996, Hinokio el al. 1999), 
many more studies have looked at the evidence for ROS-related DNA damage in diabetes 
and its complications (Donnini el al. 1996, Hannon el al. 1998). Most, if not all, of this 
research has been carried out in diabetic individuals with long-standing diabetes (10 years or 
more), some of whom already have established signs of vascular damage. This implies the 
need for caution when interpreting these results, as oxidative damage (Lorenzi et al. 1987, 
Meplan el al. 2000) is also increased with age and concurrent disease (Dc Bont el al. 2004, 
Lieber el al. 2004). However, the amount of evidence showing an increase in oxidative DNA 
damage in diabetic patients is overwhelming and has been accepted among the scientific 
community. 
1.5. Cellular responses to hypoxia 
The ability to sense and respond to changes in O2 concentration is a fundamental property of 
all cells. Tissue oxygenation is strictly regulated to ensure the availability of substrate for 
oxidative phosphorylation through the mitochondrial electron transport chain while 
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minimizing the production of ROS which can damage cellular DNA, lipids and proteins 
(Lahiri et al. 2006). In 1993, Wang et al. published details of the isolation of the 
transcription factor HIF-l (hypoxia-inducible factor I) which binds to the hypoxic response 
element (HRE) at the 5' UTR of hypoxia regulated genes, thereby facilitating the adaptation 
and survival of cells in response to changes in oxygen tension (Goldberg 1988, Semenza et 
al. 2000 and Coulet et al. 2003). 
HlF-1 is a basic helix-loop-helix heterodimer which consists of two subunits HIF-Ia and 
HIF-IP (Wang et al. 1995). Both ofthese subunits contain the basic-helix-Ioop-helix domain 
which is required for dimerization and DNA binding. Under normoxic conditions the HIF-I P 
subunit is constitutively expressed while the HIF-I a subunit is subjected to proteasomal 
degradation. It is this HIF-la subunit which is tightly regulated by the cellular oxygen 
concentration and presents the most crucial step in the activation of HIF-I (Wang et al. 
1995). It is only when both subunits are activated that HIF-l translocates into the nucleus 
and leads to the increased transcription of genes such as glucose transporters, glycolytic 
enzymes, VEGF, erythropoietin, inducible nitric oxide synthase (iNOS) and insulin-like 
growth factor -2 (lGF-2) (Lando et al. 2000 and Semenza, 2000). It is now thought that HIF-
1 controls several hundred hypoxia responsive genes in the human genome (-5%) 
(Manalo el al. 2005). 
Remarkable progress has been made in understanding HlF-1 signalling and cellular oxygen 
sensing. In the late I 990s, it was discovered that HIF -I (l degradation is controlled by 
binding of the von Hippel-Lindau protein (vHL) which is the recognition component of the 
E3 ubiquitin-protein ligase which targets HIF-I (l proteasomal degradation (Huang et al. 
1998, Kallio et al. 1999 and Maxwell et al. 1999). vHL binding is dependent on the 
hydroxylation of HIF-I (l proline residues (402 & 564) for which prolyl hydroxylases (PHD) 
are responsible (Jaakkola el al. 200 I, Ivan el al. 2002 and Fandrey el al. 2006). This 
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provides a mechanism through which changes in oxygen concentration can be directly 
translated into changes in gene expression. However, many other factors have been shown to 
playa role in oxygen sensing and HIF-I activation, such as asparaginyl hydroxylase (Lando 
et al. 2002a), cytokine activation, growth factors and environmental stimuli (Ke et al. 2006 
and Lee et al. 2000) via the activation of the MAPK or PI3K signalling pathway (Li et al. 
2004). 
1.5.1. H1F-1 a and the mitochondria 
Despite being a key promoter for the adaptive responses to cell survival in hypoxia, HIF-Ia 
paradoxically also mediates hypoxic cell death and apoptosis. Several pro-apoptotic genes 
induced by HIF-Ia have been reported (Bruick et al. 2000, Chen et al. 2003, Kim el al. 2004 
Harada et al. 2006). In 2004, Lee et al. showed that the HGTD-P gene (HIF-Ia dependent 
pro-apoptotic molecule), formerly known as a novel gene expressed in human dendritic cells, 
acts as a novel HIF-Ia responsive pro-apoptotic molecule. It activates mitochondrial 
apoptotic cascades through the induction of the mPTP, thus transmitting apoptotic signals 
which are sensed by HIF-la to the mPTP (Lee et al. 2004). 
It has been proposed that HIF-I activity requires a functional mitochondrial electron 
transport chain (Guzy et al. 2005). Mitochondrial generation of superoxide radicals (at 
complex I and III of the ETC) and the subsequent formation of hydrogen peroxide are 
required for the induction of HIF-l activity and the transcription of its downstream targets in 
hypoxic cells (Chandel et al. 1998). Furthermore, the mitochondrial antioxidant, Mn-SOD, 
has been shown to be responsible for the conversion of superoxide radicals into hydrogen 
peroxide (Wang el al. 2005). The induction of HIF-Ia and subsequent VEGF expression is 
suppressed in human breast carcinoma MCF-7 cells. This would indicate that mitochondrial 
overproduction of ROS, with a subsequent rise in Mn-SOD activity is detrimental rather than 
beneficial for the induction of the cellular HIF-I response to hypoxia. 
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These findings are in agreement with the second hypothesis established by Ehleben et al. 
(1998) who suggested that an NAD(P)H oxidase of unknown origin converts O2 into 
superoxide radicals and onwards into hydrogen peroxide via the enzyme SOD. A reduction 
in O2 concentration would lead to a reduction in ROS and subsequently reduce the cellular 
signalling pathways which lead to the activation of HIF-l. In accordance with this 
hypothesis, Vaux et al. (2001) published evidence for the HIF-l activation in hypoxia even 
in the absence of a functional mitochondrial respiratory chain as well as showing a reduction 
in cellular ROS production in response to hypoxia. 
1.5.2. Tissue hypoxia and disea~e progression 
Due to the realisation that hypoxia has a strong impact on cell biology and signalling 
processes, there has been an enormous interest in the biology ofHlF-l and its role in human 
disease (Semenza et al. 2000). Tissue hypoxia plays a crucial role in cardiovascular disease, 
tumour growth and diabetic retinopathy due to hypoxia-mediated remodelling of the 
vasculature (Ikeda et al. 2005). Angiogenesis is one of the most important adaptive 
responses to hypoxia as it attempts to restore oxygen transport to ischemic tissues by 
increasing vessel growth. HIF- I -mediated activation of VEGF promotes new vessel growth 
in diabetic retinopathy in an attempt to circumvent the hypoxic area and restore blood flow 
(Ferrara et al. 2003). Vascular remodelling can, however, also contribute to disease 
progression, such as conferring resistance to chemotherapy and radiotherapy through the 
remodelling of the tumour vasculature, by a direct change in the cellular phenotype 
(Kobayashi et al. 2006), and abortive vessel growth during the proliferative stage of diabetic 
retinopathy leading to hemorrhage, retinal detachment and loss of vision (Cukiemik et al. 
2004). New vessel growth has been associated with a reduction in the luminal diameter of 
the pulmonary artery, resulting in an increased resistance to blood flow and progressive heart 
failure (Semenza et al. 2001). In addition, it has been linked to cerebral ischemia (Marti et 
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af. 2000) and pregnancy disorders, such as pre-eclampsia and intra-uterine growth 
retardation (Rajakumar et af. 2004 and Malamitsi-Puchner et af. 2005). 
1.6. Intracellular pathways involved in cellular response to hyperglycaemia and 
hypoxia 
1.6.1. The pofyol pathway 
The polyol pathway converts glucose into sorbitol and onwards into fructose (Fig.l.2). 
Under nonnal physiological conditions, this pathway only accounts for a small percentage of 
the total blood glucose metabolism since the conversion of glucose into glucose-6-phosphate 
by hexokinase (glycolysis) is the favoured mechanism for the nonnal metabolism of glucose. 
As the blood glucose levels rise, hexokinase becomes saturated and a two to four fold 
increased flux through the polyol pathway can be observed (}Iotta el al. 1995). The 
selectivity of this mechanism is due to the high Km of aldose reductase, the rate limiting 
enzyme. 
During the polyol pathway, glucose is converted into sorbitol by the enzyme aldose 
reductase (Fig.1.2). This reaction utilises nicotinamide-adenosine dinucleotide phosphate 
(NAOPH) as a hydrogen donor, converting NAOPH into nicotinamide adenine dinucleotide 
phosphate, oxidized form (NAOP+-). Sorbitol is then converted into fructose by the enzyme, 
sorbitol dehydrogenase (SOH). In contrast to the first reaction, nicotinamide-adenosine 
nucleotide (NAD+) is favoured as a hydrogen acceptor, converting NAO+ into NAOH (King 
el al. 1996). Sorbitol is thought to accumulate in the tissue and thereby contribute to the 
pathogenesis of chronic diabetic vascular complications (Hotta el al. 1995). However, 
despite the investigations into the direct consequence of the accumulation of sorbitol and 
fructose, it appears that chronic vascular damage is the result of many factors which 
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contribute to a change in cellular redox state rather than a direct toxicity effect (Gries et al. 
1995). 
A direct consequence of the altered redox state within the cell is a depression in reduced 
glutathione levels and the resulting loss of the intrinsic protection against oxidative stress 
(Williams el al. 1999), as well as the reduction in myoinositol, leading to a reduced Na+1K + 
- ATPase activity (Gries el al. 1995). 
1.6.2. Advanced Glycation End Products (AGE) 
As seen with the polyol pathway, glucose can lead to macromolecular changes. Advanced 
glycation end products (AGE) are produced by glucose-mediated changes to 
macromolecules. It is believed that the modification of tissue proteins by reducing sugars 
contributes to the pathological changes which lead to diabetic vascular complications 
(Baynes el 01. 1999). 
In the very early stages of the disease and in the presence of high glucose concentrations, 
glucose attaches rapidly to the amino groups of proteins fonning Schiff bases (Maillard 
reaction) (Yim el 01. 1995). These rearrange quickly to fonn more irreversible Amadori 
products and early glycation products. The last step in this protein glycation cascade is the 
fonnation of stable and irreversible advanced glycation end-products from early glycation 
products (Giardino et al. 1997, Mohamed et al. 1999). Since AGE products are irreversible, 
they will accumulate within the tissues or vessel walls over time and contribute to the 
chronic pathological changes in the vasculature. The more advanced the protein 
rearrangement, the more pennanent these changes become. In addition, these early glycation 
products can generate free radicals due to their ability to undergo auto-oxidation (Ahmad el 
01. 1998, Ahned el al. 2005). This will contribute to protein cross-linking and various other 
fonns of cellular damage in diabetes (Goldin et 01. 2006). 
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AGE can directly alter protein function and associated signal transduction and gene 
expression (King et 01. 1996). Three mechanisms of AGE play an important part in the 
generation of tissue damage, all of which may lead to a change in vessel structure, reduction 
in their elasticity, abolishion of vessel tone and increased fluid filtration across the vessel 
walls (King et 01. 1996). Consequences include the impaired regulation of blood flow (R6sen 
et 01. 2001) and a contribution to the development of atherosclerosis (King et 01. 1996) 
through the highly thrombogenic and pro-coagulant state of the vessel wall (R6sen et 01. 
200 I), all of which are characteristic clinical signs within the population of diabetic subjects. 
Associated with the above effects is the concept of AGE-induced acute oxidative stress 
(Baynes et 01. 1991, King el 01. 1996, Mohamed el 01. 1999, R6sen el 01.2001). Binding of 
AGE to its receptor (RAGE) and the subsequent mediation of signal transduction leads to the 
generation of ROS (King el 01. 1996, Mohamed el 01. 1999) and hence depletion of the 
antioxidant defence mechanisms. Increased oxidative stress levels result in the activation of 
the free-radical sensitive transcription factor, NF-ICB. NF-ICB regulates the expression of 
many genes associated with haemodynamic control and cellular microcirculation of tissues 
(Mohamed et 01. 1999, R6sen el 01. 200 I). Therefore the activation of NF-ICB is critical in 
the pathogenesis and progression of diabetes and atherosclerosis (Mohamed el 01. t 999). 
1.6.3. PKC pathway 
One of the most extensively researched pathways activated by high circulating blood glucose 
levels is the expression of protein kinase C (PKC). Its activation by elevated glucose 
concentration has to date been confirmed in nearly all tissues (King et 01. 1996, Ways el 01. 
2001), but the extent of its involvement in the pathogenesis of vascular complications 
remains unclear (Mohamed et 01. 1999). PKC belongs to the group of serine/threonine 
kinases. The entire PKC family is involved in a large number of cellular processes, ranging 
from host defence mechanisms to the development of neural function required for long-term 
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memory (Gomperts et af. 2003). During nonnal cellular processes, PKC catalyses the 
phosphate group transfer from adenosine triphosphate (A TP) to multiple cellular proteins 
required for nonnal cellular function (Rosen et af. 200 I). PKC isofonns can be classified 
into three subfamilies, namely conventional (or classical), novel and atypical based on their 
second messenger requirements. Conventional PKCs (isofonns a, ~h ~2' y) are 
diacylglycerol (DAG) and Ca2+ sensitive, whereas novel PKCs (isofonns 5, e, 1'\, e, Il) are 
DAG-sensitive but Ca2+ insensitive (Koya et af. 1998). DAG is synthesised in response to 
either the hydrolysis of phopshatidylinositides (PIs) or from the metabolism of 
phosphatidyIcholine (PC) by phospholipase C (PLC) or D (PLD) (Koya et af. 1998). In 
response to hyperglycaemia there is an increased flux through the glycolytic pathway 
resulting in an increased production of DAG and a subsequent change in the NADHINAD+ 
ratio. Atypical PKCs (isofonns ~ t, A) require neither Ca2+ nor DAG for activation (Koya el 
al.1998). 
Since high levels of PKC, mainly the r3- and 5-isofonns, are present in most diabetic tissues, 
a number of pathogenic mechanisms have been proposed by which PKC contributes to the 
development of vascular changes (Meier el af. 2000). These include: 
• impaired vascular reactivity through the inhibition of NO mediated vasodilation 
(Rarnzy el af. 2006) 
• reduced cellular Na + /K+ - ATPase activity leading to a disruption of cellular integrity 
and nerve conduction velocity (NCV) 
• changes in vascular penneability (PKCa) (Hempel et af. 1997) 
• basement membrane thickening and a change in vascular blood flow 
Evidence of these changes can be found in all major tissues contributing to atherosclerosis 
(Yuan el al. 2000), retinopathy and neuropathy (Eichberg el af. 2002) as well as providing a 
link to many other pathogenic mechanisms associated with the vascular complications of 
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diabetes. It has been suggested that the activation of the DAG-PKC pathway is a common 
downstream pathway through which high circulating blood glucose levels exert their 
pathogenic effect (Aleksandrovski et al. 1998, Koya et al. 1998, Opara et al. 2002). 
1.6.4. p42144 MAPK and PI3K1akt pathways 
P42/44 MAPK belongs to a family of highly conserved serine/threonine protein kinases 
which are involved in a number of cellular regulatory events such as differentiation, cell 
survival and migration (Cobb et al. 1999). The p42/44 MAP kinase pathway is a protein 
kinase cascade which links growth and differentiation signals with a resulting effect on cell 
proliferation (Ho et 01. 2000). In addition, p42/44 phosphorylation and activation during 
reperfusion has been shown to be beneficial in limiting reperfusion-induced injury (Brar et 
al. 2000). It is though that ischaemic preconditioning, the most powerful protection against 
infarction, activates PI3Kinase (PI3K)/AKT and P42/44MAPK (Wynne et al. 2005). 
PI3K and Akt are downstream effectors of insulin signaling (Galetic et 01. 1999) and are 
important in the regulation of angiogenesis (Jiang et 01. 2000) proliferation (Varma et al. 
2005), microvascular permeability (Lal et 01. 200 I) and survival (Franke et al. 1997) of 
endothelial cells. High glucose is thought to induce HUVEC apoptosis via PI3K1Akt 
signaling as well as causing the generation of ROS via a PI3K1 Akt dependent pathway (Sheu 
et al. 2005) while hypoxic induction of PI3K1Akt plays an important role in tumour 
angiogenesis through the induction of vascular endothelial growth factor (Mitzukami et al • 
2006; Kobayashi et al. 2006). 
1.7. Therapeutic targets for vascular complications in diabetes mellitus 
As the treatment options for diabetic vascular complications are limited, the development of 
novel therapeutic agents and approaches is an important focus of diabetes research. One of 
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the first targets identified as having great potential for the treatment of diabetic 
microvascular complications was the polyol pathway and its rate-limiting enzyme, aldose 
reductase (Fig. 1.2). Aldose reductase inhibitors were first developed in 1973 (Dvomik el al. 
1973) and together with flavonoid antioxidants, which have also been proposed to have 
aldose reductase inhibiting potential (Vanna el al. 1977), fonned the first generation of 
promising therapeutic agents for the treatment and prevention of vascular complications of 
diabetes which are still being investigated to date. However, due to our continuously 
evolving appreciation of the biochemical mechanisms involved, focus has since shifted to 
other promising agents such as PKCP inhibitors (Kunisaki el al. 1994) and most recently 
poly(ADP-ribose) polymerase (PARP) inhibitors (Soriano el al. 2001). 
1.7.1. Aldose reductase inhibitors 
Since the first isolation of rat lens aldose reductase (Hayman el al. 1965) aldose reductase 
and its inhibitors have been extensively researched as potential therapeutic agents for the 
treatment and/or prevention of diabetic vascular complications. Despite showing promising 
results in animal and in vitro studies, aldose reductase inhibitors have failed to show any 
outstanding benefit in the multitude of clinical trials that have been conducted with the 
exception of some beneficial effects on neuropathy. 
The greatest benefits to humans were seen in the prevention of a reduction in nerve 
conduction velocity in diabetic neuropathy (Goto el al. 1990). This has led to the licensing of 
certain aldose reductase inhibitors (tolrestat. epalrestat) in some European countries (Hotta et 
al. 1995) for the prevention of diabetic neuropathy. In addition aldose reductase inhibitors 
(ARI) investigated by the Sorbinil Retinopathy Trial Research Group (Sorbinil Retinopathy 
Trial Research Group (1990» have shown encouraging results in the prevention of diabetic 
retinopathy (Zenon et al. 1990). 
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Consequences of inhibiting the rate-limiting enzyme of the polyol pathway can easily be 
extrapolated from our insight into the outcomes of polyol pathway expression. Research 
carried out in this area (Costantino et al. 1999) has shown that aldose reductase inhibitors 
improve nerve conduction velocity and endoneurial blood flow, improve endothelial NO-
mediated vascular relaxation, improve nerve and vascular smooth muscle cell Na + /K+ -
ATPase activity, lead to an incremental increase in the oxygen supply of peripheral nerves 
and reduce the incidence of capillary micro-aneurysms in the retina. 
The limited data obtained from clinical trials suggests that the clinical role of the aldose 
reductase inhibitors is confined to a slowing of the pathogenic progression rather than the 
reversal of vascular damage (Costantino et al. 1999). This suggestion is further confirmed by 
studies which have shown that early administration of ARls to galactose-fed rats can slow 
cataract formation. This suggests that further investigation of the beneficial effects of ARls 
should focus on early intervention and prevention of vascular dysfunction (Kador et al. 
1985) rather than the treatment of a manifested vascular compl ications. 
1.7.1.1. Structural requirements offlavonoid aldose reductase inhibitors 
Aldose reductase inhibitors can broadly be categorized into four structural groups: 
carboxylic acids, flavonoids, cyclic imides (mostly hydantoins) and "other compounds" 
(Sato et al. 1990). As none of the flavonoid aldose reductase inhibiting compounds have 
made it to the clinical trial stage, more potent and less toxic aldose reductase inhibitors need 
to be identified. Special attention is paid to the NADPH binding conformation and the 
identification of the structural pharmacophoric and stereometric properties. 
In 2002 Matsuda et al. identified essential structural requirements of potent flavonoid ARI. 
These include: 
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The more water-soluble flavonoid antioxidant compounds contain the 4-oxo-4H-chromen 
ring system which is essential for improved ARI activity. These compounds interact with the 
enzyme at a site which is different from that of the substrate. Conformational change of the 
enzyme is achieved by nucleophilic attack at the carbonyl group of the inhibitor (Kador et al. 
\983). It is because of these effects that many antioxidants have been investigated for their 
therapeutic potential in the treatment of the vascular complications of diabetes. 
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Overall, the data obtained from studies with aldose reductase inhibitors do not live up to 
their promise as potent effective treatments for all vascular complications in diabetes. 
Research into these novel therapeutic agents is still ongoing (Hotta el 01. 2001, Bril el 01. 
2006), although attention has now shifted to other more promising therapeutic targets such as 
PKCI3 and PARP inhibitors. 
1.7.2. PKCP inhibitors 
Recent developments focus on the usefulness of specific PKC-isoform inhibitors as novel 
therapeutic agents in the treatment and prevention of diabetic vascular complications 
(Cooper el 01. 1997, Ways el 01.2001, B100mgarden el 01.2002), and although they seem to 
show some improvement, one main hurdle is to establish their long-term consequences, since 
PKC is involved in a multitude of normal cell processes. 
In 1996 the PKCI3 inhibitor L Y333531 was one of the first to be synthesised and shown to be 
a competitive reversible inhibitor of PKCP. and 1311 (Ishii el 01. 1996). Since then, it has been 
extensively tested against the hypothesis that PKCj3-induced ROS underlies the vascular 
dysfunction in diabetes (Zhou el 01. 2006). L Y333531 has since been shown to ameliorate 
diabetes-induced retinal hemodynamic abnormalities (Aiello el al. 2006), and calcium 
homeostasis of diabetic sensory neurons (Tahara el al. 2006) as well as being beneficial in 
preventing diabetes associated CV complications (Boyle el al. 2005; Zhou el al. 2006) in 
rats. L Y333531, also known as Ruboxistaurin, is quickly emerging as a potential novel 
therapeutic agent for the treatment of diabetic microvascular diseases (Joy et al. 2005, 
Avignon el al. 2006) such as peripheral neuropathy (Casellini el al. 2007). 
1.7.3. Antioxidants 
As mentioned above, antioxidants have been investigated as potential therapeutic agents for 
diabetes since Varma el 01. (1977) hypothesised a potential role for them as aldose reductase 
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inhibitors. Antioxidants are free-radical scavengers which prevent or delay the oxidation of 
substrates. Two types of endogenous antioxidants exist, antioxidant enzymes and small 
antioxidant molecules. In addition, antioxidants are ingested in a healthy, balanced diet and 
in some cases vitamin supplementation. 
To date, a large number of studies have given conclusive evidence that free radical-generated 
cellular damage plays an important role in the pathogenesis of many chronic diseases 
(Hannon el at. 1998). As such, three of the four largest and most important long-term clinical 
trials carried out in diabetes have had nutritional intervention as a major element in their 
investigation. These include the Epidemiology of Diabetes Intervention and Complications 
Study (EDIC) (a follow-on study of the DCCT (NIDDK National Diabetes Information 
Clearinghouse), the Diabetes Prevention Program (DPP) (World Health Organisation 1990) 
and the Look AHEAD (Action for Health in Diabetes 2002) study. 
As explained earlier, ROS play an important role in the pathogenesis of diabetic vascular 
damage (Section 1.4). It has therefore been hypothesised that the use of antioxidants as 
therapeutic agents could be beneficial in the treatment and prevention of diabetic vascular 
complications and other chronic diseases. Particular attention has been paid to antioxidants 
such as Vitamin E and C in the prevention of cardiovascular disease. Results from large-
scale clinical trials are controversial depending on the study size, risk groups investigated 
(primary or secondary prevention), race, and dose of Vitamin E administered. The most 
interesting evidence was produced by the CHAOS (Cambridge Heart Antioxidant Study) 
study in 1996 (Stephens el al. 1996) which looked at the effect of Vitamin E on the 
secondary prevention and improvement in mortality in CV disease patients. Results revealed 
a 60% reduction in non-fatal myocardial infarctions. A second landmark trial, the Heart 
Outcomes Prevention Evaluation (HOPE) study (Kleinert el at. 1999), in contrast, found that 
long-term vitamin E supplementation does not prevent major cardiovascular events in 
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patients with vascular disease or diabetes mellitus, and may even increase the risk for heart 
failure (Lonn et af. 2005). This highlights the potential importance for the use of antioxidants 
in diabetes and the prevention ofCV complications. 
Alpha lipoic acid (another powerful anti-oxidant) has been shown to be particularly suited 
for the prevention andlor treatment of diabetic complications that arise from the 
overproduction of ROS (Packer et af. 2001). A randomised controlled trial investigating the 
usefulness of alpha lipoic acid, selenium and D-alpha-tocopherol in 80 randomly assigned 
diabetic patients confirmed that oxidative stress played a role in promorting the development 
of long-term diabetic complications (Kahler et af. 1993). Its combination with an aldose 
reductase inhibitor (ARI) has been suggested to be a suitable future treatment strategy 
(Cameron et af. 1999). 
Although many different types of antioxidants exist, flavonoid antioxidants have largely 
been the focus of antioxidant research and will now be reviewed in more detail. 
1.8. FlavoDoids 
Flavonoids are a group of polyphenolic antioxidant compounds, of which 3000 varieties are 
known to date. They can be found in a variety of plants, fruits and a number of beverages 
such as teas, wine and beer (Gtlkmen, 2002; Miller, 2002). 
The core structure of all flavonoids includes two benzene rings on either side of a 3-carbon 
ring (Fig. 1.3). Depending on the further chemical structure, flavonoids are divided into five 
sub-groups: anthocyanidins, flavoneslflavonoles, flavanones, catechinslleucoanthocyanidins 
and proanthocyanidins (Gtlkmen, 2002). These structural differences are responsible for the 
multitude of therapeutic activities that flavonoids have been shown to possess. 
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The therapeutic properties of flavonoids have been explored for centuries with the health 
benefit of teas and plant extracts well known to ancient Chinese medicine. Scientific interest 
in flavonoids has led to many studies being carried out since the 1940s. These studies have' 
shown that flavonoids have antibacterial, anti-inflammatory (Nair et 01. 2002), antiallergic, 
antiviral, anti-thrombic and vasodilatory activity (Narayana et 01. 200 I, Kris-Etherton et 01. 
2002). Most of these effects can be attributed to their potent antioxidant and radical 
scavenging capacity, as oxidative stress is an underlying factor in many of these diseases 
(Jovanovic et 01. 2000, Cotelle et 01. 2001). Flavonoids also inhibit a number of enzymes 
including aldose reductase, xanthine oxidase, phosphodiesterase, Ca2+ ATPase, Jipo-
oxygenase and cyclooxygenase and regulate certain hormones (Wang el al. 2000), making 
them applicable to a wide range of therapeutic approaches. In principle, the potent anti-
oxidant activity of flavonoids is thought to be attributable to two main mechanisms of action: 
a radical scavenging activity which occurs through the donation of hydrogen atoms from free 
hydroxyls found on the flavonoid nucleus, and a metal chelating activity which is mediated 
through the phenolic OH groups (Sugihara et 01. 1999). Research into the structure-activity 
relationship of flavonoids has identified three basic criteria which predict the potency of the 
flavonoids' radical scavenging ability. These include (i) the ortho-dihydroxyl structure in the 
B-ring, (ii) the 2,3-double bond allowing electron delocalization from the B-ring, and (iii) 3-
and 5-0H with 4-oxo function in the A- and C-rings. In general, research suggests that 
flavonoids act as antioxidants in biological systems through their radical scavenging ability. 
However, in the presence of certain metal ions, flavonoids will form complexes which will 
dictate their effect as either anti- or pro-oxidants (Sugihara et 01. 1999, Areias et 01. 2001). 
A Finnish prospective study which looked at the relationship between average dietary 
flavonoid intake and the development of chronic diseases in 10,054 men and women 
between 1966 and 1972 found an inverse relationship between flavonoid intake and the 
development of disease (ischaemic heart disease, cerebrovascular disease, lung & prostate 
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cancer, type 2 diabetes and asthma), with most of the beneficial effects attributed to 
quercetin (Knet et al. 2002). This inverse relationship between average dietary flavonoid 
intake and cardiovascular risk has also been summarised in a review by Cotelle in 2001. 
Despite the multitude of scientific data, there is controversy over the supplementation of our 
diet with flavonoid extracts. As there is no evidence to suggest that a lack in polyphenols 
causes serious harm (unlike some vitamin deficiencies), the consensus seems to be that 
dietary intake of flavonoids through fruit and vegetables is more advisable than essential 
supplementation (Duthie et al. 2003). 
1.9. Quercetin and the French Paradox 
Quercetin is one of the most extensively studied flavonoids and is deemed to be one of the 
most potent antioxidants among the flavonoid group (Fig.l.4) (Formica et al. 1995). Large 
amounts of quercetin can be found in apples (Boyer et al. 2004), onions, kale, french beans, 
broccoli, lettuce and tomatoes as well as red wine, grape, lemon and tomato juice. Because 
of its wide distribution, quercetin constitutes an unavoidable component of our diet which is 
positive given the extensive health benefits attributable to flavonoids. 
Fig. 1.4: Illustration showing the chemical structure of the flavonoid quercetin 
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(Adapted from: Dictionary of Natural Products (DNP) on CD-Rom, Version 9:2. Copyright 
(c) 1982-2001 Chapman & HaIVCRC.) 
Quercetin is said to be of particular benefit to the cardiovascular system (Boyer et 01. 2004) 
as well as having a positive effect on inflammatory and vascular diseases, atherosclerotic 
plaque formation and viral and carcinogenic activity (Formica et 01. 1995). However, other 
reports question the ability of quercetin to reverse diabetic oxidative stress overall (Sanders 
et 01. 2001). 
Despite the convincing results which confirm the health benefits of dietary flavonoids, 
something referred to as the "French paradox" (Criqui et al. 1994) questions our 
understanding of their mechanism of action. The mediterranean diet is saturated with 
flavonoids and other antioxidants and vitamins through the high dietary intake of fish, 
vegetables, fruit and red wine. This can be correlated to the low incidence in cardiovascular 
disease, cancer, diabetes and obesity in these countries. However studies show that 
flavonoids (especially quercetin) are susceptible to microbiological degradation in the lower 
bowel (Renauld et 01. 1992) and poor absorption with only 0.3%-0.5% of quercetin being 
absorbed from the gut (Formica et 01. 1995). Thus, it remains unclear as to how the health 
benefits can be achieved with the relatively low concentration of active compound reaching 
the affected area. 
1.10. Silymarin 
Silymarin or Silibum marianum is a biennial herb commonly known as milk thistle. The 
Greeks and Romans used the extracts and derivatives of the milk thistle in the 111 century, 
and evidence for this is found in the writings of many famous physicians of the past such as 
Dioscorides, Pliny the Elder, Hieronymus Bock, Jacobus, Theodorus and Culpepper 
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(Pepping et al. 1999). Historically, it is used for conditions of the liver, spleen and 
gallbladder. 
Silymarin became available for clinical use in Europe and America in 1969. Until then, 
silymarin was thought to be a pure compound. Detailed analysis revealed that silymarin is 
made up of a number of different flavonoid isomers: silibinin, isosilibinin, silidianin and 
silichristin (Fromming et al. 1999) (Fig. 1.5). Of these, silibinin is thought to be responsible 
for the majority of therapeutic effects seen with silymarin (Zhao et al. 1999). Further HPLC 
analysis revealed that silymarin also contained taxifolin (Fig.l.6), another flavonoid 
compound structurally closely related to quercetin (Fig.1.4), as well as linoleic and oleic 
acids (approx. 20% of dry weight) (Carrier et al. 2004). The seeds of the milk thistle are said 
to contain a number of other flavonolignans such as dehydrosilybin, desoxysilcristin, 
desoxysilydyanin, silandrin, silybinome, silyhermin and neosilyhermin. Nothing is known 
about their therapeutic effectiveness. 
A recent analysis of the active components of silymarin suggests that silymarin contains 
impurities which have a more potent antioxidant capacity than any of the flavonoid isomers 
themselves, indicating that the higher the purity of the milk thistle extract the lower its 
antioxidant capacity (Kvasni~ka el af. 2003). 
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Fig.I.S: Illustration showing the different flavonoid structures found in the silymarin 
compound (Adapted from: Dictionary of Natural Products (DNP) on CD-Rom, Version 9:2. 
Copyright (c) 1982-2001 Chapman & Hall/CRC). 
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1.10.1. Therapeutic properties ofsifymarin 
Silymarin is mainly used as a hepatoprotective drug. It is marketed as Legalon70® by the 
German company Madaus (Koln) and is licensed for the treatment of toxic liver damage and 
the supplementary treatment of chronic inflammatory liver disease and liver cirrhosis. 
Despite the large amounts of convincing research investigating the usefulness of milk thistle 
in liver disease, its mechanism of action is still poorly understood. To date it is thought that 
silymarin exerts its hepatoprotective effect through four main mechanisms (Fraschini el af. 
2002), namely as a potent antioxidant radical scavenger, a cell membrane stabiliser and 
permeability regulator, a promoter of ribosomal RNA synthesis and an inhibitor of the 
transformation of stela hepatocytes into myofibroblasts. 
Since silymarin is a flavonoid antioxidant, its theoretical benefits for a multitude of chronic 
diseases is evident. Despite research focusing on silymarin in the treatment of liver disease, 
other useful properties have been discovered over the years and research attention has 
widened to include other diseases such as cancer, inflammatory diseases and diabetes. 
The use of silymarin in cancer treatment and prevention is a field of growing interest. 
Particular attention has been paid to its ability to protect against skin cancer development 
through the reduced phosphorylation of the Shc gene (Ahmad et af. 1998) as well as the 
inhibition ofMAPKlERK1&2 pathway (Zi el af. 1999) and subsequent cell cycle arrest (G2-
Ml phase). Silymarin has also been shown to inhibit VEGF expression in cancerous 
BUVEe cells (Jiang el af. 2000) and has a potential anti-angiogenic effect in colon cancer 
(Yang et al. 2003). 
Since inflammation is a contributory factor in many disease pathologies, research has also 
investigated the potential anti-inflammatory properties of silymarin (De La Puerta el al. 
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1996). Evidence has been published showing silymarin is able to suppress the action ofNF-
ICB (Saliou et al. 1998, Saliou et al. 1999), inhibit the action of TNFa-induced adhesion 
molecules, VCAM-I, ICAM-l, E-selectin and the TNFa induced binding of NF-ICBlRel 
(Kang et al. 2003). It has also been shown to prevent LDL oxidation and expression of iN OS 
(Kang et al. 2003) making it a potential therapeutic agent for diseases such as arthritis 
(Gupta el al. 2000) asthma (Breschi el al. 2002) and cardiovascular diseases. This is 
supported by additional findings showing a reduction in plasma cholesterol levels (~kottova 
el al. 1998, ~kottova el al. 1999, Kang el al. 2003), platelet aggregation in rat blood (Yao-
Cheng et al. 1991) and cytoprotective and cell regenerating effects (Valenzuela et al. 1994). 
Since diabetes is a major risk factor for CV disease silymarin might be a suitable agent to 
slow the onset and progression of diabetes associated macrovascular complications (Psotova 
et al. 2002). 
1.10.2. Use ofsilymarin in diabetes 
The usefulness of silymarin in diabetes prevention and treatment was first suggested in the 
early 1990s (Zhang el al.1993). Since then only a few research reports have taken a closer 
look at the issues surrounding diabetes mellitus. In 1998 the first ever study was published 
which specifically looked at the treatment of alloxan-induced diabetic rats with silymarin 
(Soto et al. 1998). The study showed that silymarin prevents a rise in plasma glucose 
concentration and lipid-peroxidation as well as showing an increase in pancreatic and plasma 
glutathione levels. Following on from this study the same research group published further 
evidence in 2003, suggesting that silymarin restores the levels of antioxidant enzymes SOD, 
glutathione peroxidase (GSHPx) and catalase (CAT) in the pancreas of alloxan-induced 
diabetic rats. In addition, they observed a recovery of normal blood glucose levels. Their 
explanation is based on previous work carried out by Sonnenbichler el al. (1976), who 
reported that transcription of RNA is accelerated in the liver of rats and mice in the presence 
of silymarin. This leads to an increase in the rate of protein synthesis. The prevention of 
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pancreatic j3-cell destruction through the maintenance or increase of glutathione levels is 
thought to be responsible for the restoration of the blood sugar levels observed (Shafer el af. 
2001). 
Another study investigating the long-term (23 months) effects of silymarin administration in 
cirrhotic diabetes patients found a significant decrease in fasting and mean daily blood 
glucose levels as well as a significant reduction in the mean exogenous insulin requirements 
(Velussi el af. 1997). These results were confirmed by a subsequent study looking at the 
compound silybin-beta-cyclodextrin in patients with type two diabetes mellitus and 
concurrent chirrosis (Lirussi el al. 2002). 
Despite the limited amount of research which has gone into silymarin, both the in vitro and 
in vivo results seem to be promising. From research reports carried out on other tissues, 
certain mechanisms have been identified which strengthen the argument for research into the 
usefulness of silymarin in diabetes. Silymarin has, for example, been shown to be a potent 
radical scavenger, preventing radical-mediated DNA damage (Anderson et af. 1994, Yu el 
af. 1997, Kang el af. 2003) and a depression of antioxidant enzymes (Soto el af. 2003). It has 
also been shown to prevent lipid peroxidation (Soto el of. 2003, Kang el of. 2003) and to 
protect cellular glutathione levels (Shafer el af. 2001, Soto et af. 2003). Other effects such as 
the inhibition ofVEGF (Jiang el af. 2000), NF-lCB (Saliou elof. 1998), and the production of 
iNOS (Kang el 01. 2003) could also have implications for the development of diabetic 
vascular disease. Despite intense research, however, the exact mechanism(s) of action of 
silymarin remain uncertain and the need for further research into the usefulness of silymarin 
and its flavonoid isomers such as silibinin and taxifolin in the prevention and treatment of 
diabetes mellitus and its complications remains. The main question raised is whether 
silymarin acts by improving the cellular environment due to its antioxidant capacity or if it 
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acts through a different mechanism which is independent of its antioxidant activity all 
together. 
1.10.3. Silymarin as a possible aldose reductase inhibitor 
One proposed mechanism of action for silymarin suggests that silibinin, the most 
therapeutically active component of silymarin is an aldose reductase inhibitor based on 
findings in 14 type 1 diabetic patients (Zhang et al. 1993). Hyperglycaemia is known to 
result in sorbitol production. The inhibition of aldose reductase as the rate-limiting enzyme 
of this pathway has a number of positive effects with respect to alteration of NADPINAD 
ratio (King et ul. 1996) (Section 1.6.1) which is thought to be associated with the 
manifestation of cellular dysfunction. The ARIs will theoretically restore the redox state, 
leading to the restoration of protein tyrosine phosphatase activity (Evans el af. 2002), 
normalisation of glutathione levels and improved membrane integrity as a result of improved 
myoinositol mediated Na+/K+ ATPase activity. Other knock-on effects would include the 
prevention of PKC and AGE activation as well as MAPK-mediated phosphorylation of 
transcription factors and the subsequent alteration of gene expression patterns which 
contribute to changes in DNA damage and the subsequent development of vascular 
complications (Tomlinson et al. 1999). 
Silymarin has also been shown to depress glutathione levels (GSH) in the liver (Soto el af. 
2003) and inhibit iN OS production in HUVECs (Kang el al. 2003). Furthermore, it has been 
shown to improve nerve conduction velocity in diabetic neuropathy (Zhang el al. 1993), act 
as a membrane stabiliser (Fraschini el al. 2002) and prevent ROS-induced DNA damage (Yu 
el af. 1997). Although all of these effects were observed in a multitude of different cell types 
using many different methods, they seem to tentatively support the argument for the action 
of silymarin as an aldose reductase inhibitor, bearing in mind that silymarin also acts through 
other mechanisms to reduce glutathione. 
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t.lt. Silibinin 
Silibinin (3,5, 7-trihydroxy-2-[3-( 4-hydroxy-3-methoxyphenil)-2-hydroxymethyl-l ,4-
benzodioxan-6-il]-chronan-4-one) is the main polyphenolic flavonoid isomer of silymarin 
and is mainly thought to be responsible for the antioxidant properties of the silymarin 
compound (Valenzuela et af. 1994). Some of the identified actions of silibinin include, an 
anti-inflammatory action by inhibiting intrahepatic NF-KB and subsequent activation of 
TNF, IFN-y, IL-2 and iNOS (Dehmlow et al. 1996, SchUmann et al. 2003), iron chelation 
useful in the treatment of chronic iron overload such as Cooley'S anaemia (Borsari et al. 
2001), a potent antioxidant action which shows protection against oxidative injury and an 
increase in protein synthesis while improving lipid peroxidation and reducing triglyceride 
levels (Lirussi et al. 2002). 
Studies which looked at the benefits of silibinin in diabetes revealed that it improved nerve 
conduction velocity in type 2 diabetic patients (Zhang et af. 1993) as well as preventing the 
onset of diabetic neuropathy by inhibiting excessive mono-ADP-ribosylation in rat cervical 
ganglia (Gorio el al. 1996). A more recent study looking at the effect of silibinin on red 
blood cell sorbitol levels in diabetic patients suggests that silibinin might be a powerful 
aldose reductase inhibitor and therefore valuable in the prophylaxis and treatment of diabetic 
complications (Zhang el af. 2002). 
Studies looking at the effect of silibinin on blood glucose levels reported no beneficial effect. 
However, using the new oral formulation silybin-beta-cyclodextrin a reduction in blood 
glucose levels in 42 type 2 diabetic patients (with associated chronic liver disease) was 
observed after six months of oral administration (Lirussi el af. 2002). This is thought to be 
due to a reduction in lipid peroxidation and improved insulin activity as a result of the 
improved bioavailability of silibinin (SALAM Research, 2005). Silibinin is a water-soluble 
flavonoid which is a proven liver protectant (Dehmlow el af. 1996). Similar to other 
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flavonoids it is not well-absorbed and has been converted into a more lipid-compatible 
molecular complex. As such it is able to transition from a hydrophilic environment into the 
lipid-friendly environment of the outer cell membrane, and from there into the cell, finally 
reaching the blood (Kidd et 01. 2005). Silibinin-beta-cyclodextrin is an oligosaccharide 
widely used in drug delivery formulation. It alters the release pattern, solubility and stability 
characteristics of the drug (Timmy et 01. 2002). 
More recently, silibinin has been investigated as a therapeutic agent for diseases other than 
hepatic disorders the main focus being on oncological and chemotherapeutic applications, 
such as prostate (Singh et 01. 2006), skin (Gu et 01. 2006) and bladder cancer (Tyagi et 01. 
2006). Numerous new effects of silibinin have been discovered, such as the modulation of 
drug transport via P-glycoproteins (Patel el 01. 2004), its activity on oestrogen receptors 
(Crocenzi el 01. 2001) and its effect of NF-kB and caspase regulated endothelial cell 
apoptosis (Yoo el 01. 2004), where it is thought to affect the mitochondrial regulated 
apoptosis cascade (Mohan et 01.2004). 
l.ll. Taxifolin 
Taxifolin is a polyphenolic flavanone compound with a catechol ring similar to quercetin. It 
is referred to as dihydroquercetin as it is the hydrophilic non-planar equivalent to quercetin 
(planar, hydrophobic) (Fig. 1.4; Fig. 1.6). 
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(2R,3R)-form 
Taxifolin (dihydroquercetin) [ClsHI207] 
Fig. 1.6: Structure of taxifolin, a flavonoid compound found in silymarin and structurally 
closely related to quercetin. Taxifolin is also known as dihydroquercetin. 
(Adapted from: Dictionary of Natural Products (DNP) on CD-Rom, Version 9:2. Copyright 
(c) 1982-2001 Chapman & Hall/CRC). 
Taxifolin can commonly be found in citrus fruits, such as oranges and grapefruit and, like all 
flavonoids, it has been found to possess anti- and pro-oxidant effects. Research suggests that 
it is a weaker antioxidant than quercetin which is in accordance with the structural prediction 
criteria for flavonoid radical scavenging ability mentioned in Section 1.8 above. In addition, 
taxifolin binds more strongly to Fe2+ than quercetin (Areias et 01. 200), which ultimately 
determines its pro-oxidant activity. 
Taxifolin was found to have a similar anti-oxidant activity profile to alpha-tocopherol 
(Tesekin el 01. 1996), inhibiting superoxide anion production, protecting mitochondria from 
peroxy) radical damage and inhibiting the activation of NADPH-dependent cytochrome P4SO 
reductase induced by microsomal lipid peroxidation (Haraguchi el 01. 1996). Recently, 
taxifolin has been investigated by the food industry for its usefulness as a prophylactic 
measure against oxidative stress. It is thought to be valuable since it lacks adverse effects 
such as embryotoxicity, tetratogenicity, allergenicity and mutability (Tiukavkina et 01. 1997). 
However, with respect to its potential pro-oxidant activity, the use of taxifolin as a dietary 
supplement needs to be dealt with cautiously. 
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1.12.1. Therapeutic properties o/taxi/olin 
Only a limited amount of research has investigated the properties and mechanisms of 
taxifolin. Some studies have shown its therapeutic potential and the first suggestion for a 
possible signalling mechanism has been made. In 1996, an Italian research team found a 
cytoprotective effect for both quercetin and dihydroquercetin which could protect 
neurovascular structures in the skin from oxidative stress. This effect was enhanced when 
quercetin was paired with ascorbic acid. Taxifolin remained unaffected by the presence of 
ascorbic acid (Skaper el al. 1996). A few years later, a Korean research team also managed 
to show a neuroprotective effect of quercetin and taxifolin against oxidative injuries in 
cortical cells induced by hydrogen peroxide and xanthine / xanthine oxidase (Dok-Go el al. 
2003). 
The most interesting research, however, was carried out at the University of Berkeley in 
2002 (Bito et al. 2002). The team investigated the effect of tax if olin on the expression of the 
intercellular adhesion molecule, ICAM-l, which is known to be important in mediation of 
inflammatory reaction. ICAM-l is a fundamental component of all immune-related 
processes. It is associated with receptors of the integrin family mediating cell-cell 
interactions and allowing signal transduction. The paper presents evidence that taxifolin 
significantly inhibits tyrosine phosphorylation of JAKI (a member of the Janus family of 
tyrosine kinases which is an integral component of the IFNy signalling cascade), thereby 
inhibiting the INFy-induced expression of ICAM-l. This suggests that the JAK-STA T 
pathway may be a potential molecular site of action for taxifolin (Bito el 01. 2002). This is in 
contrast to quercetin, which inhibits ICAM-l expression in endothelial cells by inhibiting the 
JNK pathway (Kobuchi et al. 1999). Due to the differences in molecular pathways and 
antioxidant capacity of the two flavonoids, it is thought that the effect observed in taxifolin is 
independent of its antioxidant capacity. As inflammatory changes are an underlying cause in 
many chronic diseases, there might be a place for the therapeutic benefits of tax if olin in their 
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treatment. These results raise the critical question of how much, if any, of the beneficial 
effect seen with silymarin in the treatment of acute and chronic liver diseases is attributable 
to taxifolin. 
Taking current literature into consideration, there appears to be a need to further our 
understanding of the molecular contributions which lead to the development of endothelial 
changes early in the development of diabetes-related vascular complications. Since oxidative 
stress appears to playa crucial role in this pathology, it is important to further understand 
how oxidative stress contributes to endothelial changes which will inevitably provide 
pointers to potential new drug targets such as silymarin which can be explored in this 
context. 
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1.13. AIM AND OBJECTIVES OF STUDY 
This study aims to detennine the effect of hyper glycaemia and hypoxia on DNA damage in a 
human endothelial cell line and to detennine if silymarin is able to ameliorate any observed 
changes. 
Objectives 
1. Detennine the effect of hypoxia and! or glucose on the level of DNA damage in an 
endothelial cell line. 
2. Correlate findings with changes in cellular mitochondrial activity and the production 
of reactive oxygen species in response to changing glucose and oxygen 
concentrations. 
3. Detennine the role of antioxidants on the cellular parameters indicated above. 
S4 
CHAPTER TWO: Materials and Methods 
ss 
2.1. Materials 
All chemicals were obtained from Sigma-Aldrich (Poole Dorset, UK) unless otherwise 
stated. 
2.2. Methods 
2.2.1. Human umbilical vein endothelial cell (HUVEC) 
A transformed HUVEC line was purchased from the European Collection of Cell Culture 
(ECACC) and stored in liquid nitrogen. An immortalised cell line differs from a primary cell 
line, as it has acquired the ability to proliferate indefinitely (Chaudry el of. 2004) and serves 
as a model systems for studies of endothelial function, in response to changes in glucose and 
oxygen levels (Zanetti elol. 2001; Fang el 01. 2005). BUVEC are isolated from normal 
human umbilical vein, cryopreserved at the end of primary culture and propagated. Cells 
were used from passage ~ 24 onwards for the duration of the study and showed a consitent 
response to conditions. BUVEC are responsive to cytokine stimulation in the expression of 
cell adhesion molecules. These cell systems are commonly used for physiological and 
pharmacological investigations, such as macromolecule transport, blood coagulation, and 
fibrinolysis (Furie et al. 1988, Wojta et al. 1993). The cells are positive for factor VIII-
related antigen expression and Oil-Ac-LOL uptake. Each batch is tested for HIV, Hepatitis B 
and Hepatitis C as well as mycoplasma. bacteria. yeast, fungi (Personal communication, 
ECACC Technical services). 
2.2.2. HUVEC storage and resucitation 
The cells were resuscitated by incubating the vial in a 37"C water bath under gentle agitation 
for 3 - 4min until completely thawed. The resulting cell suspension (1 ml) was pi petted into a 
25ml Sterilin (Fisher, Loughborough) and 4ml of standard cell culture media containing 
glucose-free Glasgow Minimum Essential Medium x 1 (GMEM), 10% (v/v) foetal calf 
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serum (FCS), L-glutamine (200mM), penicillin (10 000 U/m\) and streptomycin (I Omglml) 
(all supplies obtained from Gibco, Paisley); (this is subsequently referred to as standard 
medium). All media are warmed to 37°C before use. The resulting 5ml cell suspension was 
centrifuged at 4000g for 10min (room temperature) to pellet the cells. The supernatant was 
discarded and the cell pellet re-suspended in Iml GMEM cell culture media (5mM glucose, 
10% (v/v) FCS) before seeding an appropriate volume of the cell suspension in 25cm2, 
75cm2 flasks, 6 well or 96 well plates as required (Coming, Lutherworth). 
2.2.3. Counting of HUVECs 
The HUVEC pellet was re-suspended in J ml of appropriate cell culture media (GMEM). A 
10J.l1 aliquot was removed and added to an Eppendorf tube containing 20J.l1 cell culture 
media and 30J.l1 of 0.4% (v/v) Trypan blue (GlBCO, Paisley). Trypan blue will stain dead or 
dying cells dark blue as their cell membrane is damaged and more permeable to the staining 
solution. The tip of the pipette containing the cell suspension was directed between the glass 
plate and the cover slip of a Neubauer Improved Haemocytometer and the cell suspension 
taken up by capillary action before obtaining a cell count within the defined areas. From the 
cell count the appropriate seeding density for the experimental setup was determined. The 
following seeding densities were used: 0.1 x 1 06/ml for 96 well plates; 0.05x 1 06/ml for 2-well 
chamber slides; 0.1 x 104 cells/ml for 16 well chamber slides and 2x 1 04 cells/gel for the comet 
assay. 
2.2.4. Propagation of HUVECs 
Flasks were placed in the incubator and maintained at 37°C in normoxia (5%COi 200100i 
75% air, subsequently referred to as normoxia) until confluent. Further passage of the cells 
occurred at approximately 80% confluency. The cell culture media was discarded and cells 
washed three times with 5ml HBSS without Ca2+ and Mg2+ (Gibeo, Paisley). Three ml 
trypsin 0.25% (v/v) was added to the flask (25cm2 flasks) and replaced in the incubator for 
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tOmin. HUVECs were lifted by gentle shaking and the suspension decanted into a 25ml 
sterile container. Two ml of 10% (v/v) FCS was added to the cell suspension (2% (v/v» to 
neutralise the action of trypsin before centrifugation at 4000g for tOmin (room temperature). 
The supernatant was poured ofT and the cell pellet re-suspended and seeded into the cell 
culture flask as described above. 
Where further treatment of the cells was required, this was carried out at approximately 70% 
confluence. The cell culture media was discarded and the cells washed three times using 5ml 
of HBSS (GIBCO, Paisley) before the addition of Sml of standard glucose free/ serum free 
(GF/SF) medium. Flasks were returned to the incubator and maintained at 37°C under 
normoxic atmosphere (5%C02/ 20%Oi 75% air) overnight. The following morning, the 
media was taken ofT and cells washed 3 x with HBSS before the addition of standard 
glucose-free GMEM cell culture media, supplemented with either 5mM or 20mM 
filter/sterilised D-glucose. Where appropriate, the cells were supplemented with silymarin 
50~M, silibinin 25~M, taxifolin 600~M, a-lipoic acid t OO~M, and PKCplI/EGFR Inhibitor 
(4,5-bis(4-Fluoroanilino)-phthalimide) 2~M (Calbiochem, Nottingham) and 2-deoxy-d-
glucose (5mMl 20mM), 3-ortho-metyhl-glucose (SmM/ 20mM), PD98059 (2'-Amino-3'. 
methoxyflavone, MEK inhibitor) 1 ~M respectively (Calbiochem, Nottingham). Where 
appropriate, dimethylsulfoxide was used as the solvent at a final concentration of:S 0.7% 
(v/v). Cell culture flasks were then placed in the incubator and maintained at 37°C in 
normoxia (5%COi 20%Oi 75% air) or hypoxia (5%COi 5%Oi 90% air subsequently 
referred to as hypoxia) for time periods specified in the relevant texts. 
2.2.5. Cell proliferation assay 
Cell proliferation was determined using the AlamarBlue™ assay as described by Fields el al. 
(Fields el al. 1993). The assay is based on the chemical reduction of the colorimetric growth 
indicator, AlamarBlue™ (Serotec, Oxford) during cellular metabolism. The extent of the dye 
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reduction is directly proportional to the cell proliferation rate and allows monitoring of cel ls 
over extended periods of time. Cells were seeded into a 96 well plate at a density of 
0.1 x I 06/ml and made up to a total volume of 200~I/per well with the appropriate cell culture 
media alongside the relevant media controls (Fig.2.1). Cells were incubated in standard 
medium in normoxia overnight to allow attachment of the cells before the addition of20fll of 
AlamarBlue™ to each well. A baseline absorbance reading (t = Oh) was taken us ing a FL600 
Microplate Fluorescence Reader (Biotek, Warminster, UK) set at a wavelength of 570nm. 
The plate was then returned to the incubator and analysed for up to 48h. Any alteration to the 
culture conditions is speci fied in the relevant texts. 
GMEM GMEM 5mM 5mM 20mM 20mM 5mM 20mM 
control control Gluco e luco e luco e Gluco c SM SM 
GMEM GMEM 5mM 5mM 20mM 20mM 5mM 20mM 
control control luco e luco e luco e luco e M M 
GMEM GMEM 5mM 5mM 20mM 20mM 5mM 20mM 
control control lucosc luco e luco c lucose M M 
GMEM GMEM 5mM 5mM 20mM 20mM 5mM 20mM 
control control luco e luco e Gluco e luco e M M 
GMEM GMEM 5mM 5mM 20mM 20mM 5mM 20mM 
control control lucosc luco e Gluco e luco c M M 
GMEM GMEM 5mM 5mM 20mM 20rnM 5mM 20rnM 
control ontrol luco e luco c luco c Iu ose SM M 
Fig.2.]: Example of a 96 well plate layout used in an AlamarBlue™ a ay. A parallel plate 
was used to incubate in hypoxia (5%C02/ 5%Oi 90% air). 
2.2.6. Statistical analysis 
All experiments were carried out in triplicate (to assess and control for intra-assay 
variability) and on three separate occasion (unles otherwise stated) to assess variability 
amongst prearations, resulting in an n-value of3. Non-parametric analy is throughout is used 
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to reflect the limitations in sample size as it makes no assumptions about the sample 
distribution. Unlike their parametric equivalents non-prametric tests do not compare the 
means of the sample groups but tests equality of population medians among groups. For 
multiple samples groups a Kruskal-Wallis analysis of ranks is used, which is an extension of 
the Mann-Whitney U test used when two samples are compared. 
For some data sets which show considerable variance in the control group the data was 
normalised to 100% (control) to reflect any consistent changes in the mean of the test group 
compared to control. As the process of normalisation ranks the data, the control group has 
zero variance making the use of a parametric test a more appropriate method of analysis as 
the mean of the test group is compared to 100% (Mean - 100%1 SEM = t( df n-I). At-test 
was carried out for all data of this nature and where multiple sample means were compared 
a One way analysis of variance (ANOVA) was carried out with a post-hoc Tukey's test. 
The level of significance was expressed as ·p<0.05, "p<O.OI, p···<0.005. No significant 
difference was assigned to samples where p>O.05. 
2.3. Resolution orDNA using agarose gel eledrophoresis 
DNA was extracted using a commercially available column-based DNA extraction kit 
(GenElute™ Mammalian Genomic DNA Purification Miniprep Kit GtN-70). Sample DNA 
concentration was determined using spectrophotometric analysis measuring the absorbance 
at 260nm based on the assumption that a DNA concentration of 1 mglml gives an absorption 
of 20. The purity of the DNA was determined by calculation of the ratio at 260/280nm and 
was routinely found to be between approximately 1.8 and 2.1. 
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Agarose gel electrophoresis was established in 1960s (Rapp et al. 1968). It is based on the 
separation of DNA fragments in a porous gel that acts like a filter when exposed to an 
electric current. Linear DNA gives a characteristic DNA banding pattern from which the 
fragmentation extent can be identified and the size of each individual fragment can be 
calculated based on the principle that there is an inverse relationship between the distance 
moved and the size of the DNA fragment in [log bp]. 
To each standardised DNA sample (SOllg), 10JlI of standard loading dye (1S% Ficoll® 400, 
0.03% bromophenol blue and xylene cyanolFF, 0.4% orange G, lOmM Tris-HCI (pH7.S) 
and SOmM EDTA) (New England BioLabs, Ipswich, UK) was added and mixed thoroughly. 
Each sample was loaded into the wells of a 1.2% (w/v) agarose gel (Biological grade) 
(Loughborough, UK) in 1 x TBE buffer (4SmM Tris Base, 44mM Boric acid, 1.3mM EDTA 
(Na salt». The gel contained SOJlg/ml ethidium bromide to visualise DNA fragments after 
electrophoresis. Electrophoresis was carried out at lOOY for I h and DNA fragmentation 
analysed using a UVltec Transilluminator with camera support (Cambridge, UK). DNA 
fragments were sized by comparison with simultaneous resolution of DNA fragments of 
known size (Promega, Southampton) (Table 2.1). 
This long-established method has, with time, evolved into a more sophisticated method, 
namely the single cell gel electrophoresis (SCGE) or comet assay (Singh et al. 1988). This 
method allows the investigation of DNA fragmentation within individual cells embedded on 
agarose covered microscope slides. It is widely used and can be applied to any cell 
population, provided they have been isolated from tissue without degradation (Lovell et al. 
1999). 
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DNAmarken DNAmarken 
50-1000bp 125-2313bp 
Fragment size Number of base Fragment size Number of base 
pairs (bp) pairs (bp) 
1 1000 7 23,130 
2 750 8 9,416 
3 500 9 6,557 
4 300 10 4,361 
5 150 11 2,357 
6 50 12 2,057 
13 564 
14 125 
Table 2.1: DNA markers used for the determination of DNA fragments if size unknown. 
2.4. Comet Assay 
The single cell electrophoresis assay is a sensitive method for detecting DNA strand breaks 
and was first developed by Ostling and Johanson in 1984. As the original protocol only 
allowed the detection of double stranded DNA breaks, Singh el al. modified the protocol 
four years later to include alkaline conditions (pH> 13) (Singh et al. 1988). The comet assay 
enables the supercoiled DNA to relax and unwind, allowing the investigation of DNA 
fragmentation within individual cells through electrophoresis. The DNA of each cell 
migrates through the gel of an agarose covered microscope slide giving a characteristic 
pattern that correlates with the degree of fragmentation. 
HUVECs were cultured as described above (Section 2.2). After 1,6 and 24h incubation the 
cells were trypsinised as previously described. Cells were lifted by adding I ml of standard 
medium, which was gently pipetted to avoid exogenous cell damage. 
62 
A 1 ml cell suspension containing 1 x 1 OS cells/ml was transferred to an Eppendorf tube and 
placed on ice prior to centrifugation at 200g at 4°C for 10min. The supernatant was poured 
off and the cell pellet re-suspended in ice-cold PBS. Cells were washed a further two times. 
A positive DNA damage control sample was prepared using hydrogen peroxide (100J.lM 
H20 2 in phosphate buffered saline; PBS) for Smin. HUVECs (2x104 cells/gel) were 
suspended in 1 % (w/v) low melting point agarose (LMP); (Invitrogen, Paisley) in dH20 
(37°C) and pipetted onto pre-coated (1% (w/v) agarose in dlhO) microscope slides (Fisher, 
Loughburough). Each gel was covered with a cover slip (18x t 8mm, Fisher-Scientific, 
Loughburough). The agarose gels were allowed to set in the fridge for Smin, the cover slips 
were removed and the slides immersed in lysis solution (2.5M NaCI, 0.1 M EDT A, IOmM 
Tris, 10mM NaOH pHIO, 1% (v/v) Triton X-lOO) at 4°C for at least lhr. Cells were washed 
with dlhO after lysis to prevent NaCI residues affecting the electrophoresis conditions. 
Slides were then placed in a 21 Omm wide electrophoresis tank (Thistle Scientific, Glasgow) 
containing cold (4°C) electrophoresis buffer (0.3M NaOH, ImM EDTA) for 40min. 
Electrophoresis was carried out at 21 V for 30min at 4°C. Slides were washed in a 
neutralising solution (0.4M Tris, conc. HCI to pH 7.5) (Fisher-Scientific, Loughburough) for 
5 min (repeated three times) before staining with 20J.ll of 1 J.lg/ml DAPI (4'6-diamidine-2-
phenylindol dihydrochloride) immediately before scoring (22 x 22mm cover slip) (Fisher-
Scientific, Loughburough). Fluorescent nucleoids were scored visually using a Leica DML 
fluorescent microscope. Prior to quantitation the identity of the slides were coded by an 
independent individual and only revealed after the scoring had been completed. One hundred 
comets from each gel (selected at random) were assigned a number between 0 (undamaged) 
and 4 (maximal damage) (Fig. 2.2). The total score for 100 comets could therefore range 
from 0 (all undamaged) to 400 (all maximally damaged) and is expressed as arbitrary units 
(au). 
63 
•' \ ', il' -
. ' 
o 2 3 4 
Fig. 2.2: Illustration of different comet types and visual scoring allocation (Collins el al. 
2004). 
2.4.1 . Statistical analysis 
Each experiment was performed in triplicate and repeated on three separate occasions. The 
test distribution was assumed not to be normal to account for the limitation in ample s ize . 
Statistical s ignificance was determined u ing a Kruskal -Wallis test or Mann-Whitney U test 
against the test hypothes is (Ho) that there are no difference between the mean of the 
samples. Where p< 0.05 the Ho must be rejected and the HA (there i a difference between 
the means of the samples) accepted . Where data wa normali sed (100%) a tudent 's t-test 
(Mean - 100%/ SEM) and/or AN VA (with Tukey' po t-hoc te t) was carried out. The 
leve l of significance is expressed as . p< 0.05, •• p< 0.01 or ••• p< 0.001. No ignificant 
difference was as igned to ample where p > 0.05. 
2.5. Mitochondrial staining 
Fluorescent dyes are widely used to monitor change in mitochondrial function . 
MitoTrackerGreen FM (5J-lM in OM SO) (Molecular Probes, Paisley, UK) is a mitochondrial 
specific green fluorescent dye which allow the locali ation of mitochondria within cells. 
RedoxSensor Red CC- I (1 J-lM in OMSO) (Molecular Probes, Paisley, UK) is a redox 
sensitive red fluorescent dye which allow the detennination of the redox state of the cell. 
Any red fluorescent dye present in the mitochondria indicates the proliferative state of the 
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cell, while accumulation of the dye outside the mitochondria indicates lysosomal staining of 
quiescent cells. 
HUVECs were cultured on round plastic cover slips (40 x 40mm supplied by Intracel, 
Royston) using the method described in Section 2.2. After 24h incubation with the standard 
cell culture medium MitoTracker Green FM and RedoxSensor Red CC-} fluorescent dye(s) 
were added to the medium and the cover slips returned to the incubator for 10min. The 
media was then taken ofT and the cover slips washed three times with PBS to remove any 
excess dye before fitting the cover slips into a flow through chamber (Intracel, Royston) 
which allows the continuous perfusion of BUVECs with the appropriate cell culture 
medium. The medium was perfused at O. I ml/min (37·C) while fluorescent dye(s) 
distribution was determined using a Leica DML fluorescent microscope and Leica QWin 
imaging software. MitoTracker Green FM was imaged using an excitation and emission 
wavelength of 490/S1Snm while RedoxSensor Red CC-l utilised an excitation lemission 
wavelength of 5461590nm filter. A 400x magnification was used throughout. 
For cells grown and analysed in hypoxia, the standard cell culture medium substituted with 
5mM or 20mM filter sterilised D-glucose used with the continuous perfusion systcm was 
bubbled with Nitrogen gas (N2) and its p02 concentration monitored using a p02 meter 
(Strathkelvin Instruments, Model 782, Glasgow). When the p02 concentration had dropped 
to 5%, I mM sodium sulphite anhydrous (Na2S03) was added to induce chemical hypoxia 
and maintain the p02 concentration of 5% throughout the experiment. The pH of the culture 
media was checked using a pH metcr (Mettlet Toledo, Leicter) to ensure that neither the N2 
nor the addition of Na2S03 contributed to a pH change which could influence the results. The 
pH of the cell culture media was recorded to be 7.5 before and after the addition of Na2S03. 
Na2S03 has been shown to induce O2- in human neutrophils within Smin of exposure while 
affecting gene expression without altering any biological processes after long periods of 
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substitution (Labbe et al. 1998). Cells were monitored for any morphological changes for the 
duration of the short-term exposure. 
2.5.2. Ouantitation and Statistical analysis of fluorescence intensity 
Image analysis software (Image] freeware) was used to capture and analyse images obtained 
using MitoTracker Green FM (5J.1M in DMSO) and RedoxSensor Red CC-l (lJ.1M in 
DMSO) fluorescent staining (using Leica QWin software). The background of all pictures 
was subtracted before measuring cell size using the "freehand selection" tool to identify the 
circumference of each individual cell. The output detailed the circumference of the cell 
expressed as number of pixels and the total fluorescence intensity of MitoTracker Green FM 
expressed as mean grey level intensity. The fluorescence intensity of RedoxSensor Red CC-I 
in the same area was measured. Mean cell size values (pixel) were calculated and any values 
above and below two standard deviations (SDev) identified were excluded. In order to 
standardise fluorescence intensity (mean grey level per unit area) for both MitoTracker 
Green FM and RedoxSensor Red CC-l fluorescence, values were adjusted for cell size 
before calculating the mean and standard error of the mean (SEM) for all samples. 
All experiments were carried out in triplicate with a total of 50 cells per sample. Analysis 
was carried out by converting the mean grey level intensity (and pixel) into percentage 
values to illustrate the relative percentage change between samples (inter-sample variation) 
compared to SmM glucose nonnoxia (100%). The test distribution was assumed not to be 
normal to account for the limitations in sample size. Statistical significance was determined 
using a Kruskal-Wallis test or Mann-Whitney U test against the test hypothesis (Ho) that 
there are no differences between the means of the samples. Were p< 0.05 the Ho must be 
rejected and the HA (there is a difference between the means of the samples) accepted. 
Where data was normalised (100%) a Student's t-test (Mean - 100%1 SEM) and/or ANOVA 
with Tukey's post-hoe test was carried out. The level of significance is expressed as .p< 
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0.05, •• p< 0.01 or ••• p< 0.001. No significant difference was assigned to samples where p 
>0.05. 
2.5.3. Co-localisation of fluorescent staining 
Images showing the distribution of MitoTracker Green FM (51lM in OM SO) and 
RedoxSensor Red CC-I (1 f.1M in OM SO) fluorescent dye(s) in identical cells (obtained using 
Leiea QWin software) were superimposed using Image] freeware. Co-localised staining was 
evident as yellow staining and occurs in proliferating cells while accumulation of 
RedoxSensor Red CC-l stain outside the mitochondria accumulates in Iysosomes in 
quiescent cells. To con finn the distribution of both dyes the images were converted to Stacks 
(Image] freeware) and identical cross-sections analysed after subtraction of the background. 
Pixel values obtained for each cross section were nonnalised to 100 pixels which allows both 
sets of values to be superimposed and allows the identification of any shift in RedoxSensor 
Red CC-I staining from mitochondrial to lysosomal. 
2.5.4. Mitochondrial measurement 
Images of HUVECs loaded with MitoTracker Green FM were coded by an independent 
individual and selected at random. A standardised section (6mm length) obtained from a 
400x magnified calibration bar was selected from each picture (at random) and individual 
mitochondria measured using the "freehand line selection" tool in ImageJ freeware. The 
output obtained was given as "length - no of pixel". A total of six cells per sample (selected 
at random) were analysed. The test distribution was assumed not to be nonnal to account for 
the limitations in sample size. Statistical significance was dctennined using a Kruskal-Wallis 
test or Mann-Whitney U test. Where data was nonnalised (100%) a Student's t-test (Mean-
100%1 SEM) and/or ANOV A with Tukey's post-hoc test was carried out. The level of 
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significance is expressed as .p< 0.05, •• p< 0.01 or ".p< 0.001. No significant difference 
was assigned to samples where p> 0.05. 
2.6. Superoxide radical activity measurement 
2.6.1. HUVEC preparation for use with SOD Assay Kit -WST 
Cells (9xl0s) were grown and treated as described in Section 2.2. After 24h incubation with 
standard medium cells were trypsinised (Section 2.2.4), harvested and centrifuged at 2000g 
for 10min at 4°C. The supernatant was discarded and the cells washed four times by adding 
1 ml PBS and centrifuging at 1000g for 10min at 4°C. After removal of the PBS HUVECs 
were broken up using the freeze-thaw method (-20°C for 20min, 37°C for lOmin, repeated x 
2). One ml of PBS was added to the cell pellet and cells centrifuged at 10 OOOg for 1 Smin at 
4°C. The supernatant was carefully taken ofT and 1 O~I of a I mM potassium cyanide (KCN) 
in dH20 solution (Fisher-Scientific, Loughburough) was added to block the cytoplasmic 
fraction of CU/Zn SOD. Twenty III of the resultant supernatant was removed and added to a 
96 well plate. 
A commercially available superoxide radical activity testing kit (SOD Assay Kit -WST, NBS 
Biological, Huntington) was used to measure superoxide radical fonnation. The kit is based 
on the reduction of water-soluble tetrazolium salts (2-( 4-iodophenyl)-3-( 4-nitrophenyl)-S-
(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt) by superoxide radicals resulting in a 
colorimetric reaction. The amount of coloured product fonned is proportional to the amount 
of superoxide radical present (Ukeda et al. 2005). All solutions where made up according to 
kit instructions. A 20~1 volume of the sample solutions and all control solutions were added 
to the 96 well plate in triplicate. This was followed by 200111 of WST working solution (NBS 
Biological, Huntington) and 20J-l1 of enzyme solution (0.1 M xanthine oxidase) and incubated 
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for 20min and kept at 37°C in either normoxia or hypoxia, as previously described. The level 
of activity was determined by measurement of absorbance at 450nm using a FL600 
Microplate reader (Biotek, Warminster, UK). 
2.6.2. Statistical analysis 
The mean absorbance values (n = 3) were converted into a percentage value to illustrate the 
relative change between samples compared to total superoxide radical formation in 5mM 
glucose normoxia (100%) samples. The normalised data was analysed using either a 
Student's t-test (Mean - 1000/01 SEM) and/or ANOV A with Tukey's post-hoc test was 
carried out. The level of significance is expressed as .p< 0.05, "p< 0.0 I or ••• p< 0.001. 
No significant difference was assigned to samples where p > 0.05. 
2.7. Hypoxia inducible fador-la (HIF-la) antisense 
In order to determine the role played by HIF-Ia in the induction of DNA damage, a HlF-
la antisense oligonucleotide probe was used. HUVECs were seeded into a 96 well plate at 
three different concentrations (O.lxIO~, O.SxIO\ O.lx104 cells/ml) and the plate analysed at 
intervals of 24h, 48h and 72h in order to determine the optimal seeding density of HUVECs 
onto 16 well chamber slides and this was used in all subsequent antisense experiments. 
Absorbance values were obtained for three independent samples each with seven replicates. 
HUVECs were prepared as previously outlined and seeded into a 16 well chamber slide 
using standard media. A fluorescently labelled control oligonucleotide (2).IM) (Biognostik<l>, 
Gottingen) was added to the cells for periods of 1, 2, 4, 8, 24 and 48 hour intervals. After the 
incubation was complete, the media was removed and the slides were fixed using 4% 
paraformaldehyde (CH20ln /GMEM for Smin, before dehydrating slides using a graded 
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series of ethanol (C2l-1t,O) (70% - 100%) (Fisher-Scientific, Loughborough). The uptake time 
of the oligonucleotide was identified by detecting the intensity of the fluorescent FlTC 
(4S0/SISnm; excitation/emission) signal using a Leica DML fluorescent microscope. The 
efficacy of HIF-Ia antisense to reduce protein levels in the HUVECs was determined by 
immunocytochemical detection of HIF-Ia protein following the addition of IIIF-
la antisense (2f.1M); (Biognostik~, Gottingen) for 2,8 and 24hours. 
2.7.1. Immunocytochemistry 
Following incubation of HUVECs with HlF-la antisense (2J.1g) for 24h, cells were fixed in 
4% paraformaldehyde for 5 minutes and frozen at _20DC until required for subsequent 
immunocytochemical detection of HIF-Ia protein. Prior to use, the slides were removed 
from the freezer and allowed to thaw at room temperature for 60 minutes. This was followed 
by a further 5 minute incubation in Tris buffered saline pH 7.6 (TBS) (O.OSM tris/HCI. 
O.ISM NaCI Buffer, to I L in dH20). This latter process was repeated twice. A I :200 dilution 
of primary antibody (HIF-Ia); (Affinity Bioreagents, Cambridge, UK) in TBS was added to 
each cell chamber section and left at 4DC overnight. The following morning, the excess liquid 
was removed and the slides washed in TSS for a further 3 x 5 min at room temperature. A 
I :300 dilution of secondary antibody (rabbit a-mouse biotinylated) (ABR, Cambridge, UK) 
was prepared in TBS and added to respective cell samples. Cells were again washed in TBS 
for 10min and this was repeated twice. The StreptABComplex (DAKO Ltd, Cambridgeshire, 
UK) was prepared as recommended by the manufacturer, added to the samples and incubated 
for 30min. The sections were washed in TBS for 3 x 10min followed by the addition of SOIlI 
of substrate (20mM naphtol AS-MX disodium salt, 18mM Fast red, 14mM levamisol) 
prepared in veronal acetate buffer (48mM sodium acetate dehydrate, 8mM Sodium diethyl 
barbiturate, 0.1 M HCL to pH 9.2) for I to 3min. Slides were washed in water to remove any 
non-specific staining. Slides were again washed in dH20, allowed to air dry and mounted in 
70 
aqueous penn anent mounting medium (DAKO Ltd. Cambridgeshire). Analysis of the 
staining intensity and distribution was carried out using a Leica DML light microscope. 
2.S. Reverse Transcriptase - Polymerase chain reaction (RT -peR) 
HUVECs were grown and treated as described in section 2.2. RNA was isolated using 
Qiashredders and the Qiagen RNeasy kit (Qiagen, Crawford, UK) from the cells that had 
previously been incubated under standard conditions and from cells incubated in the 
presence of HIF] a. antisense, as previously described. After 24h incubation. cell culture 
flasks were placed on ice and washed three times using sterile PBS before the addition of 
600J.l1 of RLT lysis buffer (Qiagen, Crawford, UK) containing 10J.ll mercaptoethanol 
(0.1 IlM)/1 mt RL T buffer. The resulting cell lysate was collected using a cell scraper and any 
clumps dispersed by gentle pipetting. All solutions used in the isolation of RNA were treated 
with diethylpyrocarbonate (DEPC) 0.1% prior to use to remove any endogenous RNases. 
A fixed volume of 450J.l1 of the collected cell lysate was added to each Qiashredder column 
(Qiagen, Crawford) and centrifuged for 2min at 8000g to homogenise the lysate. This was 
followed by the addition of 70% ethanol (Fisher-Scientific, Loughborough) to the 
homogenised lysate before transferring 600J,l1 of the homogenate to each RNeasy mini 
column. A further 600J.lI ofRWI buffer was added to the column and centrifuged for 15sec 
at 8000g before transferring the column into a new collection tube. Cells were washed by 
adding 500J,l1 of RPE buffer followed by centrifugation at 8000g for ISsec. After discarding 
the flow through. a further SOOJ,ll of RPE buffer was added to the column and centrifuged at 
8000g for 2min to dry the RNeasy membrane. Again the column was placed into a new 
collection tube and centrifuged at maximum speed for a further 1 min. Finally 30J.ll of RNase-
free water was directly pipetted onto the RNeasy membrane and the column centrifuged for 
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I minute at SOOOg. The purity of the sample was checked by running a 10Jil sample of RNA 
through a 1.2% (w/v) agarose electrophoresis gel. In all samples, ISS and 2SS ribosomal 
RNA (rRNA) bands were evident, with no evidence of RNA degradation. 
2.S.I. RNA Ouantitation 
RNA sample concentration was determined spectophotometrically, assuming that one optical 
density unit is equivalent to 40Jiglml RNA. The purity of the RNA was determined by 
measuring the absorbance at 2S0nm and determining the 260nrnl 280nm ratio. This was 
routinely found to be within the range 1.9 - 2.1. The RNA was further concentrated by the 
addition of 3 times the volume of ice cold ethanol (100%) and sodium acetate at 52mM (pH 
5.2) followed by incubation at -20°C for at least 2h. This was followed by centrifugation at 
8000g for 5min before washing the pellet twice using 70% (v/v) DEPC treatcd ethanol and 
centrifuged at 8000g. The pellet was allowed to air dry before adding 20,.d of RNAse free 
water and the RNA stored at -20°C prior to use. 
2.S.2. Preparation and amplification of cDNA 
To each sample tube (thin walled PCR tube) containing 5J1g of re-precipitated RNA I mglml 
of oligo - deoxythymidine (13mer) (Sigma Genosys, Poole) was added and incubated at 
70°C for 10min. The PCR tubes were placed on ice and all sample droplets around the edge 
of the tube were collected using a pulse-spin. To each tube 4Jil of reaction buffer, 25mM of 
nucleotide mix (Roche. Burges Hill, UK), 0.1 M DTT and 100units of reverse transcriptase 
(Qiagen, Crawley) were added and mixed gcntly. The PCR reaction mixes were incubated at 
room temperature for 10min before placing the PCR tubes in the Thermocycler and 
incubating them at 42°C for 50min followed by 95°C for 5min when the reaction was 
completed. To each tube SOJiI of DEPC treated water was added and samples were stored at -
20°C prior to use. 
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Primer sequences specific for the amplification of HIF-la. were determined using the 
database facilities of the Human Genome Mapping Project and the specificity was 
determined by BLAST search analysis. To 5J.l1 of purified cDNA, 5J.l1 (I OmM concentration) 
of HIF-Ia. primer (Sigma Genosys, Poole) or ~2-Microglobulin primer (Sigma Genosys, 
Poole) (Table 2.2) were added. Samples were placed in the Thermocycler (lcycle, 94.5oC, 
2min; 33cycles, 55°C, Imin; lcycle, noc, 2min). The samples were stored at -20°C prior to 
resolution using agarose gel electrophoresis if not used immediately. 
Primer Sequence Product size (bp) 
HIF-la. 5'TGCTTCACTCATCCCATTCA3' 385 
3' TTTTGCTCTTTGTGGTTGGA S' 
(32-Microglobulin 5' CCTTGAGGCTATCCAGCGTACTCC 3' 321 
5'CCATGATGCTGCTTACATGTCTC3' 
Table 2.2: DNA sequences of oligonucleotide PCR primers. 
A 1.2% (w/v) ultrapure agarose (Biological Grade Agarose) gel in 1 x TBE buffer was 
prepared. Ethidium bromide (50~g) was added to the resulting solution to visualise DNA 
fragments in the gel. Loading dye (2.5~I) and dlhO (5J.lI) was added to each 5J.l1 sample of 
amplified cDNA and loaded into the wells. DNA fragments of known size (Promega, 
Southampton, UK) were added as reference markers which act as controls allowing the size 
determination of amplified DNA fragments (Table 2.1). Electrophoresis was carried out at 
IOOV for Ihr. Following amplification the size of the resulting fragments was determined by 
comparison with the known standards. The specificity of the amplification was subsequently 
confirmed by sequencing (Aberdeen University Sequencing Unit) and shown to be > 98% 
homologous with predicted sequence (Wang el al. 1995). 
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2.9. Capillary Zone Electrophoresis 
2.9.1. Apparatus 
Capillary electropherograms were obtained usmg a Hewlett-Packard 3D capillary 
electrophoresis system (Waldborn, Germany). Electrophoresis and sweeping experiments 
were performed in fused silica capillaries 50Jlm x 65cm obtained from Composite Metal 
Services (I1keley, UK). The detection wavelength was set at 200 and 280nm. 
2.9.2. Sample preparation 
Stock solutions of 400mM sodium dodecyl sulphate (SOS) «BOil, Poole) and 250mM di-
sodium hydrogen phosphate (OSHP), pH 2; (Fisher Scientific, Loughborough) were made up 
in water and diluted as required for the preparation of running buffer. The running butTer 
was prepared by diluting 2.0 ml of SDS and 2ml of DSHP with 2.5ml of HPLC grade 
methanol (0.1 M) (Fisher Scientific, Loughborough) and making up to a final volume of 
10m!' Stock solutions of silymarin, taxifolin and silibinin (I M) were made up in HPLC 
grade methanol and further diluted in 50mM DSHP to give secondary stock solutions of 1:25 
silymarin, 1:25 silibinin and 1:625 taxifolin. 
2.9.3. Capillary electrophoresis procedure 
Prior to each analysis, the capillary was flushed with 0.1 M sodium hydroxide for 2min 
followed by the running buffer (80mM SOS; 50mM DSHP; 25% Methanol) for 3min. The 
sample was then injected for 300 seconds using pressure (50mbar) and a voltage of 30kV 
was applied until all peaks were separated (30min). Calculation of individual components 
could then be determined using the area under the curve (AVC). 
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CHAPTER THREE: Effect of glucose concentration and 
oxygen tension on DNA integrity in human umbilical vein 
endothelial cells 
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3.1. Hypothesis 
Changes in glucose concentration and oxygen tension have an effect on the DNA integrity of 
human umbilical vein endothelial cells. 
3.2. Introduction 
Oxidative stress plays a significant role in the development of diabetic complications with 
ROS-related DNA damage levels elevated in both type 1 and 2 diabetic patients (Dandona el 
al. 1999). It has been shown that high glucose (20mM) prolongs cell cycle traversal in 
cultured human macrovascular endothelial cells (Lorenzi el al. 1987), which is important 
when investigating the contribution of high blood glucose levels in the development of 
vascular complications. Changes in cellular oxygen tension also have to be taken into 
account. Aerobic life is dependent on molecular oxygen for ATP generation and cell 
viability (Michiels el al. 2002), but the range at which optimal oxygen tension is achieved is 
very narrow. An increase in oxygen tension leads to a simultaneous increase in ROS and 
increased DNA damage, while a reduction in cellular oxygen tension impairs energy 
availability, thereby impacting on cell viability (Michiels et al. 2002). Until recently, both 
events (hyperglycaemia and hypoxia) have been investigated as separate mechanisms in the 
pathogenesis of diabetes mellitus. 
If we are to fully understand the processes which lead to the development of these 
detrimental vascular changes, we need to take both factors into consideration. This notion 
supported by two recent publications confirms that both hypoxia and hyperglycaemia are 
two separate events which could have a potentially additive effect on the molecular changes 
in microvascular endothelial cells (Catrina et al. 2004, Nyengaard et al. 2004). 
Thus, the effect hypoxia and hyperglycaemia on cell proliferation and endothelial DNA 
damage over a 24h period were examined. 
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3.3. Materials and Methods 
The effect of glucose concentration and oxygen tension on cell growth was determined using 
the Alamar blue proliferation assay (Fields el 01. 1993) (Section 2.2.5). Any effect of these 
conditions on DNA integrity was determined using agarose gel electrophoresis (Section 2.3) 
and the comet assay (Section 2.4). HUVECs challenged with equimolar concentrations of 
glucose and mannitol (latter used to control for changes in osmolarity) for 24h were cultured 
as described in Section 2.2.4 and their DNA extracted as described in section 2.3. A further 
challenge of HUVECs with ImM 1120 2 for 24h was included as positive control. This high 
concentration of 1120 2 was used to induce maximal DNA damage (Astley el al. 1999; 
Lockett el 01. 2006). Comet scores are expressed as arbitary units (au) unless otherwise 
stated. 
Each experiment was performed in triplicate with three internal replicas per sample. The test 
distribution was assumed not to be normal to account for the limitations in sample size. 
Statistical significance was determined using a Kruskal-Wallis test or Mann-Whitney U test 
against the test hypothesis (Ho) that there are no differences between the means of the 
samples. Were p< 0.05 the Ho must be rejected and the Ih (there is a difference between the 
means of the samples) accepted. Where data was normalised (100%) a Student' s t-test was 
used (Mean - 1000/01 SEM). The level of significance is expressed as .p< 0.05, "p< 0.01 or 
••• p< 0.00 I. No significant difference was assigned to samples where p > 0.05. 
3.4. Results 
3.4. t. Effect of glucose concentration and oxygen tension of HUVEC proliferation 
The effect of glucose concentration and oxygen tension on HUVEC proliferation was 
determined over a period of 24h. The rate of cell growth was significantly increased in the 
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presence of high glucose concentration (20mM; 0.30 ± 0.006) when compared to growth in 
5mM (0.20 ± 0.007) (p=0.004) and further increased with a reduction in oxygen tension 
(20mM H) (0.40 ± 0.007) (p=0.003) (Fig.3.1) when compared to respective glucose controls. 
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Fig 3.1: Effect of 5mM & 20mM glucose, normoxia and hypoxia on cell proliferation of 
human umbilical vein endothelial cells as determined by Alamar blue assay after 24h. 
Significance of conditions on cell growth was determined using a Kruskal-Wallis test and 
level of significance at p < 0.00 I is denoted •••. 
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3.4.2. Effect of glucose concentration and oxygen tension on DNA integrity 
DNA was extracted and purified from HUVECs and 50J,lg resolved by agarose gel 
electrophoresis. From visual inspection, there was no evidence of DNA degradation in 
normoxia (Fig.3.2a), while DNA damage was evident in HUVECs cultured in 20mM 
glucose in hypoxia for 24h as shown by intense fluorescence in regions of gel corresponding 
to < SOObp (Fig.3.2b). Samples incubated with equimolar concentrations of mannitol show 
no comparable DNA damage. 
The comet assay was used to examine in more detail the effect of glucose concentration and 
oxygen tension on DNA fragmentation. Blinded analysis showed that IIUVECs exposed to 
ImM Ih02 presented with a high score in the comet assay (343 ± 9) which were 
significantly higher than the control (37 ± 9) (p < 0.00 I) (FigJJb). FigJJa illustrates 
comets representative of this score. 1120 2 treatment was used as a positive control and 
incorporated in every subsequent experiment. The positive control routinely showed high 
levels of DNA damage (p > 0.05). The data presented is representative of three separate 
experiments with difference between experimental means of 5.4 (au). 
DNA damage that may be attributed to the processing of the cells was determined using 
DNA purified from cells prior to incubation and is subsequently referred to as t = Oh. There 
was no significant increase in DNA fragmentation between cells at t = Oh and cells incubated 
in SmM glucose normoxia for 24h. Hypoxic conditions increased DNA damage levels 
significantly when compared both to t = Oh (45 ± 3.6) (p = 0.003) and normoxia (70 ± 5) 
(p=0.OO4) at an equivalent time period (Fig.3.4). DNA damage values stayed below a total 
score of 100 (au) indicating minimal overall DNA damage. Inter-sample variation was small 
(t = Oh: 60±2.9; t=24h N: S9±3.7; t=24h H: 84± 5.4). 
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Fig. 3.2: Agarose gel showing DNA isolated from HUVECs exposed to a range of glucose 
concentrations and oxygen tension. The DNA was visualised using UV light. From left to 
right (a) Normoxia (5%COi 20%02/ 90% air): 1. DNA marker 125-2313bp, 2. t = Oh, 3. 
5mM glucose, 4. 20mM glucose,S. SmM mannitol, 6. 20mM mannitol, 7. DNA marker 50-
1000bp. (b) Hypoxia (5%C02/ S%Oi 90% air): 1. DNA marker one 125-2313bp, 2. t = Oh, 
3. 20mM mannitol, 4. 5mM mannitol,S. 20mM glucose, 6. 5mM glucose, 7. DNA marker 
two 50-1000. 
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Fig 3.3: Effect of H20 2 (lmM) on HUVEC DNA damage using the comet assay. (a) 
Illustration of representative comets for minimal and near to maximal DNA damage as seen 
with the positive control using the comet assay. (b) quantitative analysis of the DNA damage 
induced by H20 2 cells. The results are expressed as mean ± SEM from three separate 
experiments (n = 3) (Mann-Whitney U test: **.p < 0.001). 
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Fig. 3.4: DNA damage in HUVECs for 24h. Cells were cultured in 5mM glucose normoxia 
or hypoxia for 24h and analysed using the comet assay. The results are expressed as mean ± 
SEM from three separate experiments (n = 3) (Kruskall-Wallis test: "p < 0.01). 
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A change in DNA integrity was detennined in response to high glucose and low oxygen 
culture conditions for 24h. High glucose concentration (20mM) significantly increased DNA 
damage in HUVECs (119±7) when compared to 5mM glucose in nonnoxia (70±5) (p<O.OOl) 
(Fig.3.5). Furthennore, cells incubated in high glucose conditions (20mM) in hypoxia 
showed a further significant increase in DNA damage when compared to nonnoxia (237±15) 
(p < 0.001). The greatest increase in DNA damage can be seen in cells incubated in both 
high glucose (20mM) and low oxygen tension suggesting an additive effect of DNA damage 
by these conditions (237±15) (p < 0.001). 
To identify the effect of time on the observed DNA damage DNA integrity was analysed 
after 24h & 48h in cells incubated in hyperglycaemic conditions (20mM). There was a 
significant increase in DNA damage both in cells incubated in nonnoxic (166±2) as well as 
hypoxic (200±1) conditions after 48h when compared to 24h (p < 0.001) (Fig.3.6). Further, 
the effect of re-oxygenation on cells exposed to hypoxic conditions for 24h was detennined 
by incubating the cells in nonnoxic conditions for a further 24h (199±9) (p < 0.001). The 
DNA damage observed was not significantly different from the level of DNA damage found 
in HUVECs exposed to hypoxic conditions for a total of 48 h. 
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Fig. 3.5: DNA damage in HUVECs due to glucose concentration (5mM & 20mM) and! or 
oxygen tension (N = normoxia and H = hypoxia) as determined by the comet assay. The 
results are expressed as mean ± SEM from three separate experiments (n = 3) (Kruskal-
Wallis test: ".p < 0.001). 
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Fig. 3.6: Effect of incubation time and re-oxygenation (N = normoxia and H = hypoxia) on 
HUVEC DNA damage. Cells were stepped down overnight in glucose free/serum free media 
prior to incubation and DNA damage is determined by the comet assay. The change in DNA 
damage is expressed relative to control (20N = 100%). The results are expressed as mean ± 
SEM from three separate experiments (n = 3) (Student's t-test: .... ·p<O.OOl). 
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To determine the significance and the specificity of glucose mediated DNA damage, 
HUVECs were treated with equimolar concentrations of mannitol (SmM & 20mM) and 
compared to glucose treated HUVECs (Table 3.1). HUVECs treated with 20mM glucose 
showed a significant increase in (%) DNA damage when compared to SmM glucose 
(Normoxia: p < 0.01; Hypoxia: p < 0.001) confirming earlier observations (Fig. 3.S). The 
DNA damage score seen in HUVECs induced with equimolar concentrations of mannitol is a 
lot higher throughout (88±4.98) when compared to samples treated with glucose (40±0.99). 
When adjusted for baseline (SN = 100%) however, there is no significant change between 
mannitol treated samples (Kruskal-Wallis test: p> O.OS). 
5mM 20mM 5mM 20mM 
Normoxia Normoxia Hypoxia Hypoxia 
Glucose 
Mean± SEM 40± 0.99 53 ± 4.38 55 ± 2.89 83 ± 5.03 
(+ 33%) (+ 37%) (+ 108%) 
Mannitol 
Mean± SEM 88 ± 4.98 94± 3.67 87 ± S.63 107 ± S.48 
(+7%) (+9%) (+ 22%) 
Negative 39± 3 Positive 379 ± 1 
control control 
Table 3.1: DNA damage induced by equal concentrations of mannitol & glucose (SmM & 
20mM) on HUVECs, as determined by the comet assay. The relative percentage difference is 
compared to each SmM glucose or SmM mannitol sample incubated in normoxia (100%). 
The results are expressed as mean ± SEM from three separate experiments (n = 3). 
89 
3.S. Discussion 
The analysis of DNA integrity and proliferation of HUVECs in response to glucose 
concentration and oxygen tension in an established cell culture model has yielded significant 
findings. Results demonstrated that both high glucose and low oxygen significantly increases 
HUVEC proliferation. Accelerated endothelial cell proliferation in response to hypoxia is 
well established in the literature since it is a characteristic feature of tumour cell growth. 
Increasing tumour mass results in progressively more nutrient deprived and hypoxic areas 
(Scheurer et al. 2004). In order to improve oxygen tension a number of adaptive responses 
are triggered including the activation and translocation of the transcription factor hypoxia 
inducible factor (HIF-I). HIF-I increases vascular endothelial growth factor (VEGF) 
transcription, which results in new vessel growth and accelerated cell proliferation (Zgouras 
el al. 2003). 
Accelerated proliferation rates in response to 20mM glucose, however, is not consistent with 
other observations (Curcio et al. 1992; Varma et al. 2005). Most studies report a reduction in 
primary HUVEC proliferation rate over time when treated with glucose (Varma et al. 2005). 
This is believed to be due to the pro-apoptotic effects of glucose resulting from oxidative 
stress-regulated signalling pathways (Buttke et al. 1994; Vaux et al. 1996). Involvement of 
ROS in the induction of apoptosis by high glucose has been demonstrated in cultured human 
endothelial cells (Du et al. 1999). More recently, it was shown that high glucose 
concentration, induces NF-kappaB-related up-regulation of COX-2 via PI3K1Akt signalling, 
which in tum triggers caspase-3 activity that facilitates HUVEC apoptosis and reduced cell 
proliferation (Sheu et al. 2005). Most studies however, use primary isolates of HUVECs or 
excessive concentrations of glucose (up to 40mM) (Varma el al. 2005) it is therefore difficult 
to establish a direct comparison to our results. 
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The combination of high glucose and low oxygen concentration induced the most significant 
increase in HUVEC proliferation rate. The effect of simultaneous exposure of 
hyperglycaemia and hypoxia on HIF-Ia protein stability in primary dermal fibroblasts and 
endothelial cells has been reported (Catrina et al. 2004). They suggest that hyperglycaemia 
abolishes the hypoxia afforded protection of the HIF-Ia subunit against proteasomal 
degradation. This may effect a loss of HIF-Ia, and subsequent HIFI activity leading to a 
reduction in cell proliferation rate due to the loss in VEGF expression. However, this is not 
supported by the current data. Furthermore, since cellular proliferation rates seem to be 
closely linked to the production of ROS and apoptosis, the determination of cellular DNA 
damage and repair has also been of great interest (Chai et al. 2000). Several studies looking 
at DNA damage in diabetes mellitus have reported an increase in DNA damage in both type 
1 and type 2 diabetes patients (Dandona et al. 1996). 
In our agarose gel electrophoresis results the effect of high glucose (20mM) or low oxygen 
tension in HUVECs for 24h failed to show any DNA fragmentation (Fig. 3.2 and Fig. 3.5), 
while the combined effects of high glucose concentration and low oxygen tension showed 
significant evidence of DNA degradation (Fig. 3.2 and Fig. 3.5). Since agarose gel 
electrophoresis requires the cumulative extract of cultured cellular DNA there are many 
possible explanations for the lack of fragmentation observed with glucose alone. Given the 
very short time frame in which the HUVECs were exposed to the detrimental conditions it is 
most likely that the level of DNA damage inflicted is too small to be measurable by agarose 
gel electrophoresis. A more sensitive method of analysis such as the single cell gel 
electrophoresis assay is required to determine the extent of DNA damage inflicted. 
An increase in BUVEC DNA damage using the comet asay has previously been reported 
after five days exposure to 45mM glucose supplemented culture medium (Shimoi et al. 
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2001) but no-one has reported damage in the combined conditions of hypoxia and 
hyperglycaemia over a 24hour period. 
Although hyperglycaemia and hypoxia are known to cause cell damage (Shimoi et 01. 2001), 
little has been reported about the combined and acute effect of both these conditions on 
endothelial cells. One of the earliest studies carried out in HUVECs reported that 
hyperglycaemia induced apoptosis after 72h chronic exposure to 30mM glucose 
(Baumgartner-Prazer et 01. 1995). This was supported by further work which reported a rapid 
rise in ROS after only 2-6h exposure of HUVECs to 30mM glucose concentrations (Du et 01. 
1999). Furthennore, hypoxia induced a significant increase in DNA damage which appears 
to be independent to that of glucose. Although the effect of hypoxia and its highly developed 
adaptive responses in endothelial cells has been well documented for CV disease (Giordano 
et 01. 2005; Verrier et 01. 1996) and cancer (Fuks et 01. 2005), the consequences of hypoxia 
on the development of diabetic vascular complications has been less well investigated. 
One possible indication of the mechanisms involved lies in the observation that the DNA 
damaging effects of glucose and hypoxia seem to be additive (Fig. 3.S).1t is documented that 
glucose induces a state of "pseudohypoxia" due to its effect on NO and the free cytosolic 
NADHlNAD+ ratio (Williamson et 01. 1993). The known additive effects of high glucose 
and low oxygen concentrations can be rationalised as cytosolic NADH levels are increased 
by both hypoxia and hyperglycaemia-mediated pathways via different yet additive 
mechanisms (Nyengaard et 01. 2004). Since the net energy charge of the cytosol seems to be 
an indicator of a cells commitment for further proliferation, the observed increase in cell 
proliferation rate seem to be in line with this hypothesis (Breiter-Hahn et 01. 1998). 
To add an even more interesting dimension to these results, Fig. 3.6 shows that the DNA 
damage inflicted within the first 24h is not reversed by subjecting cells to an equal time 
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period of re-oxygenation. There appears to be a steady increase in DNA damage over time 
an observation which is of immense importance with respect to the cumulative damage 
inflicted on endothelial cells in hyperglycaemic orland hypoxic conditions. 
3.6. Limitations of the study 
As mentioned before comparison of the current data to most published research in the area is 
limited by the fact that this study uses an established HUVEe line. The use of a cell line is a 
well established model system for preliminary studies of endothelial function in response to 
changes in glucose and oxygen levels (Zanetti et 01. 2001; Nachman et a1. 2004; Fang et 01. 
2005) often providing important infonnation to justify the progression of the research to a 
primary cell model or an in vivo setting. A cell line can be distinguished from primary cells 
in that they possess the ability to proliferate indefinitely. This allows their use to much 
higher passage numbers but is arguably limited by the use of cultured clones. The use of 
endothelial cells in culture, whether primary or a cell line, are not likely to be entirely 
reflective of the processes which occur in the tissues as they lack the interaction with other 
tissue factors, a limitation avoided by the use of an in vivo model (Bricknell, 2004). 
However, the data provides important preliminary infonnation on which to base further 
studies to elucidate the processes involved. 
A further limitation is the experimental definition of hypoxia and nonnoxia when using vein 
endothelial cells. Nonnal oxygen pressure in human umbilical vein blood is 3.2% to 5.1 % O2 
(ie, pOz=22 to 35 mm Hg) (Casanello el 01.2005), therefore the use of 5%02 in hypoxia and 
20% in nonnoxia is not entirely reflective of the physiological conditions but it does provide 
a stable system for the investigation of the effect of reduced oxygen availability and 
facilitates the investigation of the mechanisms underlying this phenomenon. Stable oxygen 
levels below 5% are notoriously difficult to achieve with the equipment used and although 
true hypoxia is not achieved the use of 5%02 is widely established in the literature (Namiki 
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et al. 1995; Buras et al. 2000) and it is the response to the relative reduction of oxygen 
tension that is of interest in this study. 
3.7. Conclusion 
In conclusion, we can state that both glucose and oxygen exhibit distinct yet potentially 
additive effects on endothelial cells which results in an increase in cell proliferation, DNA 
damage a nd possibly DNA repair mechanisms over a 24hour period. The generation of 
oxidative stress in response to hyperglycaemia and the expression of potential hypoxia 
dependent mechanisms such as the expression ofHIF-1 are now investigated to facilitate our 
understanding of these events. 
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CHAPTER FOUR: Role of mitochondrial ROS production 
in hypoxia- and hyperglycaemia-induced endothelial DNA 
damage 
95 
4.1. Hypothesis 
Mitochondrial ROS production, playa role in hypoxia- and hyperglycaemia-induced 
endothelial DNA damage. 
4.2. Introduction 
A change in mitochondrial regulation, such as increased ROS production and mitochondrial 
DNA damage, has been shown to contribute to disease and ageing (Kang et al. 2005). 
Mitochondria are therefore fast emerging as a selective target for distinct therapeutic 
approaches (Armstrong el al. 2006). The first association of a defect in oxidative 
phosphorylation with diabetes was made as far back as 1959 by Bierman et al. Since then, a 
multitude of signalling pathways have been identified which all contribute to the excessive 
ROS production by the mitochondria during hyperglycaemia and more recently, hypoxia 
(Nyengaard et al. 2004). More recently, it has been suggested that mitochondrial superoxide 
production is the missing link between diabetic hyperglycaemia and the activation of a 
number of biochemical pathways known to be involved in the pathogenesis of diabetes such 
as PKC, AGE and the Polyol pathway (Nishikawa et al. 2003). Furthermore, damaged 
mtDNA amplifies oxidative stress by reducing the expression of certain proteins critical for 
electron transport and mitochondrial regulation. This initiates a cycle of ROS production and 
mitochondrial dysregulation which eventually triggers apoptosis and vascular damage (van 
Houten et al. 2006). 
The events associated with the increased DNA damage seen in Chapter Three will be further 
elucidated. The effect that hypoxia and/or hyperglycaemia have on mitochondrial number, 
morphology as well as on ROS production in human umbilical vein endothelial cells is 
determined. 
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4.3. Materials and Methods 
The effect of glucose concentration and oxygen tension on HUVEC size was determined 
using specialised imaging software (Section 2.5). The effects of increased glucose 
concentration and/or decreased oxygen tension on mitochondrial number and morphology 
were determined using MitoTracker Green FM fluorescent dye (Section 2.5) which was co-
localised with the fluorescent dye RedoxSensor Red CC-l to determine the cellular redox 
potential. The resulting images were analysed using ImageJ software. The cellular 
production of superoxide radical formation was also measured using a commercially 
available kit (Section 2.6). HUVECs challenged with glucose and oxygen for 24h were 
cultured as described in Section 2.2 and mitochondria were visualised as described in 
Section 2.5.1. 
Each experiment was performed in triplicate and repeated on three separate occasions. The 
test distribution was assumed not to be normal to account for the limitations in sample size. 
Statistical significance was determined using a Kruskal-Wallis test or Mann-Whitney U test 
against the test hypothesis (Ho) that there are no differences between the means of the 
samples. Where p< 0.05 the Ho must be rejected and the HA (there is a difference between 
the means of the samples) accepted. Where data was normalised (100%) a Student's t-test 
(Mean - 100%/ SEM) and/or ANOV A (with Tukey's post-hoc test) was carried out. The 
level of significance is expressed as .p< 0.05, "p< 0.01 or ••• p< 0.001. No significant 
difference was assigned to samples where p > 0.05. 
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4.4. Results 
4.4.1. Co-localisation ofROS production with mitochondria 
Co-localisation and cross-sectional distribution of both MitoTracker Green FM and 
RedoxSensor Red CC- I was carried out to verify the specificity of the RedoxSensor Red 
CC-l fluorescent stain for the mitochondria (Fig. 4. I). Co-localisation of both dyes occurs in 
proliferating cells while the accumulation of RedoxSensor Red CC-l stain (a redox sensitive 
dye) outside the mitochondria accumulates in Iysosomes, indicative of contact inhibited cells 
(Shukla et of. 2003). 
4.4.2. Identification ofROS production from HUVEC mitochondria 
To determine if the cellular ROS production is directly associated with the mitochondria, 
HUVECs were perfused with the protonophore carbonyl cyanide 
p-(trifluoromethoxy)phenylhydrazone (FCCP) (I J.1M) (Fig. 4.2). The FCCP collapses the 
membrane potential (Aronis et 01. 2002). This shows that the ability of the cell to take up the 
oxidised CC-l product requires an intact membrane potential. Changes in the intensity of the 
RedoxSensor Red CC-l fluorescence dye were visualised and measured using ImageJ 
freeware (Fig.4.3). Statistical analysis using a Mann-Whitney U test shows a significant 
reduction in fluorescence intensity in HUVECs perfused with FCCP (1.S3±0.01) compared 
to untreated cells (S. 74±0.12), (p < 0.001). 
4.4.3. Changes in HUVEC size in response to glucose and oxygen 
In order to investigate if glucose concentration and oxygen tension has an effect on cell 
morphology such as size and appearance, any potential changes in HUVEC size over time 
(6h & 24h) were determined using ImageJ freeware. This will help with the interpretation of 
any results (such as mitochondrial numbers and cellular ROS production) gathered in this 
context. 
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Changes in cell size were detennined relative to control and expressed as a percentage of 
control (t = Oh) (Fig.4.4). Neither glucose (5mM & 20mM) nor oxygen concentration had 
any significant effect on HUVEC size in cells incubated for 6h (SN: I02±6; 20N: I08±1; SH: 
116±8; 20H: 110±7) and 24h (SN: 10S±0; 20N: 108±4; SH: 104±3; 20H: 111±S). These 
values were obtained using a Student's t-test in which changes in cell size were detennined 
relative to control (t = Oh) at 6h and 24h. A calculation of the level of significance comparing 
samples with each other was carried out using an ANOV A plus Tukey's post-hoc test also 
failed to highlight any significant differences between samples (p > 0.05). 
4.4.4. Changes in MitoTracker Green FM and RedoxSensor Red CC-l fluorescence intensity 
in response to glucose and oxygen 
Changes in both MitoTracker Green FM and RedoxSensor Red CC-l fluorescence intensity 
were detennined using ImageJ freeware. The percentage change in fluorescence intensity for 
both markers was detennined relative to control (t = Oh 100%). Statistical analysis using a 
Student's t-test analysing the percentage changes in MitoTracker Green FM fluorescence 
intensity relative to control (t = Oh) showed neither glucose (SmM & 20mM) nor oxygen 
concentration (nonnoxia and hypoxia) to have a significant effect on MitoTracker Green FM 
fluorescence intensity after 6h (5N: 102±13; 20N: 122±37; SH: 139±30; 20H: 108±12) or 
24h (SN:114±33; 20N: 111±19; 5H: 81±16; 20H: 105±6) (p > 0.05) (Fig. 4.5). Additional 
analysis of the significance for each individual experiment was carried out using an ANOVA 
with a post-hoc Tukey's test to confinn that there was no significant change in MitoTracker 
Green FM fluorescence intensity at either time point (p > 0.05). 
RedoxSensor Red CC-l fluorescence intensity in HUVECs was analysed in an identical 
manner. There was a significant reduction in fluorescence intensity in HUVECs which had 
been incubated for 24h (SN: 133±56; 20N: 128±37; SH: 141±21; 20H: 141±14) compared to 
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6h (5N: 337±26; 20N:427±46; 5H: 349±12; 20H: 450±63) (p < 0.05) in varying glucose 
(5mM & 20mM) and oxygen conditions (nonnoxia & hypoxia) when compared to control 
(Fig. 4.6). A Student's t-test, confinned these findings (p :s 0.05). 
100 
a 
(a) 
50 
-
45 
:I 
~ 40 '-" 
~ 
- 35 
'" C 
~ 30 c 
~ 25 
<J 
c 20 CIJ 
<J 
'" ~ 15 ... 
0 
:I 10 r;:: 
5 
0 
I 
, 
I 
' , 
b c 
I 1I'IT 'r" 
9 17 25 33 41 49 57 65 73 81 89 97 
Pixe l 
101 
-+-- MT 
• CC- I 
(b) 
50 
45 i 
"" • 
40 
~ 
:::: 
..:;. 35 
~ -MT 
'" 
30 c 
~ 
c 25 
• ((- I 
... 
<.J 20 c 
... 
<.J 
'" 15 ... 
I-
0 
:::: 10 !;: 
5 
0 
6 II 16 21 26 31 36 41 46 51 56 61 66 71 76 81 86 91 96 
Pixel 
(c) 
60 
S- 50 J. ,e, 
.£ 40 
'" c 
... 
.5 30 
... 
-M-I' 
" c 
... 
" 20 '" ... • CC- I 
I-
0 
:::: 
!;: 10 
0 
6 II 16 21 26 31 36 41 46 51 56 61 66 71 76 81 86 91 96 
Pixel 
Fig. 4.1 : Examples of co-localisation staining and cross-sectional distribution of both 
MitoTracker Green FM (5IlM) stain and RedoxSensor Red CC- l (111M) stain in a human 
umbilical vein endothelial cell line (Magnification: 400x). 
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Fig. 4.2: Images showing the relationship between the ability of the mitochondria to take up 
oxidised CC-l product and its membrane potential (400x Magnification). 1) MitoTracker 
Green FM dye (5J.lM); 2) RedoxSensor Red CC-l (IJ.lM); 3) RedoxSensor Red CC-I 
fluorescence after collapsing the membrane potential using carbonyl cyanide 
p-(trifluoromethoxy)phenylhydrazone (I J.lM). Samples analysed from left to right: (a) 5mM 
glucose Normoxia; (b) 20mM glucose Normoxia; (c) 5mM glucose Hypoxia; (d) 20mM 
glucose Hypoxia. The images are representative of samples from three different experiments 
(n = 3). 
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Fig. 4.3: Effect of the protonophore carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone 
(FCCP) (1 /lM) on RedoxSensor Red CC-I (I /lM) fluorescence intensity in HUVECs. The 
change in fluorescence intensity was analysed using a Leica DML fluorecent microscope and 
ImageJ freeware. The results are expressed as mean ± SEM from three separate experiments 
(n = 3 total of 150 HUVECs) (Mann-Whitney U test: ••• p < 0.001). 
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Fig. 4.4: Determination of the effect of time. glucose (5mM & 20mM) and oxygen 
concentration (N = normoxia. H = hypoxia) on size of human umbilical vein endothelial 
cells. The change in cell size is expressed relative to control (t = Oh 100%). The graph is 
representative of the mean ± SEM of three separate experiments (n = 3) with 50 observations 
per sample (ANOV A plus post hoc Tukey's test: p> 0.05). 
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Fig. 4.5: Effect of time, glucose (5mM & 20mM) and oxygen concentration (N = normoxia 
and H = hypoxia) on MitoTracker Green FM fluorescence intensity in human umbilical vein 
endothelial cells. The change in fluorescence intensity is expressed relative to control (t = Oh 
100%). The graph is representative of the mean ± SEM of three separate experiments (n = 3) 
with 50 observations per sample (AN OVA plus post hoc Tukey's test: p> 0.05). 
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Fig. 4.6: Effect of time, glucose (5mM & 20mM) and oxygen concentration (N = normoxia 
and H = hypoxia) on RedoxSensor Red CC-l fluorescence intensity in human umbilical vein 
endothelial cells. The change in fluorescence intensity is expressed relative to control (t = Oh 
100%). The graph is representative of the mean ± SEM of three separate experiments (n = 3) 
with 50 observations per sample (ANOVA plus post hoc Tukey's test: *p < 0.05; up < 
0.01). 
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4.4.5. Morphological changes of mitochondria in response to glucose and oxygen 
In a blinded analysis the effect of glucose (5mM & 20mM) and oxygen (nonnoxia and 
hypoxia) on mitochondrial morphology in HUVECs over time (6h & 24h) was assessed. 
Adaptive stress responses lead to changes in mitochondrial morphology (Fig. 4.7) and are 
indicative of cellular response mechanisms. A quantitative analysis of the mitochondrial 
length (Fig. 4.8) showed no significant changes in mitochondrial length between samples 
over time compared to control (6h - 5N:27±3; 20N: 37±5; 5H: 35±8; 20H: 52±8 & 24h -
5N: 35±5; 20N: 42±8; 5H: 36±10; 20H: 38±8) (p > 0.05). In addition no consistent changes 
in mitochondrial morphology with a change in culture conditions could be observed (Fig.4.7) 
4.4.6. Superoxide radical production in response to glucose and oxygen 
Using a commercially available kit, the total cellular superoxide radical production in 
response to 5mM and 20mM glucose as well as nonnoxic and hypoxic conditions was 
detennined. The percentage proportion of superoxide radicals found in mitochondria and the 
cytoplasm was analysed. The results showed no significant change in total cellular 
superoxide radical production between samples (5N: 100±0; 20N: 100±2; 511: 102±3; 2011: 
103±2) (p > 0.05) (Fig.4.9a). Most of these superoxide radicals seem to be produced in the 
mitochondria with a significant increase in cells incubated in hypoxia (5mM glucose) 
compared to nonnoxia (5N: 66±3; 5H: 81±2) (Fig. 4.9b). This increase is reflected by a 
corresponding decrease seen with cytoplasmic radical fonnation in the same samples (5N: 
34±3; 5H: 22± I) (p < 0.05) (Fig. 4.9c). 
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Fig. 4.7: Illustration of the morphological changes seen during the mitochondrial fusion and 
fission process in HUVECs (400x magnification). (1) Mitochondria appear long and strand 
like (2) Fission i.e. break up and shortening of mitochondria is visible (3) Mitochondria 
appear punctate, fission is complete. 
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Fig. 4.8: Quantitative blind analysis of mitochondrial length in response to changes in 
glucose (5mM & 20mM) and oxygen concentration (N = normoxia; H = hypoxia) in 
HUVECs. Twenty random mitochondria were measured per cell. The results are expressed 
as mean ± SEM from six separate cells (n = 6) with 10 observations per cell (Kruskal-Wallis 
test: p > 0.05). 
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Fig. 4.9: Determination of changes in cellular superoxide radical formation in response to 
changes in glucose (5mM & 20mM) and oxygen concentration (N = normoxia; H = hypoxia) 
in HUVECs. The change in superoxide radical formation is compared relative to total 
cellular superoxide radical control (5N = 100%). (a) total superoxide radical formation in 
HUVECs (b) percentage proportion superoxide radical formation found in mitochondria (e) 
percentage proportion superoxide radical formation found in the cytoplasm. Samples were 
analysed using a SOD-WST kit. Each bar represents the mean ± SEM from three different 
experiments (n = 3) (ANDY A plus post hoc Tukey's test: * p> 0.05). 
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4.5. Discussion 
The focus of this chapter was to determine the effect that hypoxia and hyperglycaemia have 
on endothelial mitochondrial number, morphology and cellular ROS production to determine 
if this may offer an explanation for the effect of increased cell proliferation and increased 
DNA damage observed in the previous chapter. The type of quantitation carried out to 
determine the number of mitochondria and ROS production was highly dependent on a 
consistent cell size within the population studied. We demonstrated that, with different 
concentrations of glucose and oxygen, there was no significant difference in cell size (p > 
0.05) between treatment groups after 24h exposure (Fig. 4.4). Changes in cell size are highly 
cell-type dependent, with some reports of changes in cell size, such as swelling (Schmiedl et 
al. 2001) and changes in cell structure (Mandai et al. 2006), in response to hyperglycaemia-
induced oxidative stress. However, evidence corresponding to a time-frame of24h is hard to 
find, as exposure times vary considerably. It would be unrealistic to expect cell size to stay 
constant, given the processes involved in oxidative stress such as apoptosis, but for the 
interpretation of our results it is important to know that cell size remains unaffected after 
only 24h incubation to allow for an accurate interpretation of the results which have been 
gathered from HUVECs treated in the various conditions. 
Analysis of the mitochondrial content also showed no significant change between treatment 
groups after 6h and 24h (Fig. 4.5). However, the relatively large SEM values indicate a high 
degree of variability which is indicative of the heterogeneity of the mitochondrial population. 
Although mitochondria are known to form a reticulum, evidence exists that mitochondria 
within individual cells can also form morphologically heterogeneous and physically distinct 
entities (Collins et al. 2002). This allows the mitochondria to function independently with 
respect to their individual d'l'm, Ca2+ uptake and mPTP activation. It is therefore perceivable 
that the large variability in MitoTracker Green FM fluorescence is indicative of either (a) an 
increase in mitochondrial permeability, as a result of cell structure changes in response to 
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prolonged exposure to oxidative stress, (b) a possible increase in mitochondrial 
fragmentation or (c) a simple variability in dye uptake due to changes in ~'I'm (Keij et af. 
2000, Buckman et af. 2001, Pendergrass et af. 2004). 
It is known that mitochondrial morphology is regulated by the fusion and fission processes 
described earlier, which are strongly linked to oxidative stress. Therefore, changes in 
mitochondrial fragmentation in response to oxidative-stress-induced apoptosis (Frank et af. 
2001) may lead to an increase in fluorescence intensity, depending on the extent of the 
fragmentation. Although this is pure speculation as our data cannot verify these assumptions 
we do see a modest reduction in MitoTracker Green FM fluorescence in hypoxia-treated 
samples but it does not reach statistical significance. Since hypoxia has been reported to 
increase mitochondrial length and reduce fission (Skulatchev et al. 2001) we would possibly 
expect to see a drop in fluorescence intensity. At this point, however, we cannot make any 
assumptions about changes in mitochondrial morphology and it is sufficient to bear in mind 
that total cellular MitoTracker Green FM fluorescence does not show any significant change 
after 24h exposure to hyperglycaemia and hypoxia (Fig. 4.5). 
There is, however, a significant difference between mitochondrial ROS production at 6h 
compared to 24h (p < 0.05); (Fig. 4.6). The RedoxSensor Red CC-l stain passively enters 
live cells where the non-fluorescent probe is either oxidised in the cytosol and accumulates 
in the mitochondria, or the probe is transported to the Iysosomes where it is oxidised. The 
differential distribution of the oxidized product between mitochondria and. Iysosomes 
appears to depend on the redox potential of the cytosol (Chen et al. 2000) and on the 
proliferation rate, with predominantly mitochondrial staining in proliferating cells and 
lysosomal staining in contact-inhibited cells (Chen et al. 2000). The observed change in 
cellular redox potential in response to glucose and/or hypoxia is in agreement with the 
literature reports (Nakajima et al. 2006, Zhang et al. 2007). Co-localisation studies show that 
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most if not all of the oxidised product accumulates in the mitochondria (as seen in Fig. 4.1.). 
These findings are supported by Fig. 4.2 and Fig. 4.3, which demonstrate that the 
RedoxSensor Red CC-l signal is significantly reduced when the mitochondrial membrane 
potential is artificially collapsed using FCCP (l ~M) (p < 0.00 I). Artificially collapsing the 
membrane potential also identifies the close relationship between glucose- and/or hypoxia-
generated oxidative stress and the mitochondrial membrane potential. Although it has been 
shown that mitochondrial ROS production is dependent on the L\'I'm with a high membrane 
potential seemingly favouring the production of ROS (Kaden bach et 01. 2003, Zhang et 01. 
2007), no direct reports exist for this interdependence in response to hypoxia and/or 
hyperglycaemia. 
Our findings confirm an early change in cellular redox potential in response to glucose and 
hypoxia within the first 6hours of exposure. Since we have shown that neither cell size nor 
mitochondrial numbers change under identical conditions, this rise cannot be explained by an 
increase in intensity-to-size ratio (i.e. smaller cells: increased fluorescence or more 
mitochondria: increased fluorescence) but could reflect either an impaired ability of the 
mitochondria to take up the oxidised CC-l product or a decrease in the cellular redox 
potential. 
The results from Chapter Three have demonstrated that HUVECs exhibit an increase in 
DNA damage after 24h incubation. Furthermore, the net increase in ROS seen here, together 
with the knowledge that overproduction triggers apoptosis almost as a fail-safe mechanism 
to prevent the cells from uncontrolled proliferation in the presence of oxidative stress 
(Kannan el al. 2000), may represent a distinct but related phenomena. It also needs to be 
considered that the significant increase in ROS production after 6h is a possible consequence 
of the pre-treatment culture conditions for HUVECs. HUVECs are incubated with glucose 
free/serum free media overnight in order to ensure all cells are in the same stage of the cell 
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cycle prior to treatment with different glucose and oxygen concentrations. The rise in ROS 
production could be a consequence of the HUVECs resuming "normal" cellular function. As 
there is no significant difference in ROS production between samples, cellular ROS 
production may not be the sole cause for the observed loss of DNA integrity with high 
glucose concentration and low oxygen tension. 
It is, however, important to distinguish between cytoplasmic and intra-mitochondrial 
oxidative stress (Kristal et al. 1997). Mitochondrial DNA (mtDNA) is very susceptible to 
ROS-induced DNA damage, more so than nuclear DNA (nDNA). In 1974, Clayton et a/. 
found that UV- induced pyrimidine damage was not repaired in mtDNA, a result interpreted 
as a complete absence of repair capacity in mitochondria. It has since been shown that 
mtDNA repair enzymes are encoded for in the nucleus and are transported into the 
mitochondria via the membrane potential (Bohr et af. 2002). Subsequently, a~y change in 
mitochondrial membrane potential will affect the transport efficiency and repair capacity of 
mtDNA repair enzymes. 
An interesting study carried out as far back as 1997 reported that H20 2-induced mtDNA 
damage incurred after 15min was repaired efficiently within 1.5h after 1120 2 withdrawal. 
However, extension of H20 2 treatment from 15 to 60min led to persistent mtDNA lesions 
refractory to repair up to 24h after treatment (Yakes et al. 1997). They observed that 
prolonged exposure to H20 2 damage correlated with a loss of mitochondrial function and 
eventually cell death. They hypothesised that a vicious cycle exists whereby oxidative 
mtDNA damage leads to faulty gene expression, deficiency of key electron transport 
enzymes, subsequent ROS production and ultimately cell death (van Houten et af. 2006). 
Therefore, it is fair to say that the redox status of the cell has a multilayered effect on cell 
survival and cell death. 
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As mentioned above mitochondrial fusion and fission are integral to the mitochondrial 
responses to oxidative stress (Section 4.2). A recent paper by Yu et al. (2006) observed that 
dynamic changes in mitochondrial morphology are associated with high glucose-induced 
overproduction of ROS. Mitochondria undergo rapid fragmentation with a concomitant 
increase in ROS formation after exposure to high glucose concentrations. They suggest that 
mitochondrial fragmentation mediated by the fission process is a necessary component for 
high glucose-induced respiration increase and ROS overproduction (Yu et al. 2006). 
Considering this hypothesis we analysed our samples for any evidence of increased fusion 
and fission processes. Figure 4.7 shows examples of cells exhibiting long and strand like 
mitochondria (a) and their increased level of fragmentation (b) until nearly all mitochondria 
are fragmented and fission is complete (c). However, although there is evidence of individual 
cells having undergone fission to a more or less advanced extent, the analysis of individual 
mitochondrial length did not result in any significant differences between samples and time 
points (Fig. 4.8). Since our results did not confirm the recent literature findings (Yu et al. 
2006), we are unable to extrapolate whether a hyperglycaemia and/or hypoxia-induced rise 
in respiration with subsequent ROS overproduction is dependent on mitochondrial 
morphology. 
One key aspect of cellular stress is the antioxidant defence enzymes, such as superoxide 
dismutase and glutathione peroxidase. They, alongside other antioxidants, ultimately 
determine the availability and increased production of ROS since they are very effective 
free-radical scavengers. In order to understand the effect that glucose and hypoxia have on 
their activity, mitochondrial superoxide radical formation was analysed in response to high 
glucose and low oxygen levels (Fig. 4.9). 
Superoxide dismutase together with catalase is responsible for scavenging superoxide 
radicals (ot) in the cytoplasm (CulZn-SOD) and the mitochondria (Mn-SOD). The 
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overproduction of mitochondrial superoxide has been hypothesised to be the missing link 
between hyperglycaemia and the activation of the known biochemical pathways involved in 
the development of vascular complications (Nishikawa et al. 2000). 
These data demonstrate that total cellular superoxide levels do not change in response to 
glucose and/or oxygen concentration alone. The highest level of O2'. radicals can be found in 
the mitochondria, where a significant increase in generation was observed in 
normoglycaemic samples exposed to hypoxia for 24h. The inverse is true for ot radical 
production in the cytoplasm (CulZn-SOD). Although the high mitochondrial ot radical 
levels could be interpreted as confirmation that superoxide radicals are predominantely 
produced in the mitochondria, their levels do not seem to change in response to 
hyperglycaemia. On the contrary, mitochondrial ot levels are significantly increased in 
normoglycaemic cells when exposed to hypoxia for 24h, but remain unaffected in response 
to glucose. From these results, it appears unlikely that mitochondrial superoxide radical 
formation is the sole cause for oxidative-stress-mediated DNA damage in IIUVECs, and 
other factors relating more specifically to hypoxia will have to be considered. 
The study carried out by Brownlee et a/. (2005) verified the hypothesis that hyperglycaemia 
induces superoxide radical formation through the mitochondrial electron-transport chain by 
over-expressing UCP-I (collapsing the mitochondrial membrane potential) or Mn-SOD. The 
results indicated that hyperglycaemia does not increase ROS production when UCP-I is 
over-expressed, verifying that ROS production is associated with the mitochondrial electron-
transport chain. Secondly, over-expression of Mn-SOD led to a similar reduction in ROS 
production in response to hyperglycaemia indicating that the ROS produced are indeed 
superoxide radicals. In addition, they tested the effect of Mn-SOD and UCP-l over-
expression on the activation of all known biochemical mechanisms involved in causing 
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vascular complications (i.e. Polyol, AGE and PKC) and found that none of the pathways 
were expressed in response (Du et al. 2001, Brownlee et al. 2005). 
4.6. Conclusion 
This study has identified that mitochondria play an important role in the immediate 
responses to oxidative stress in endothelial cells. As the results do not support a correlation 
between hypoxialhyperglycaemia and cellular ROS production on changes in DNA damage, 
the involvement of hypoxia in the endothelium mediated oxidative stress response will now 
be investigated. Thus, evidence for hypoxia-mediated survival signalling via the 
transcription factor HIF-I will now be presented. 
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CHAPTER FIVE: Role of IIIF-la in bypoxia- and 
byperglycaemia-induced 
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damage in 
5.1. Hypothesis 
The transcription factor HIF-l <X plays a role in hypoxia- and hyperglycaemia-induced 
endothelial DNA damage. 
5.2. Introduction 
HIF-l<x mediated VEGF expression plays a crucial role in oxygen-dependent diabetic 
diseases, such as proliferative diabetic retinopathy (Arjamaa et aT. 2006), diabetes-related 
cardiovascular disease (Marfella et al. 2002), neuropathy (Chavez el aT. 2005) and diabetic 
wound healing (Ozawa el al. 2001). It has been proposed that HIF-l activity requires a 
functional mitochondrial electron transport chain and that the generation of mitochondrial 
superoxide radicals (at complex I and III of the ETC) and subsequent formation of hydrogen 
peroxide are required for the induction of HIF -1 activity and the transcription of its 
downstream targets in hypoxic cells (Chandel et al. 1998). 
Although HIF-l<x expression is strongly hypoxia associated, evidence is accumulating which 
suggests that hyperglycaemia alone can impact on HIF-l<x regulation (Catrina et al. 2004). It 
has been shown that high glucose concentration increases basal HIF-la mRNA expression in 
streptozotocin diabetic rat heart (Marfella et al. 2002), as well as interfering with hypoxia 
induced proteasomal dependent stabilisation of HIF-la and its transcriptional activation 
(Catrina et al. 2004). This implies that hyperglycaemia can directly regulate HIF-ln activity 
and stabilisation identifying a more complex regulatory mechanism for HIF-ln in diabetes 
highlighting a need for investigating the role of HIF-la in the pathology of diabetes mellitus 
and its complications. 
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In this Chapter the contribution of HIF-Ja to glucose and hypoxia mediated changes in 
endothelial cell DNA damage and mitochondrial ROS production was assessed to further 
elucidate the involvement of hypoxia in the endothelial mediated oxidative stress responses. 
5.3. Materials and Methods 
The optimisation of HUVEC seeding density used with 16 well chamber slides to ensure that 
the cells remain within the proliferation phase during the experiment was carried out in 96 
well plates using the Alamar blue proliferation assay as described in Section 2.2.5 The 
uptake ofFITC labelled control oligonucleotide using fluorescent imaging (Section 2.7) was 
also determined in order to optimise the time frame for incubation with the antisense. HIF-
la protein was detected using immunocytochemical analysis (Section 2.7.1) and HIF-la 
mRNA was detected using the reverse transcriptase polymerase chain reaction (Section 2.8). 
The effect of glucose concentration and oxygen tension on DNA integrity, cell size, 
mitochondria number and cellular redox potential was determined as described in previous 
Chapters (Sections 2.4, 2.5). 
HUVECs exposed to 5 or 20mM glucose and/or 5 or 20% oxygen for 24h were cultured as 
described in Section 2.2. 
Each experiment was performed in triplicate with three internal replicas per sample. The test 
distribution was assumed not to be normal to account for the limitations in sample size. 
Statistical significance was determined using a Kruskal-Wallis test or Mann-Whitney U test 
against the test hypothesis (Ho) that there are no differences between the means of the 
samples. Were p< 0.05 the Ho must be rejected and the HA (there is a difference between the 
means of the samples) accepted. Where data was normalised (100%) a Student's t-test (Mean 
- 100%1 SEM) and/ or ANOV A plus Tukey's post hoc test was used. The level of 
128 
significance is expressed as *p< 0.05, **p< 0.01 or ***p< 0.001. No significant difference 
was assigned to samples where p > 0.05. 
5.4. Results 
5.4.1. Effect ofHIF-la antisense on the level ofHIF-la protein and mRNA 
Optimal seeding density (Fig. 5.1) was determined for the immunocytochemical analysis of 
HIF-1a activity in HUVECs grown on 16 well chamber slides for 24h ± HIF-la antisense 
oligonucleotide. An alamar blue assay was carried out to determine the optimal seeding 
density based on the proliferation rate profiles of three different HUVEC samples (lx10', 
0.5x104, O.1xl 04). As Fig.5.1 shows cells seeded at 1 xl OS and 0.5xl 04 reach a plateau in their 
proliferation phase between 24h & 48 h after which cell proliferation levels off while cells 
seeded at density of 0.1xl04 continue to grow throughout the 48 h period. Subsequent 
immunocytochemical detection of HlF -1 a was carried out using a 0.1 x 104 cells/well seeding 
density. 
5.4.2. Uptake of control oligonucleotide 
Optimal oligonucleotide incubation time was determined using a FITC labelled control 
oligonucleotide representative of the HIF-la antisense oligonucleotide which will be used 
during the experiment. The fluorescently labelled oligonucleotide was maximally taken up 
into the cells within 6h and was still present after 24h (Fig. 5.2). All future results were 
conducted using a 24h incubation time. 
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Fig. 5.1: Determination of the optimal seeding density of HUVECs to be used with 16well 
chamber slides. Cell proliferation of HUVECs seeded at three different concentrations 
(O.lxlOs, O.Sxl04, 0.1xl04) was determined using the Alamar blue assay. Each bar represents 
the mean ± SEM from six different experiments with six replicates per sample. 
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Fig. 5.2: Determination of the optimum incubation time for the cellular uptake of the FITC 
labelled control oligonucleotide (IUF-Ia antisense control). (a) Oh, (b) lh, (c) 6h, (d) 24h 
incubation. A 2J1M concentration of FITC labelled control oligonucleotide was directly 
added to 16well chamber slides containing O.lxl04 cells/well before analysis using a Leica 
DML Fluorescent microscope. The above images are representative of samples from six 
different batches ofHUVECs (n = 6). Magnification: 200x 
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5.4.3. Effect ofHIF-Ia antisense on the level ofHIF-Ia protein and mRNA 
Detection of the HIF -1 a protein was carried out to confirm that the HIF -1 a antisense is 
capable of blocking the expression of HIF-Ia protein in HUVECs. As Fig. 5.3 illustrates, 
cells grown in hypoxic conditions for 24h without antisense show intense red staining 
corresponding to HIF-la protein production in these cells (Fig. 5.3a). Fig. 5.3b shows the 
absence of staining in HUVECs incubated under identical conditions in the presence ofHIF-
1 a antisense oligonucleotide. This confirms the ability of HIF-l a antisense oligonucleotide 
to block HIF-I a protein synthesis to the level of detection sensitivity of this assay after 24h, 
the chosen time point for all future experiments. 
The level of HIF-I a mRNA was also determined using the reverse transcriptase polymerase 
chain reaction following cDNA preparation from RNA isolated from cells incubated in the 
presence of HIF-la antisense. The integrity of the RNA was confirmed following 
electrophoretic separation and the amplification of 132 microglobulin from the cDNA 
(Fig.5.5a or b). Clear separation of both I8S and 28S ribosomal rRNA confirm the purity of 
the extracted RNA sample and confirm the suitability of this sample for use with PCR (Fig. 
5.4). A HIF-la PCR product was detected irrespective of the presence ofHIF-la antisense. 
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Fig. 5.3: Immunocytochemica l detection of HI F- I a protein 111 human umbilica l ve ll1 
endothelial ce ll s treated with and without HI F-I a antisense. (a) 20mM glucose hypoxia, no 
antisense (24h), (b) 20mM glucose hypoxia + HI F-I a anti sense (24h), Magnifica tion: 200x. 
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Fig. 5.4: Resolution of RNA iso lated from HUVECs. Representative agarose ge l ( 1.2% 
w/v) demonstrating separation of total RNA with no evidence of degradation of RNA 
sample. RNA was visualised by staining with ethidium bromide and viewed under ultrav iolet 
light. 
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Fig. 5.5: Agarose gel (1.2% w/v) showing (a) ~2-Microglobulin (~2Mg) and (b) HIF- I a pe R 
product compared to marke rs of known s ize. The products conformed to predicted size 
analysis of 321 bp and 390bp for ~2Mg and HIF- I a respective ly. The images are 
representative of three different experiments (n = 3). 
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5.4.4. Effect ofHIF-la antisense treatment on DNA damage 
As reported in the previous chapters, DNA damage is increased in high glucose 
concentration and/or decreased oxygen concentration with the most significant increase in 
DNA damage observed in cells exposed to both conditions simultaneously (p < 0.001). 
These results are consistent with those obtained in Chapter Three (Fig. 3.5). In nonnoxic 
conditions, the addition ofHIF-la antisense to HUVECs had no effect on the level of DNA 
damage seen in response to high (20mM) glucose concentration (p > 0.05) (Fig. 5.6). 
However, HUVECs cultured in hypoxia in the prescence of HIF-Ia antisense show 
significantly less DNA damage in response to both 5mM and 20mM glucose (p < 0.001). 
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Fig_ 5.6: Determination of the effect HIF-I a antisense (AS) (211M) on glucose (SmM & 
20mM) and oxygen (N = normoxia and H = hypoxia) induced HUVEC DNA damage. Cells 
were stepped down overnight in glucose free/serum free media and incubated for 24h prior 
to analysis with the comet assay. The results are expressed as mean of three experiments ± 
SEM (n = 3) (Kruskal-Wallis test: ***p < 0.001 ; NS: p > 0.05). 
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5.4.5. Effect ofHIF-Ia. antisense on ROS production and sub-cellular location 
The effect of glucose concentration and oxygen tension on HUVEC size over time was 
determined following HIF -I a. antisense treatment of HUVECs using ImageJ freeware. The 
percentage change in cell size was determined relative to control (t = Oh 100%) (Fig.5.7) and 
was found to be non significant using a Student's t-test (p > 0.05). There also was no 
significant difference between sample groups (p > 0.05). Results show no change in HUVEC 
size in response to HIF-Ia. antisense treatment alone (6h - 5N: 99±1; 20N: 106±7; 5H: 
104±4; 20H: 102±5; 24h - 5N: 98±3; 20N: 104±6; 5H: 102±5; 20H: 97±8) (p > 0.05) and 
when compared to untreated HUVECs (6h - 5N: 102±6; 20N: 108±1; 5H: 116±8; 20H: 
1l0±7; 24h - 5N: 105±0; 20N: 108±4; 5H: 104±3; 20H: 1l1±1). 
Changes in both MitoTracker Green FM and RedoxSensor Red CC-I fluorescence intensity 
were determined using ImageJ freeware. The percentage change in fluorescence intensity for 
both markers was determined relative to control (t = Oh 100%) and analysed individually for 
all three experiments (Fig.5.8). 
MitoTracker Green FM fluorescence was not affected by HIF-l a. antisense treatment when 
compared to control (6h - 5N: 140±21; 20N: 94±19; 5H: 152±26; 20H: 113±17; 24h - 5N: 
145±21; 20N: 130±13; 5H: 110±24; 20H: 112±59) (Fig.5.8) as determined by Student's t-
test (6h & 24h p > 0.05). There was also no statistically significant difference between 
sample groups treated with HIF-Ia. antisense as analysed by ANOVA plus post-hoc Tukey's 
test. 
RedoxSensor Red CC-I fluorescence intensity in contrast does change significantly over 
time (Fig. 5.9). When compared to control there is a significant increase in RedoxSensor Red 
CC-l fluorescence intensity in AS treated samples after 6h in normoxia (6h - 5N: 337±26; 
5NAS: 499±77; 20N: 427±46; 20NAS: 517±62) (p < 0.05). The fluorescence intensity of 
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control samples was significantly reduced after 24h which is in agreement with earlier 
findings (Fig. 4.6) (5N: 133±56; 20N: 128±37; 5H:141±21; 20H:141±14). The addition of 
AS to normoxia samples after 24h leads to a significant reduction in CC-l fluorescence 
intensity which contrasts the results obtained after 6h (SNAS: 7S± 28; 20NAS: 69±8) (p < 
0.05). 
In hypoxia the addition of antisense significantly reduced CC-l fluorescence intensity after 
6h and 24h in 20mM glucose samples (6h - 20H: 4S0±63, 20HAS: 283±28; 24h - 20H: 
141±21, 20HAS: 63±25) (p < 0.05). These results indicate that HIF-}a has a direct effect on 
ROS production in hypoxia which mayor may not contribute to the DNA damage seen in 
these conditions. The mechanisms, through which this occurs is unknown but appears to be 
different from that in normoxic conditions. 
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Fig. 5.7: Determination of the effect HIF-la. antisense (AS) treatment (2J1M) has on size of 
human umbilical vein endothelial cells compared to untreated (as shown previously in Fig. 
4.3). Cells were stepped down overnight in glucose free/serum free media before incubation 
with glucose concentration of either 5mM or 20mM and oxygen concentrations (N = 
normoxia and H = hypoxia) for 24h. The change in cell size is expressed relative to control 
(t = Oh 100%). The above graph is representative of the mean ± SEM of three separate 
experiments (n = 3) with 50 observations (SEM values range from 1-8% within a group) per 
sample (Student's t-test and ANOV A plus post-hoc Tukey's test: p> 0.05). 
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Fig. 5.8: Effect of HIF-la antisense (AS) treatment (2JlM) on MitoTracker Green FM 
fluorescence intensity in human umbilical vein endothelial cells compared to untreated (as 
shown previously in Fig. 4.4). Cells were stepped down overnight in glucose free! serum free 
media before incubation in glucose concentrations of either 5mM or 20mM and oxygen 
concentrations (N = normoxia and H = hypoxia) for 24h. The change in fluorescence 
intensity is expressed relative to control (t = Oh 100%). The above graph is representative of 
the mean ± SEM of three separate experiments (n = 3) with 50 observations per sample 
(Student's t-test and ANOVA plus post-hoc Tukey's test: p> 0.05). 
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Fig. 5.9: Effect of lllF-la antisense (AS) treatment (2J..lM) on RedoxSensor Red CC-l 
fluorescence intensity in human umbilical vein endothelial cells compared to untreated (as 
shown previously in Fig. 4.5). Cells were stepped down overnight in glucose free/ serum free 
media before incubation in glucose concentration of 5mM & 20mM and oxygen 
concentrations (N = normoxia and H = hypoxia) for 24h. The change in fluorescence 
intensity is expressed relative to control (t = Oh 100%). The above graph is representative of 
the mean ± SEM of three separate experiments (n = 3) with 50 observations per sample 
(Student's t-test and ANOYA plus post-hoc Tukey's test: *p < 0.05; **p < 0.01; 
***p<O.OOl). 
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5.5. Discussion 
Although HIF-Ia is recognized as a key mediator for a number of the cellular adaptive 
responses under hypoxic conditions (Section 5.2), little has been reported about its direct 
effect on endothelial DNA damage in response to hypoxia and/or hyperglycaemia. HlF-ia 
mediated adaptive responses appear to protect the cell in hypoxic conditions although its pro-
apoptotic involvement has also recently been shown (Brunelle et 01. 2002, Lee et 01. 2004). 
HIF-l has been shown to induce the expression of genes encoding glycolytic enzymes such 
as glucose transporter (GLUT-I) under hypoxic conditions (Semenza el 01. 1994). It is 
suggested that increased glycolysis is necessary to produce energy when low oxygen will not 
support oxidative phosphorylation within the mitochondria. In contrast, Papandreou et 01. 
(2006) found that, while HIF-I stimulates enzymes required for glycolysis, it also actively 
represses mitochondrial function and oxygen consumption by inducing pyruvate 
dehydrogenase kinase 1 (PDKl). PDKI phosphorylates and inhibits pyruvate dehydrogenase 
from using pyruvate to fuel the mitochondrial TCA cycle. This causes a drop in 
mitochondrial oxygen consumption and results in a relative increase in intracellular oxygen 
tension resulting in increased oxygen availability and decreased cell death. On the other hand 
HIF-Ia has been shown to be pro-apoptotic with the activation of caspase-3, Apaf-l-
mediated caspase 9 and the release of cytochrome c having been reported in several cell 
types under hypoxic conditions (Brunelle et 01. 2002). It has even been demonstrated that 
HIF-Ia is associated with the activation of the mitochondrial triggered apoptosis cascade 
(Weinmann et 01.2004). 
Despite the intense research into the pro- & anti-apoptotic effects of HIF-I a, the literature 
does not indicate ifHIF-Ia is directly involved in acute oxidative stress induced endothelial 
DNA damage. Results obtained for HUVECs incubated in hypoxic and hyperglycaemic 
conditions for 24h and treated simultaneously ± HIF-Ia antisense (Fig. 5.6) show 
significantly less DNA damage in cells incubated under hypoxic conditions, irrespective of 
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the glucose concentration (p < 0.001). HIF-Ia antisense treatment has no effect on 
normoxia-induced DNA damage. These results suggest that HIF-Ia contributes to acute 
hypoxia-induced endothelial DNA damage seen in Chapter Three (Fig. 3.5), although the 
action of HIF-I does not appear to be cytotoxic as cell proliferation is not affected within 
this time frame (Fig. 3.1). 
One likely site of this effect is the mitochondria. Since HIF-Ia has been shown to influence 
mitochondrial function (Emerling et al. 2005), it is perceivable that a mechanism exists 
through which the activation of HIF-I a initially contributes to mitochondrial ROS mediated 
cell damage. A recent paper describes the requirement of mitochondrial ROS release (from 
complex III) into the cytoplasm for the hypoxic stabilisation of HIF-la (Guzy et al. 2005) 
while a second paper describes how loss of mitochondrial function impairs cellular oxygen 
sensing and hypoxic HIF-a activation (Mansfield el al. 2005). Both papers seem to suggest 
that HIF-Ia requires mitochondrial ROS production for its stabilisation and activitation. 
However, higher ROS levels also instigate more cell damage. 
In order to verify if mitochondrial ROS production is linked to HIF-Ia and the observed 
levels of DNA damage, mitochondrial ROS levels were determined in the presence of HIF-
la antisense (Fig. 5.9). There is an early change in cellular redox potential in response to 
glucose and or hypoxia measurable after 6h. This is in line with earlier findings of HUVECs 
treated without the addition of antisense (Fig. 4.6). In hypoxia. HUVECs treated with HIF-
1 a antisense for 6h show a significant reduction in RedoxSenor Red CC-I flourescence 
intensity compared to identical untreated samples (p < 0.05). These observations suggests 
that hypoxia incurs a reduction in cellular redox potential in the absence of HIF-I a and a 
potential reduction in cellular ROS formation. Since blocking HIF-Ia protein production has 
no effect on MitoTracker Green FM fluorescence intensity (Fig.5.S) or overall HUVEC size 
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(Fig.S.7), the reduction in cellular redox potential in hypoxia in the presence of HIF-
1 ex antisense seems to support the suggestions that the activation of HIF -I ex in hypoxia 
initially contributes to mitochondrial ROS production and possibly an associated increase in 
cell damage. 
One possible mechanism through which the hypoxia stimulated release of ROS could 
contribute to the regulation of HIF-Iex is through the accumulation of DAG. It has been 
reported that both hypoxia and high glucose concentration lead to DAG production (Rossi et 
al. 1991, Ternes et al. 2004). This in tum leads to the accumulation of phosphatidic acid via 
the activation of diacylglycerol kinase. Phosphatidic acid in tum is thought to regulate H1F-l 
expression (Ternes et al. 2004, Aragones et al. 2001). Furthermore, DAG and phosphatidic 
acid also leads to the direct activation of PKC (Stasek et al. 1993). PKC induces cell damage 
by reducing the mitochondrial ATP production, leading to an overload of mitochondrial Ca2+ 
and loss of mitochondrial function (Costa el al. 2006). Although PKC has not been 
implicated in the hypoxia triggered accumulation of DAG and subsequent regulation of IIIF-
I (Ternes et af. 2004), loss of mitochondrial function could lead to the loss ofHIF-l function 
ifthe above hypothesis is correct. 
Alternatively, the HIF-Iex associated increase in endothelial DNA damage under hypoxic 
conditions (Fig. 5.6) could be an indication of a more direct involvement in the mediation of 
hypoxic cell death and apoptosis. Since Lee et al. (2004) were able to establish that the 
HGTD-P gene activates the mitochondrial apoptotic cascade through the induction of the 
mPTP a link has been established between HIF-Iex and mitochodrial apoptosis signalling. 
Although our results clearly show the involvement of HIF-lex in mitochondrial redox 
changes (Fig. 5.9) (with the origin of the fluorescent RedoxSensor Red CC-l marker 
confirmed as being mainly mitochondrial Fig. 4.2) we were also able to observe a 
proliferative increase under these same conditions (Fig. 3.1). As detailed in Chapter Three 
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however (Section 3.4.1 ), an increase in HUVEC proliferation under hypoxic conditions is 
associated with the increased transcription of VEGF, which in turn is mediated by HIF-l 
(Zgouras et al. 2003). 
In normoxia, a reduction in CC-l fluorescence intensity can be observed in cells cultured in 
normoxic conditions for 24h when cultured in HIF-la. antisense compared to untreated (Fig. 
5.9). This is in stark contrast to fluorescence levels seen at 6h where HIF-I a. antisense 
seemingly induces mitochondrial ROS production significantly (Fig. 5.9). This suggests that 
HIF-Ia. plays a significant role in ROS production under normoxic conditions and although 
this could be considered to be in line with findings that the normoxic expression of HIF-
I a. is essential for macrophage function (Knowles et af. 2006) it also suggests that a 
reduction in hypoxia mediated DNA damage (Fig. 5.6) is unlikely to be due to a direct 
involvement of HIF-Ia. as the results are not consistent for both SmM and 20mM glucose 
samples. 
Clearly the reactions and interactions within the cell are complex. It is also likely that a 
plethora of other possible mechanisms activated during the oxidative stress response such as 
MAPK, PI3K, p42/44 and apoptosis will contribute to the observed effects ofHIF-Ia.. 
5.6. Conclusion 
The present results have identified that that there seems to be a close relationship between 
HIF-Ia. activity, endothelial DNA damage and cellular ROS production in hypoxia. As ROS 
production is not significantly different in SmM glucose samples in the presence of HIF-In 
antisense it appears unlikely that the DNA protective effect ofHIF-la. anisense in hypoxia is 
due to its direct effect on ROS production. It is more likely that HIF-Ia. is involved in 
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mitochondrial-mediated apoptosis signaling. More studies are required to corroborate this 
hypothesis. 
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CHAPTER SIX: Effect of glucose analogues and 
intracellular signalling inhibitors on endothelial DNA 
damage 
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6.1. Hypothesis 
Endothelial DNA damage in response to hypoxia and hyperglycaemia is mediated through 
signalling pathways such as PKC and p42/44 activation or the metabolism ofD-glucose. 
6.2. Introduction 
In order to elucidate the contributing mechanisms and signalling pathways involved in the 
development of hypoxia- and hyperglycaemia- induced loss of endothelial DNA integrity, 
DNA damage was assessed after the addition of glucose analogues (2-deoxy-D-glucose, 3-
orthomethyl-glucose) and signalling inhibitors (PKCplIIEGFR and PD98095 (p42/44 
inhibitor». 2-deoxy-D-glucose (2DG) and 3-ortho-methyl glucose (30M) are structural 
derivatives of D-glucose. Once inside the cell, 2DG is phosphorylated by hexokinases giving 
rise to 2-D-glucose-6-phosphate (2-DG-6P) during the first step of the glycolysis reaction. 
Because of its structure, the phosphorylated molecule (2-DG-6P) cannot be metabolized 
further or diffuse outside the cell leading to the inhibition of glycolysis and the accumulation 
of the metabolised by-product (2-DG-6P) inside the cell. 3-ortho-methyl glucose (30M) is 
not metabolised at all and simply enters and leaves the cell. 
Common signalling pathways activated in hyperglycaemia- and hypoxia- mediated events 
include, amongst others, protein kinase C (PKC) and p42/44MAPK (Wynne et a12005, Idris 
et al. 2006). Known inhibitors of these pathways include the highly selective PKC inhibitor 
L Y333531 and the p42/44 inhibitor PD98095. 
The assessment of the effect glucose analogues (2-deoxy-D-glucose, 3-orthomethyl-glucose) 
and the signalling inhibitors PKCplIlEGFR and PD98095 (p42/44 inhibitor) have on 
endothelial DNA damage and cell proliferation after only 24h was carried out in order to 
elucidate the molecular processes which lead to the observed rise in DNA damage in 
response to high glucose concentration and low oxygen tension. 
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6.3. Materials and Methods 
The effect of glucose concentration and oxygen tension on DNA integrity of HUVECs was 
determined using the comet assay (Section 2.4). This was carried out using equimolar 
concentrations of D-glucose and its analogues 2-deoxy-D-glucose and 3-ortho-methyl 
glucose as well as the signalling inhibitors PKCpnlEGFR inhibitor (I J.lM) and PD98095 
(2J.lM). HUVECs challenged for 24h were cultured as described in Section 2.2. and their 
DNA extracted as described in Section 2.3. 
Statistical significance was determined using a Student's t-test (Mean - 100%1 SEM) and! or 
ANOV A plus post hoc Tukey's test for normalised data. The level of significance expressed 
as .p< 0.05, "p< 0.01 or ".p< 0.001. A non significant difference (NS) was denoted for 
samples where p> 0.05. 
6.4. Results 
6.4.1. Effect ofD-glucose. 30M and 2-DG-6P on DNA integrity of HUVECs 
A comparison of the DNA damage profile of D-glucose to its analogues 2-deoxy-D-glucose 
and 3-ortho-methyl-glucose was carried out using the comet assay (Fig. 6.1). In HUVECs 
treated with D-glucose alone hyperglycaemia increases DNA damage levels significantly 
when compared to normoglycaemia (5N: 172±4; 20N: 301±1l - p < 0.001), (5H: 258±9; 
20H: S77± 12 - P < 0.001); (Fig. 6. t). DNA damage was further significantly increased in 
hyperglycaemic samples simultaneously exposed to hypoxia (20N: 301±11; 20H: 577±12 - p 
< 0.001). These observations are in agreement with earlier findings (Fig. 3.S). 
An almost identical DNA damage pattern can be seen with the glucose analogue 2-deoxy-D-
glucose (SN: 178±8; 20N: 278±6 - p<O.OOI), (SH: 26t±S; 20H: 599±19 - p<O.OOI), (20N: 
278±6 vs 20H: 599± 19 - p < 0.001) (Fig. 6.1). 
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Loss of DNA integrity by 3-ortho-methyl is significantly higher in all samples compared to 
D-glucose (5N: 489±81; 20N: 396±58; 5H: 376±109; 20H: 412±82 - p > 0.05) apart from 
20H. No significant difference in DNA integrity was seen between 3-0M treated samples (p 
> 0.05). 
ISS 
Fig.: 6.1: Comparison of the effect of D-glucose (SmM & 20mM) and equivalent 
concentrations of the glucose analogues 2-deoxy-D-glucose and 3-ortho-methyl-glucose on 
HUVEC DNA damage (N = nonnoxia and H = hypoxia). Cells were stepped down overnight 
in glucose freel serum free media before incubation. Cells were analysed with the comet 
assay. Results are expressed as mean ± SEM from three separate experiments (n = 3) 
(ANOVA plus post-hoc Tukey's test: ••• p<O.OO 1). 
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6.4.2. Effect of specific signalling inhibitors on DNA damage 
In order to elucidate contributing mechanisms which lead to the observed DNA damage in 
the different culture conditions, various inhibitors were used; namely PKCplllEGFR inhibitor 
and PD98095 (p42/44 inhibitor) (Fig. 6.2). Samples incubated with a PKC inhibitor (I JlM) 
showed a significant increase in DNA damage compared to control in all samples almost 
appearing to be toxic to the cells (5N: 650±4; 20N: 600±40; SH: S99±44; 20H: 72S±16 - p < 
0.001). While there was no significant difference between most PKC treated samples 
incubated under different culture conditions (p > 0.05), there is a significant increase in 
hypoxic conditions with an increase in glucose concentration from SmM (577 ± 12) to 
20mM glucose (725 ± 16) (p > 0.00 I). 
The addition of PD98059 (2JlM) showed no difference in DNA damage when compared to 
D-glucose control (p > 0.05). There is also no significant difference between PD98059 
samples (5N: 334±89; 20N: 224±31; 5H: 231±43; 20H: 414±31 - p > 0.05). 
158 
Fig.: 6.2: Comparison of the effects of PKC~lIIEGFR inhibitor (1 ~M) and PD98059 (2~M) 
on HUVEC DNA damage (N = normoxia and H = hypoxia). Cells were stepped down 
overnight in glucose freel serum free media before incubation. Cells were analysed with the 
comet assay. The results are expressed as mean ± SEM from three separate experiments (n = 
3) (ANOV A plus post-hoc Tukey's test: p < 0.05). 
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6.S. Discussion 
The analysis of DNA integrity of HUVECs in response to D-glucose and its analogues (2DG 
and 30M) demonstrated that 2DG gives a similar DNA damage pattern when compared to 
D-glucose, suggesting that the loss of DNA integrity in response to high glucose 
concentration and low oxygen after 24h is not linked to glycolysis or any of its downstream 
events beyond the first step of breakdown of glucose into glucose-6-phosphate. 
This is surprising, as glycolysis is essential in cellular respiration and energy production, 
feeding into the citric acid cycle (mitochondria) and subsequent mitochdonrial oxidative 
phosphorylation. The excessive formation of oxygen radicals is a well-established mediator 
ofhyperglycaemic damage to a wide range of tissues in diabetes, including neurons (Vincent 
et al. 2005), retinal cells (Robinson et al. 2000), and vascular endothelium (Zurova-
Nedelcevova et al. 2006). Metabolic oxidative stress is also regarded as crucial mediator of 
beta cell dysfunction and apoptosis under hyperglycemic conditions (Martens el al. 2007). 
Although surprising, the observation is not entirely unreasonable as some oxidative stress 
mediated pathways such as NO have a reported inhibitory effect on glycolysis. NO induced 
cellular toxicity has been reported to prevent both mitochondrial oxidative phosphorylation 
and glycolysis (Mohr et al. 1999), affecting the blood brain barrier (Hurst et al. 200 I). More 
recently, it was demonstrated that hyperglycaemia-induced overproduction of superoxide 
inhibits glyceraldehyde-3-phosphate dehydrogenase (GAPDH) another major enzyme of the 
glycolysis pathway. This is thought to trigger several pathways of injury involved in the 
pathogenesis of diabetic complications (Du et al. 2003). 
As 200 is phosphorylated by hexokinases giving rise to 2-D-glucose-6-phosphate (2-DG-
6P) during the first step of the glycolysis reaction after which it accumulates in the cell 
failing to be metabolised any further, the resultant DNA damage observed must be 
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associated with either glucose in its unmetabolised form, the hexokinase enzyme, the 
phosphorylated form of glucose or the accumulation of this product within the cell. The most 
likely explanation falls with the activation of the polyol pathway. As described in Chapter 
One (Section 1.6.1), the polyol pathway is activated as a result of the hexokinase enzyme 
becoming saturated in the presence of high glucose concentrations. It converts glucose into 
sorbitol and onwards into fructose utilising NADPH and NAD+, thereby altering the redox 
state of the cell, which in turn leads to depressed glutathione levels and the resulting loss of 
intrinsic protection against oxidative stress (Williams et a1. 1999). It has been associated 
with the activation of PKC and NF-KB (Ramana et 01. 2002), which are involved in 
mediating biochemical and functional changes in diabetic vessels (Sheetz et a1. 2002). 
As mentioned above, a study carried out by Flores el a1. in 2003 showed that hyperglycaemia 
(25mmol) stimulates the L-arginine/NO pathway in HUVECs within the first 2min of 
incubation, which is thought to occur via the activation of PKC (Flores et a1. 2003). It is 
possible that conditions of high glucose concentration result in high intracellular glucose, 
thus saturating the glycolytic pathway. ROS, such as NO will be generated which in tum 
inhibits glycolysis and the glucose is shunted into the polyol pathway, where it is 
metabolised into sorbitol and fructose, leading to changes in the cellular redox state, 
depression of glutathione reductase levels and the activation of PKC, all of which are known 
to contribute to the development of DNA damage (Williams el 01. 1999; De Mattia el 01. 
1994; Ramana et al. 2002). 
In contrast, 3-0M, a glucose derivative which is not metabolised, but simply diffuses in and 
out of the cell, had no significant effect onDNA damage. The overall level of DNA damage, 
however, is significantly increased compared to that seen with D-glucose (Fig. 6.1). 
suggesting that damage is caused by the entry of glucose into the cell even before it is 
metabolised. Alternatively the higher levels of DNA damage could be caused by a lack of 
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cellular "nutrition" as glucose enters and leaves the cell without being utilised inducing a 
high degree of cellular stress. 
Using cellular signaling inhibitors, the contribution of certain stress pathway to the observed 
. DNA damage was assessed. The use of a PKC inhibitor on hyperglycaemia/ hypoxia induced 
DNA damage shows a significant rise in DNA damage levels compared to D-glucose alone 
(Fig. 6.2), suggesting that a loss of PKC activity is detrimental rather than beneficial to the 
DNA integrity of the HUVEC. Furthermore, DNA damage levels in cells containing a PKC 
inhibitor did not vary significantly with a change in culture conditions, suggesting that PKC 
levels remain unaffected by high glucose and hypoxic culture conditions in our experimental 
setup with the exeption of an increase between SmM and 20mM glucose samples cultured in 
low oxygen tension. These results seem to exclude PKC as a possible source or contributing 
factor of hyperglycaemiaJ hypoxia-induced DNA damage, despite a huge body of literature 
observing the contrary effect. Further studies would be required to look at PKC activity and 
the effect of its inhibition at different time points throughout this 24h incubation period. 
Attention should also be paid to the method of choice since the use of the PKCIlIl/EGFR 
inhibitor almost appears toxic as HUVECs DNA damage levels are very high throughout. 
The use of the p42/44 MAPK inhibitor, PD98059, did not result in any significant changes to 
DNA damage levels obtained with D-glucose (Fig. 6.2). From these results, it appears to be 
unlikely that p42/44 plays a significant role in the development of endothelial DNA damage 
in response to glucose or hypoxia after 24h. It does, however, show a trend of reducing DNA 
damage when HUVECs are exposed to the simultaneous exposure of hyperglycaemia and 
hypoxia (p = 0.05) adding weight to our observations from Chapter Three (Fig.3.S). A study 
looking at the activation of p42/44 (ERK) in response to D-glucose (2SmM) in endothelial 
cells also failed to observe a rise in its activation (Liu et af. 2000), confirming our 
observations. The main body of evidence surrounding p42/44 (ERK) is centred around its 
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activation in hypoxia. where it has been shown to phosphorylate HIF-Ia and enhance the 
transcriptional activity of HIF-I (Richard et al. 1999). Taking our result from Chapter Five 
into account, where we were able to discern that HIF-Ia activation in response to hypoxia 
contributes to the development of endothelial DNA damage, this extrapolation to the 
involvement of p42/44 in this process seems to go someway towards explaining the observed 
DNA damage. Especially since PD98059 results in an inhibition of HIF -I a trans-activation, 
where it reduces the hypoxia-induced transcription of both the target gene and the hypoxia-
responsive reporter gene (Hur et al. 2001). However, the observed change in DNA damage 
was not statistically significant (p > 0.05) and we did not see any effect of PD98059 on 
hypoxia induced DNA damage alone. 
Since the results from the signalling inhibitor studies are inconclusive, more reliable and 
established methods should be used to analyse which signaling pathways respond to changes 
in glucose concentration and oxygen tension and how this impacts on the development of 
endothelial DNA damage. These include protein and enzyme assays such as enzyme-linked 
immunosorbent assays (ELISAs) which can be used to quantitate kinase levels and evaluate 
their activities. By incorporating a recognize protein regardless of phosphorylation state and 
a phospho-specific antibody, ELISA-based assays can be used to measure total protein and 
activated protein levels. Molecular cloning techniques may also be used to identify the role 
PKC and p42/44 play in response to changed in glucose and oxygen tension within the 
endothelium. 
6.6. Conclusion 
Results presented in this Chapter suggest a possible involvement of the polyol pathway as 
well as p42/44 signaling in the development of endothelial DNA damage observed in 
Chapter Three. A common denominator may be the involvement of HIF-Ia which is in 
agreement with the observations from Chapter Five. 
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CHAPTER SEVEN: Effect of silymarin (Silibum 
marianum) on high glucose and low oxygen mediated DNA 
damage in HUVECs 
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7.1. Hypothesis 
The flavonoid antioxidant silymarin (Silibum marianmum) has a beneficial effect on high 
glucose and oxygen mediated DNA damage in HUVECs. 
7.2. Introduction 
Amelioration of the effect of high glucose concentration and hypoxia on DNA damage in 
endothelial cells was examined using a known antioxidant, silymarin (Silibum marianum) 
(SM). Silymarin, also known as milk thistle, has been used as a therapeutic agent for over 
2000 years. It has been reported to have a protective effect against ROS-induced DNA 
damage (Anderson et al. 1994) and to prevent a reduction in the enzymes superoxide 
dismutase (Nencini et al. 2006), catalase (CAT) and glutathione peroxidase (GSHPx) 
(Aldioost et al. 2006), all of which are responsible for the removal of catalase and the 
protection against ROS induced cell damage. Further, silymarin has been shown to improve 
nerve conduction velocity in diabetic neuropathy (Zhang et al. 1993), act as a membrane 
stabiliser (Fraschini et al. 2002) and prevent ROS-induced DNA damage (Yu et al. 1997). It 
is therefore perceivable that an antioxidant such as silymarin could be beneficial in 
counteracting oxidative stress-mediated DNA damage in the endothelial models, as 
previously described in this thesis. 
The cytoprotective effect of the flavonoid antioxidant, silymarin, on high glucose and low 
oxygen-induced DNA damage and the potential mechanisms that are involved in silymarin 
mediated effects were investigated. 
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7.3. Materials and Methods 
The effect of silymarin treatment (50-5000~M) (Wen et al. 2007), in combination with 
glucose concentration and oxygen tension on cell growth was determined using the Alamar 
blue proliferation assay (Fields et al. 1993); (Section 2.2.5). Any effect of these conditions 
on DNA integrity in combination with HIF-Ia antisense (2~) was determined using the 
comet assay (Section 2.4) and the effect that silymarin treatment (50~M) has on the cellular 
uptake of HIF-Ia antisense was assessed using a FITC labelled control oligonucleotide 
(Section 2.7). The effect of these conditions on cellular mitochondrial numbers, HUVEC size 
and cellular redox potential was determined using both MitoTracker Green FM and 
RedoxSensor Red CC-l fluorescent dye (Section 2.5) and analysed using ImageJ software. 
Each experiment was performed in triplicate and repeated on three separate occasions. The 
test distribution was assumed not to be normal to account for the limitations in sample size. 
Statistical significance was determined using a Kruskal-Wallis test or Mann-Whitney U test 
against the test hypothesis (Ho) that there are no differences between the means of the 
samples. Were p< 0.05 the Ho must be rejected and the HA (there is a difference between the 
means of the samples) accepted. Where data was normalised (100%) a Student's t-test (Mean 
- 100%1 SEM) and/or ANOYA (with Tukey's post-hoc test) was carried out. The level of 
significance is expressed as *p< 0.05, **p< 0.01 or ***p< 0.001. No significant difference 
was assigned to samples where p > 0.05. 
7.4. Results 
7.4.1. Effect of silymarin on DNA damage 
Silymarin was added to HUVECs at concentrations of 50,500 and 5000~M (in :50.7% (v/v) 
DMSO) for 24h. The level of DNA damage was measured compared to DMSO control alone 
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in order to ensure that the effect of silymarin (50J.lM) used in subsequent experiments was 
not due to an effect of the DMSO alone. Results indicate that silyamrin shows a pronounced 
DNA damaging effect at concentrations above 500J.lM (5000J.lM: 232±29; p < 0.001) (Fig. 
7.1). There is no significant difference in the level of DNA damage seen with 50J.lM (68±13) 
& 500J.lM (55±8) silymarin treatment for 24h. A vehicle control (DMSO 0.7% total) was 
carried out and found to be within acceptable levels (49±8 i.e. vehicle control shows minimal 
levels of DNA damage) confirming that the potent hydroxyl radical scavenging effects of 
DMSO do not have any effect on the results obtained by the actions of silymarin. All 
subsequent experiments were carried out at a concentration of 50J.lM silymarin. 
7.4.2. Comparison ofsilymarin to alpha-lipoic acid 
In order to compare the ability of silymarin to reduce DNA damage a comparison to a-lipoic 
acid (ala) (I OOJ.lM) was carried out. In normoxic conditions, a-lipoic acid treatment resulted 
in significantly less DNA damage compared to silymarin when compared to a normalised 
control (20mM Normox: 100%) (20NSM (118±7) vs 20Nala (88±7): p = 0.024) (Table 7.1). 
In hypoxic culture conditions there was no significant difference between a.-lipoic acid and 
silymarin treated samples (20HSM (l03±4) vs 20Hala (97±6): p = 0.494). Results suggest 
that silymarin appears to be a cytoprotective antioxidant but is not as potent as alpha-lipoic 
acid. 
7.4.3. Effect ofsilymarin on cell proliferation 
As described previously, an alamar blue assay was carried out to investigate the effect 
silymarin (50J.lM) has on cell proliferation over 24h (Fig. 7.2). As before (Fig. 3.1), HUVEC 
proliferation rate is significantly increased in cells incubated in high glucose and low oxygen 
conditions for 24h (20N: 1.2±0.01; 20H: 1.7±0.01). The addition of silymarin does not 
appear to have any significant effect on cell proliferation over this 24h time frame although 
there seems to be a slight tendency for silymarin to reduce proliferation in all samples. This 
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tendency is however not statistically significant (5N: 1.1±0.02; 20N: 1.1±0.01; 5H: 1.4±0.01; 
20H: 1.4±0.04). 
7.4.4. Comet Assay - Effect ofsilymarin on glucose and oxygen mediated DNA damage 
In a blinded analysis, the effect of silymarin (50JlM) on DNA integrity in HUVECs cultured 
in varying concentrations of glucose (5mM & 20mM) and oxygen (normoxia & hypoxia) for 
24h was assessed. Results confirmed earlier findings in untreated cells (Fig. 3.5 and 5.6) 
showing that hyperglycaemia leads to a significant rise in DNA damage in cells cultured 
under both normoxia (5N: 49±8; 20N: 79±3) and hypoxia (5H: 84±3; 20H: 156±5) (Fig. 
7.3). The greatest increase in DNA damage can be seen in HUVECs cultured in both high 
glucose (20mM) and hypoxic conditions for 24h (20N: 79±3; 2011: 156±S). 
Addition of silymarin (50JlM) had no significant effect on DNA damage levels in HUVECs 
cultured in normoxic conditions for 24h (5NSM: Sl±4; 20NSM: 67±5). It did, however, 
significantly reduce DNA damage levels in HUVECs cultured in hypoxic conditions for 24h 
(5H: 84±3 vs 5HSM: 54±3; 20H: 156±5 vs 20HSM: 67±5). Since DNA damage levels in 
silymarin-treated cells seem to remain constant between all culture conditions, the results 
suggest that silymarin treatment prevents a loss of DNA integrity with a change in culture 
conditions rather than repairing existing damage. 
In order to determine how quickly silymarin exerts its protective effect, DNA damage levels 
in HUVECs cultured in 20mM glucose at I, 6 and 24h in both normoxia and hypoxia were 
determined (Fig. 7.4). As seen previously (Fig. 3.5, 5.6 and 7.3) there is a significant 
increase in DNA damage in control samples cultured in both high glucose and low oxygen 
compared to high glucose alone (20N: 61±5 vs 20H: 95±9). This effect is evident after only 
6h and increases over time. 
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The effect of silymarin on the level of DNA damage could only be observed after 24h (Fig. 
7.4). Interestingly, there was a significant rise in DNA damage in normoxia with the addition 
of silymarin after 24h (20N: 62±6 vs 20NSM: 104±7) whereas silymarin significantly 
reduced DNA damage in cell cultured in hypoxia for 24h (201-1: 137±13 vs 201-lSM: 72±3). 
These results suggest that loss of DNA integrity in endothelial cells is present after only six 
hours exposure to high glucose and low oxygen tension. Silymarin treatment appears to 
prevent DNA integrity loss in hypoxic culture conditions. 
Extending the incubation time to 48h leads to a further rise in DNA damage in both 
normoxic (20N24: 100±0 vs 20N48: 172± II) and hypoxic (20H24: I 64±6 vs 20H48: 206±5) 
conditions (Fig.7.5). The re-oxygenation of hypoxic cells for 24h did not cause any 
significant change to the level of DNA damage (20H+20N: 233±2). The addition of 
silymarin (50)lM) to the culture medium caused no significant change to the level of DNA 
damage in cells cultured in normoxic conditions (20N24SM: 121±14; 20N48SM: 147±4). 
However HUVECs cultured in hypoxic conditions, showed a significant reduction in DNA 
damage with the addition of silymarin compared to control (20H24: 164±6; 20H24SM: 
104±2; 20H48: 206±5; 20H48SM: 86± 1). This was also true for re-oxygenated samples 
(20re-ox: 233±2: 20re-ox SM: 9J±5) (Fig.7.5). 
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Fig. 7.1: Effect ofsilymarin (SM) on the level of DNA damage induced in human umbilical 
vein endothelial cells cultured in 5mM glucose normoxia for 24h. Results are expressed as 
mean ± SEM from three different batches of cells (n = 3) (Kruskal-Wallis test: ••• p < 
0.001). 
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Table 7.1: Effect of a-lipoic acid (lOOIlM) compared to silymarin (50IlM) on HUVEC cell 
DNA damage (normoxia and hypoxia). Cells were stepped down overnight in glucose 
free/serum free media before incubation and analysis with the comet assay. Results are 
expressed as relative percentage change compared to control (Mean - 100%/ SEM) ± SEM 
from four separate experiments (n = 4) (Student'S t-test: ·p<0.05, ··p<0.005, ···p<O.OOl). 
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Treatment Relative Student's Student's 
percentage change t-test t-test 
in DNA damage p < 0.05 P < 0.05 
(%) (normalised to (compared to 
20mM Normox) si lymarin 
treatment) 
20mM glucose Normox 100 
20mM glucose Normox + 118 ± 7 0.081 
50llM silymarin 
20mM glucose Normox + 88 ± 7 0.191 0.024 
100llM a - lipoic acid * 
20mM glucose Hypox 170 ± 7 0.002 0.001 
* *** 
20mM glucose Hypox + 103 ± 4 0.536 
50llM silymarin 
20mM glucose Hypox + 97 ± 6 0.710 0.494 
100llM (1 - lipoic acid 
* (p < 0.05); ** (p < 0.01); *** (p < 0.001) 
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(SmM & 20mM) and oxygen tension (N = normoxia and H = hypoxia) -induced changes in 
cell proliferation in a HUVEC line after 24h incubation . Each bar represents the mean ± 
SEM from three different batches of cells (n = 3) (Kruskal-Wallis test: ***p < 0.00 I) . 
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results are expressed as mean ± SEM from three separate experiments (n = 3) (Kruskal-
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Fig. 7.5: Effect of si lymarin (SM) (50~M), incubation time (24h & 48 h) and re-oxygenation 
(N = nonnoxia and H = hypoxia) on HUVEC DNA damage. Cells were analysed using the 
comet assay. The relative change in DNA damage is expressed as a ratio of the 20mM 
glucose damage in Nonnoxia (24h) sample (100%). The results are expressed as mean ± 
SEM from three separate experiments (n = 3) (Student's t-test: * p < 0.05 ; ** P < 0.0 I; *** P 
< 0.001). 
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In order to determine the involvement of HIF-I a on the DNA protective effect of silymarin, 
DNA damage was analysed in HUVECs treated with silymarin ± HIF-Ia antisense (2J.lM) 
(Fig. 7.6). If silymarin acts independently of HIF -I a, then a reduction in DNA damage with 
silymarin treatment is expected followed by a further reduction when HIF-Ia activity is 
blocked as indicated by the results from Chapter Five (Fig. 5.6). No significant difference 
between silymarin treated samples alone could be observed with one exception, cells 
cultured in 20mM glucose normoxia which showed a significant increase in DNA damage 
compared to 5mM normoxia (5NSM: 41±1; 20NSM: 83±2) (Fig. 7.6). A corresponding rise 
in DNA damage seen in silymarin treated samples + AS was also observed (5NSMAS: 32±1; 
20NSMAS: 69±1). 
Antisense reduces DNA damage further when compared to SM treatment alone although in 
samples incubated in 5mM glucoselhypoxia (5HSM: 62±1; 5HSMAS: 32±t). Compared to 
untreated HUVECs (as shown in Fig. 3.5), silymarin ± HIF-I a antisense seem to prevent the 
loss of DNA integrity confirming the findings of Fig. 7.3. 
In order to ensure that silymarin does not prevent HIF-Ia antisense uptake into the cell, 
which would lead to the production of false negative results seen with the comet assay in 
Fig 7.6 silymarin treated HUVECs cultured in hyperglycaemia and normoxia were incubated 
with FITC labelled control oligonucleotide. Results show no impairment of oligonc1eotide 
uptake into the cells (Fig. 7.7) confirming that the results seen in Fig. 7.6 are a true reflection 
ofthe effect HIF-Ia AS has on DNA integrity in the different culture conditions. 
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Fig. 7.6: Determination of the effect that HIF-Ia antisense (AS) treatment (211M) ± 
silymarin (SM) has on the level of DNA damage induced by SmM and 20mM glucose and 
oxygen tension (N = normoxia and H = hypoxia) in HUVECs. Cells were analysed using the 
comet assay. The results are expressed as mean ± SEM from three separate experiments (n = 
3) (Kruskal-Wallis test: **p < 0.0 I; ***p < 0.001). 
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f'il. 7.7: Detennination of the effect silymarin treatment (50J.lM) has on cellular uptake of 
the rlTc lahcllcd control oligonucleotide (1IIF-la antisense control) in hypcrglycaemic cells 
cultured under nnmluxic condition. From Icft 10 right are (a) Ohour, (b) I hour, (c) 6hour, (d) 
24hour incubation. 2J.1M rlTc lahclled control oligonucleotide wa'i directly added to 16well 
chnmhcr slidc~ containing 0.1 x 1 O· cells/well before analysis using a Leica DML Fluorescent 
microscope. The picturc~ arc representative of samples from three different batches of 
IItJVI:Cs (n - 3). MUl'-nilicalinn: 200x. 
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7.4.5. Effect of silymarin treatment ± HIF -1 a antisense on cell size 
Changes in HUVEC size over time (6h & 24h) in silymarin treated HUVECs ± HIF-la 
antisense was determined using ImageJ freeware. Percentage changes in cell size were 
determined relative to control (t = Oh 100%) and analysed for all three experiments (Fig.7.8). 
Neither silymarin (sO)lM) treatment alone nor the addition of HIF-l a antisense (2)lM) had 
an effect on cell size. 
7.4.6. Effect of silymarin treatment ± HIF-I a antisense on MitoTracker Green fluorescence 
Changes in MitoTracker Green FM fluorescence intensity over time (6h & 24h) in silymarin 
treated HUVECs ± HIF-la antisense was determined using ImageJ freeware. The percentage 
changes in fluorescence intensity was determined relative to control (t = Oh 100%) (Fig.7.9). 
Silymarin (50)lM) treatment alone reduces MitoTracker Green fluorescence intensity 
significantly in samples cultured in high glucose (20mM) and hypoxia after both 6h (control: 
108±4; SM: 59±12 - P < 0.05) and 24h (control: 105±9; SM: 60±6 - p < 0.05). There is a 
reduced trend in fluorescence intensity in all samples treated with silymarin for 24h. The 
addition of HIF-la antisense (2)lM) on the other had had no significant effect on 
MitoTracker Green fluorescence intensity despite the fact that fluorescence in most samples 
is still reduced. 
Analysis of silymarin treatment with and without HIF-la antisense on cellular ROS 
production was carried out but no reliable data was obtained. 
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Fig. 7.8: Effect of si lymarin (SM) treatment (50flM) (a) ± HIF- I a. antisense (AS) (2flM ) (b) 
on cell size in human umbilical ve in endothe lia l ce lls. The change in cell size is expressed 
relative to control (t = Oh 100%). T he above graph is representative of the mean ± SEM of 
three separate experiments (n = 3) with 50 observations per sample (Student's t-test and 
ANOYA plus post-hoc test: p > 0.05). 
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Fig. 7.9: Effect of silymarin (SM) treatment (50flM) (a) ± IDF-la. antisense (AS) (2flM) (b) 
on MitoTracker Green FM fluorescence intensity in human umbilical vein endothelial cells. 
The change in fluorescence is expressed relative to control (t = Oh 100%). The above graph 
is representative of the mean ± SEM of three separate experiments (n = 3) with 50 
observations per sample (Student's t-test and ANOVA plus post-hoc test: p > 0.05). 
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7.5. Discussion 
The primary aim of this research was to assess the potential cytoprotective effect of 
silymarin on hypoxia and hyperglycaemia induced endothelial cell changes after 24h 
incubation. 
In Chapter Three, we established that both glucose and oxygen concentration have distinct 
yet additive effects on endothelial cells which lead to an increase in DNA damage and a rise 
in cell proliferation after 24h. Since antioxidants are prime candidates for the attenuation of 
oxidative stress mediated DNA damage, silymarin presents itself as an attractive therapeutic 
agent. Although a number of different variables were being analysed each variable had its 
respective control that was used for the purpose of the statistical analysis. Results do indeed 
show a reduction in the loss of DNA integrity with silymarin compared to control after 24h 
but this effect seems to be limited to endothelial cells cultured in hypoxia. Since most of the 
research emphasis to date is based on glucose-induced cellular damage, this study adds 
weight to the notion that there is a hypoxic component in the development of high glucose-
induced endothelial damage. To our knowledge, neither the additive effect of glucose and 
hypoxia induced DNA damage in endothelial cells after 24h exposure nor the strong 
cytoprotective effect of silymarin in this context have been reported. 
Although samples cultured in hyperglycaemia and/or hypoxia showed the most significant 
reduction in DNA damage with silymarin, the level of DNA damage found in silymarin 
treated samples seems to remain constant throughout all culture conditions. This suggests 
that silymarin prevents DNA damage from occuring when endothelial cells are exposed to 
changing glucose and oxygen conditions, raising the question whether silymarin acts by 
improving the cellular environment due to its antioxidant capacity or if it acts through a 
different mechanism which is independent of its antioxidant activity. 
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One possible explanation for the mechanism(s) involved could lie with a recently established 
hypothesis by Nyengaard et al. (2004). The paper detailed the interaction between hypoxia 
and hyperglycaemia in endothelial cells via the accumulation of free cytosolic NADH by 
different yet additive pathways (Nyengaard et al. 2004), strengthening the argument that 
silymarin could achieve its cytoprotective effect by acting as an aldose reductase inhibitor 
(Nyengaard et al. 2004). However, in 2002 the predicted structural requirements of flavonoid 
aldose reductase inhibitors were published in an attempt to improve the selection process for 
novel therapeutic agents (Matsuda el al. 2002). Unfortunately, neither the structure of 
sililibinin, silichristine, silidianin or taxifolin correspond with any of these criteria or to the 
structural prediction criteria for the radical-scavenging potential of flavonoids (Rajendran el 
al. 2004), although the exclusivity of the proposed structures as aldose reductase inhibitors 
may not be comprehensive. 
If silymarin was to act as an aldose reductase inhibitor, it would improve the cellular redox 
potential through its action on NAOH. Although we were not able to measure changes in 
NADH levels per se, we attempted to measure changes in the overal cellular redox state with 
the use of the fluorescent marker CC-l. In Chapter Five, we showed that there is an early 
effect on the cellular redox state of the endothelial cell in response to changing glucose and 
oxygen conditions. Unfortunately, the results obtained for the addition of silymarin were 
inconclusive, as the CC-l results showed a very obscure fluorescence pattern making its 
interpretation near to impossible. The reason for this is unknown, but is most likely due to 
the auto-oxidation of the fluorescent marker. Literature however details numerous accounts 
of silymarin protecting against oxidative stress (Svobodova et al. 2006, Nencini el al. 2006) 
as well as reports suggesting that silymarin restores the levels of antioxidant enzymes 
superoxide dismutase (SOD), glutathione peroxidase (GSHPx) and catalase (CAT) in the 
pancreas of alloxan-induced diabetic rats (Soto et al. 1998). It is therefore perceivable that 
silymarin reduces the cellular imbalance between radical production and antioxidant 
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enzymes, thereby reducing the development of oxidative stress resulting in less intense 
changes in the cellular redox state and a reduction in oxidative stress induced DNA damage. 
Although a reduction in oxidative stress by silymarin would be in keeping with our findings, 
it is only one perceivable contributing mechanism. As shown in Chapter Five, we also 
determined that HIF-la activation in response to hypoxia contributes to the development of 
endothelial DNA damage. In combination with silymarin we were able to see a further 
reduction in endothelial DNA damage in samples cultured in 5mM hypoxia, none however 
when cultured in 20mM (despite a reducing trend). Therefore the cytoprotective effect of 
silymarin in hypoxic conditions is unlikely to be attributable to a direct effect on HIF-
Ia suggesting a multi-faceted cause of DNA damage. Further we suggeted a close 
relationship between HIF-la activity and cellular ROS production although we were not 
able to establish ifHIF-la requires a functional mtETC for its accumulation in the nucleus. 
If this were true and silymarin reduced hypoxia mediated cel1ular oxidative stress levels as 
indicated above then this would result in a reduced activation of HIF-l a which may explain 
why we are seeing less of an effect on DNA damage ofsilymarin + HlF-la AS as expected. 
Silymarin may act by improving the cel1ular environment due to its antioxidant capacity 
which may in itself influence how effective the HIF-la antisense is reducing DNA damage. 
When compared to other well established potent antioxidants (e.g. alpha-lipoic acid) (Table 
7.1) silymarin appears to be almost as potent in its cytoprotective activity, than alpha lipoic 
acid (Ziegler et al. 1999). Alpha lipoic acid is a potent neuroprotector in diabetic neuropathy 
as shown by two large scale randomized controlled trials (ALADINI and ALDIN III) 
(Ziegler et al. 1995, Ziegler et al. 1999). However, it is not clear from this data if the high 
antioxidant property directly accounts for silymarins' cytoprotective effect. 
The majority of published data using silymarin deals with hepatic diseases and cancer using 
silymarin as a therapeutic agent rather than focusing on mechanistic studies. One particular 
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problem is the lack of standardisation of the extraction process and product composition 
leading to huge variations between batches and manufacturers. The European Pharmacopoea 
states that a minimum of 1.5% of sitymarin should be expressed as silibinin and that the 
overall sample should not contain more than 2% foreign matter although "foreign matter" is 
not defined (European Phamacopoeia 2004). Even a direct request for the analytical details 
of silymarin from the German Central Laboratory for Pharmacists (quality assurance 
institution for products marketed in Germany) where silymarin is produced provides no 
further insight into the exact composition of silymarin (personal communication, July 2004). 
They do however acknowledge the presence oftaxifolin but do not indicate its role or state 
the percentage concentration in respective batches of silymarin. 
7.6. Conclusion 
Given the results so far we can confirm that silymarin is a potent cytoprotective flavonoid 
antioxidant. It protects glucose treated HUVECs under hypoxic conditions with associtated 
changes in the cellular redox state, DNA damage and possibly DNA repair mechanisms. 
Despite its strong radical scavenging potential it is not clear if silymarin acts by improving 
the cellular environment or if it acts through a different mechanism independent of its 
antioxidant activity such as an aldose reductase inhibitor for example. In order to understand 
the mechanisms behind this cytoprotective activity the activity of the compounds which are 
found in the silymarin extract were then investigated. 
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CHAPTER EIGHT: Effect of silbinin and taxifolin on DNA 
damage in HUVECs in hypoxia and high glucose 
concentration 
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S.l. Hypothesis 
The flavonoid antioxidants silibinin and taxifolin are responsible for the protective effects on 
endothelial DNA damage seen with silymarin in response to hypoxia and hyperglycaemia. 
S.2. Introduction 
Silymarin contains a number of different flavonoid isomers of which silibinin is thought to 
be the most therapeutically active component (Zhao el al. 1999). Probably less well known is 
that taxifolin can also be found in the silymarin compound although literature refers to 
taxifolin as the "parent compound" of all silymarin components (Hansel et al. 1993). During 
the extraction process of silymarin, taxifolin combines with different coniferyl alcohol 
structures from the plant cell wall to give rise to the different flavonoids known collectively 
as silymarin which suggests that taxifolin is indeed an active ingredient found in the Milk 
Thistle plant. Fig. 8.1 shows a proposed chemical reaction of taxifolin and coliferyl alcohol. 
Taxifolin is very rarely mentioned as a component of silymarin although it is speculated that 
silymarin contains impurities which have a much higher antioxidant activity than the 
identified flavonolignans (Kvasni~ka el al. 2003). It is suggested that the purer the silymarin 
compound the less active it would become. 
Therefore, the relative contribution that silibinin and taxifolin may have on the reduction in 
DNA damage mediated by silymarin, and the potential contributing mechanisms which lead 
to the development of endothelial cell changes in response to glucose and hypoxia was 
determined. 
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Fig. 8. 1: Proposed oxidation/reduction reaction oftaxifolin and coniferyl alcohol 
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8.3. Materials and Methods 
The percentage concentration of silibinin and taxifoIin within the silymarin compound was 
determined using Capillary Zone Electrophoresis (Section 2.9). The effect of glucose 
concentration, oxygen tension, silymarin (50J.lM), silibinin (25J.lM) and/or taxifolin (600J.LM) 
on DNA integrity was determined using the comet assay (Section 2.4). HUVECs were 
cultured as described in Section 2.2. 
Each experiment was performed in triplicate and repeated on three separate occasions. The 
test distribution was assumed not to be normal to account for the limitations in sample size. 
Statistical significance was determined using a Kruskal-Wallis test or Mann-Whitney U test 
against the test hypothesis (Ho) that there are no differences between the means of the 
samples. Were p< 0.05 the Ho must be rejected and the HA (there is a difference between the 
means of the samples) accepted. Where data was normalised (100%) a Student's t-test (Mean 
- 100%1 SEM) and/or ANOYA (with Tukey's post-hoc test) was carried out. The level of 
significance is expressed as .p< 0.05, •• p< 0.01 or ••• p< 0.001. No significant difference 
was assigned to samples where p > 0.05. 
8.4. Results 
8.4.1. Relative amounts of taxifolin and silibinin found within commercially available 
silymarin sample 
Analysis of the individual electrophoresis fractions of silibinin and taxifolin present in 
silymarin was carried out using capillary zone electrophoresis (CZE) analysis. Quantitative 
analysis indicated that taxifolin and siIibinin was present at levels of 4.1 % (Fig. 8.3, Table 
8.1) and 46.5% (Fig. 8.4, Table 8.1) of silymarin respectively. The equivalent concentration 
of taxifolin (600J.lM) and silibinin (25J.lM) were then used in comparative experiments. It is 
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however noteworthy that the small area under the curve (AVe) associated with taxifolin may 
be a source of inaccuracy in the calculation of the final concentration used in all subsequent 
experiments. 
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Fig. 8.2: Electropherogram showing the separation of (a) silymarin (b) taxifolin (c) silibinin. 
Capillary total length 650mm x 50llm. I.D.; running buffer (pH 2.0) containing 80mM SDS, 
50mM DSHP and 25% methanol. Detection at 200nm. Injection time 300s at 50mbar. 
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Table 8.1: Area under the curve (AVC) values for taxifolin and silibinin identified during 
CZE analysis of a 1M silymarin sample. Percentage analysis (%) indicates that taxifolin 
represents 4% of the total ofthe commercially available sample of silymarin while silibinin 
represents 46.5%. 
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8.4.2. Effect of tax if olin on DNA damage 
Analysis of all antioxidants was limited to HUVECs cultured in high glucose conditions as 
Chapters Three and Seven have shown that glucose/hypoxia mediated cytotoxicity and the 
cytoprotective effect of silymarin are limited to these conditions. Analysis of the effect of 
different taxifolin concentrations (50llM - 600IlM) on endothelial DNA damage indicate that 
all three concentrations oftaxifolin (600TX: 48±6; IOOTX: 53±9; 50TX: 48±5) as well as 
silymarin (SM: 60± II) significantly reduces DNA damage in hypoxia treated samples 
compared to untreated (20H: 78± 18) (Fig. 8.5). No effect on DNA damage of either 
silymarin or taxifolin could be observed in cel1s cultured in normoxic conditions (20mM) 
(600TX: 56±8; IOOTX: 56±6; 50TX: 59±4; SM: 67±9; 20N: 55±11). 
8.4.3. Effect of pre-incubation of HUVECs with antioxidants on DNA damage levels 
Pre-exposure of cel1s to antioxidants has to be distinguished from any effect on DNA 
integrity seen with simultaneous exposure. HUVECs (20mM) were pre-incubated with 
silymarin (50IlM) (N: 51±9; H: 38±5), taxifolin (600J,lM) (N: 50±6; H: 42±9) and silibinin 
(25IlM) (N: 64±7; H: 52±9) for 24h in hypoxic and normoxic culture conditions (Fig. 8.6). 
Pre-incubation did not lead to any changes in DNA damage profile compared to acute 
incubation (Fig. 8.6) (control (N: 60±8; H: 98±16); silymarin (N: 68±9; H:60±6), taxifolin 
(N:42±7; H:50±2) and silibinin (N:74±9; H:83±11», with the only exception ofsilibinin.lts 
cytoprotective effect appeared to be significantly enhanced in hypoxic conditions when cel1s 
were pre-incubated (20H: 98±16; 20HSB: 83±ll). These results suggest that silibinin could 
be acting through a different mechanism than taxifolin. 
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contro l (N = normox ia and H = hypox ia). Ce lls were stepped down overnight in g lucose 
free/serum free media before incubation and subseq uent ana lys is w ith the comet assay. The 
results are expressed as mean ± SEM from three separate expe riments (n=3) (Kruska l-Wallis 
test: * p < 0.05; ** p < 0.0 I) . 
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8.4.4. Effect of HlF-I a. antisense treatment in addition to silibinin and taxifolin 
As with silymarin (Fig. 7.6) the effect of HIF-Ia. antisense in addition to treatment with 
taxifolin or silibinin was assessed. This was examined across the spectrum of concentrations 
used ego SmM & 20mM in both normoxia and hypoxia. A significant decrease in DNA 
damage was observed in samples treated with taxifolin alone in response to an increase in 
hypoxia as well as glucose when compared to control (SNTX: 34± I; 20NTX: 43± I, SHTX: 
S8±1; 20HTX: 64±1) (Fig. 8.7a). This was accompanied by a further decrease in hypoxia 
and hyperglycaemia induced DNA damage in samples treated with both taxifolin and HIF-
10. antisense (SNTXAS: 28±1; 20NTXAS: 43±1, SHTXAS: 43±1; 20HTXAS: S2±I). 
Addition ofsilibinin to HUVECs did not result in a significant change of DNA damage level 
compared to control except for samples incubated in both high glucose concentration and 
hypoxia (20H: 188±2; 20HSB: 81±1). Addition ofHIF-la antisense to silibinin treated cells 
had no effect on DNA damage levels compared to silibinin treatement alone (Fig. 8.7 b). 
8.4.S. Superoxide radical production in silymarin, taxifolin and silibinin treated HUVECs 
Using a commercially available kit, the total superoxide radical production in response to 
antioxidants, silymarin (SOIlM), taxifolin (600IlM) and silibinin (25IlM) was determined. 
The percentage proportion of superoxide radicals found in mitochondria and the cytoplasm 
was analysed. The results show no significant change in superoxide radical production in and 
between any of the treatment groups (p > 0.05) (Fig. 8.8 - 8.10). However for cells incubated 
with silymarin and silibinin there was a decrease in mitochondrial SOD associated with an 
increase in cytoplasmic SOD. In contrast no such correlation was evident for taxifolin 
indicating that these antioxidants do not protect HUVECs from a loss of DNA intetegrity in 
response to hyperglycaemia and! or hypoxia by acting on superoxide radical production or 
scavenging. 
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Fig. 8.7: Determination of the effect HIF-1!l antisense (AS) treatment (2JlM) has on the level 
of DNA damage induced in taxifolin (600J.lM TX) (a) and silibinin (25J.lM SB) (b) treated 
HUVECs. Cells were stepped down overnight in glucose free/serum free media before 24h 
incubation. Cells were analysed using the comet assay. The results are expressed as mean ± 
SEM (n = 3) (Kruskal-Wallis test: * p < 0.05; ** P < 0.01; *** P < 0.001). 
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changes in glucose (SmM and 20mM) and oxygen concentration (N = normoxia; H = 
hypoxia) in silymarin (50~.I.M) treated HUVECs. The change in superoxide radical formation 
is compared relative to total cellular superoxide radical control (5N = 100%). (a) total 
superoxide radical formation in HUVECs (b) percentage proportion superoxide radical 
formation found in mitochondria (c) percentage proportion superoxide radical formation 
found in the cytoplasm. Samples were analysed using a SOD-WST kit. Each bar represents 
the mean ± SEM from three different experiments (n = 3) (Student's t-test and ANOV A plus 
post hoc test: p> 0.05). 
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Fig. 8.9: Determination of changes in cellular superoxide radical formation in response to 
changes in glucose (5 & 20mM) and oxygen concentration (N = normoxia; H = hypoxia) in 
taxifolin (600f..lM) treated HUVECs. The change in superoxide radical formation is 
compared relative to total cellular superoxide radical control (5N = 100%). (a) total 
superoxide radical formation in HUVECs (b) percentage proportion superoxide radical 
formation found in mitochondria (c) percentage proportion superoxide radical formation 
found in the cytoplasm. Samples were analysed using a SOD-WST kit. Each bar represents 
the mean ± SEM from three different experiments (n = 3) (Student's t-test: p> 0.05). 
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Fig. 8.10: Determination of changes in cellular superoxide radical formation in response to 
changes in glucose (5 & 20mM) and oxygen concentration (N = normoxia; H = hypoxia) in 
silibinin (25J.lM) treated HUVECs. The change in superoxide radical formation is compared 
relative to total cellular superoxide radical control (5N = 100%). (a) total superoxide radical 
formation in HUVECs (b) percentage proportion superoxide mdical formation found in 
mitochondria (c) percentage proportion superoxide mdical formation found in the cytoplasm. 
Samples were analysed using a SOD-WST kit. Each bar represents the mean ± SEM from 
three different experiments (n = 3) (Student's t-test: p> 0.05). 
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8.5. Discussion 
Results showing the beneficial effects of taxifolin and silibinin on reducing DNA damage 
mediated by high glucose and hypoxia facilitate our understanding of silymarin effects. 
Although taxifolin is not considered as an active component of silymarin, these results raise 
questions about its role in the protective effects of silymarin. With the lack of standardisation 
of the relative components ofsilymarin, this may contribute to variation in effectiveness. 
At a concentration of 600~M - 50~M taxifolin has a strong cytoprotective property reducing 
the loss of DNA integrity in response to high glucose and! or hypoxic conditions (Fig. 8.5). 
This effect is as potent as that of silymarin and appears to be independent of the 
concentration used in this study (Fig. 8.5). Since taxifolin is classed as a flavonoid 
antioxidant, its effect does not come as a surprise. What is surprising is that the potent effect 
of taxifolin does not appear to be concentration dependent, suggesting that its powerful 
effects can be achieved with very small quantities as low as 50J.1M equivalent to 1I12th of the 
total taxifolin concentration found in the silymarin sample tested. At this level taxifolin 
would hardly be detectable within the silymarin complex and would indeed be classified as a 
likely "impurity". The fact that it is a very potent DNA protective agent even at this very low 
concentration adds weight to the hypothesis that silymarin contains impurities which are 
more potent than silyamrin itself (Kvasnicka el al. 2003). As it was not possible to find any 
references to the amount of taxifolin commonly used in in vitro studies (or the amount 
present in the maritime bark extract), it is difficult to place these and any future work into a 
context with previous findings. 
A study looking at the cytoprotective effectiveness of 25J.1M silibinin revealed that silibinin 
is not as potent a cytoprotective agent as taxifolin (Fig. 8.6). Since the molecular weight for 
silymarin is sometimes misleadingly quoted as that of silibinin, a concentration of 50J.1M was 
chosen which is equivalent to the final concentration of silymarin used. Since the CZE 
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anlaysis (Fig. 8.4) revealed that only approx 50% of the total amount is composed of 
silibinin the effects were compared to a concentrations of 25J.IM which is representative of 
the true contribution of silibinin in the silymarin complex. 
Despite the fact that the potency of siIibinin as a therapeutic agent has been convincingly 
shown (Lirussi et al. 2002) these results would suggest that although silibinin is a potent 
cytoprotective agent, it is not the sole reason for the therapeutic effectiveness of the 
silymarin compound. Taxifolin, the "parent compound" appears to be more potent than 
silibinin. In an attempt to confirm these results a direct comparison study was carried out 
comparing 50llM silymarin against the effect of 600llM taxifolin and 251lM silibinin. As 
Fig. 8.6 clearly shows taxifolin is a more potent cytoprotective agent than silibinin 
significantly reducing hypoxia/hyperglycaemia induced DNA damage after 24h 
(simultaneous exposure). At a concentration of 25J.IM silibinin failed to induce a significant 
cyto-protective effect (simultaneous exposure). 
The protective effectiveness of neither silymarin nor taxifolin are affected in any way when 
added prior to test conditions (pre-exposure), although silibinin (25IlM) was found to be 
significantly more effective in protecting the cell against hypoxia/hyperglycaemia-induced 
endothelial DNA damage (pre-exposure), indicating that its potency is dependent on the 
activation of the mechanisms that prepare the cell to cope with the change in glucose 
concentration and oxygen tension. This could help explain the many in vivo results for 
silibinin found in the literature in which studies are carried out over a period of 
weeks/months, with silibinin content varying from product to product (and possibly batch to 
batch) due to the lack of standardisation of the extraction process and composition 
requirements for silymarin. Taken together, these results add weight to the suggestion that 
silibinin is not the sole reason for the therapeutic effectiveness of silymarin, with taxifolin 
potentially playing a very significant but potentially distinct role. 
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As demonstrated in Chapters Five and Six, HIF-Ia could potentially contribute to the 
observed hypoxia/hyperglycaemia-induced endothelial DNA damage while the cyto-
protective effect of silymarin does not seem to be attributable to a direct effect on HIF-Ia. 
Fig. 8.7 illustrates the effect ofHIF-la antisense treatment in both 600J.lM taxifolin (a) and 
25J.lM silibinin (b) treated HUVECs. As with silymarin, a reduction in DNA damage can be 
expected if either antioxidant acts on or downstream of HIF-Ia with the levels increasing 
when antisense is added. Taxifolin does not appear to act on HIF-Ia, as DNA damage levels 
are further reduced with the addition ofHIF-la antisense (Fig. 8.7a). Results for silibinin are 
less clear, since the removal of HIF-la has no effect on DNA damage levels. The most 
likely cause is a protective mechanism totally independent of HIF-Ia but mirrors the 
findings for silymarin-treated HIF-Ia antisense samples (Fig. 7.6). Although these results 
still do not offer an answer as to whether the effect of silymarin and its components is 
achieved by acting on the hypoxia inducible factor -In it appears likely that both taxifolin 
and silibinin act through two very different mechanisms with taxifolin mediated protection 
being afforded independent ofHIF-la. 
Silymarin has shown to have a potent cytoprotective effect on endothelial DNA damage 
(Fig. 7.3). This poses the question as to the type of radical(s) silymarin or any of its 
constituents acts on (if any). The literature reports evidence for silymarin acting on 
hydrogen peroxide (Wang et al. 2005), superoxide radicals (Kostyuk et al. 2004) and 
recently even phenylglyoxylic ketyl radicals (Sersen et al. 2006). 
Figures 8.8 to 8.10 show results for the effects of silymarin, taxifolin and silibinin on 
superoxide radical production in the mitochondrial as well as the cytoplasmic fraction. No 
statistical difference can be seen between any of these compounds (p > 0.05). This lack of 
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effect is surprising, since the effect of silymarin on mitochondrial generated ROS was very 
prominent and given the potent nature of all three antioxidants a change in superoxide 
radical production was anticipated. This could have been caused by the limitations in sample 
size and method of analysis. Future studies should take these limitations into account and 
include the analysis of other radicals such as 'OH or H20 2• 
These results indicate that endothelial cell DNA damage observed after 24h seen with an 
exposure of high glucose and low oxygen (Fig. 3.5) does not seem to be due to 
mitochondrial produced superoxide radicals (Fig. 4.9, 8.8-10) and other radicals such as 
hydrogen peroxide, nitric oxide and peroxynitrite need to be investigated. 
8.6. Conclusion 
Evidence provided in this Chapter suggests an important role for the formerly perceived 
impurity taxifolin as a potent cytoprotective agent in the silymarin complex. It is evident that 
both taxifolin and silibinin act via different mechanisms to exert their cytoprotective effect. 
More studies into possible mechanisms and stress pathways such as PKC, p42/44 or PI3K as 
well as the effects of the flavonoid antioxidants on these pathways need to be carried out. 
8.7. Limitations 
CZE analysis, to identify the relative amounts of silibinin and taxifolin in our commercially 
available silymarin sample was chosen over HPLC due to its lower cost, short analysis time 
and easy implementation. Silymarin samples were spiked with the compound of interest and 
the resulting electropherograms used to identify and measure the area(s) under the curve of 
silibinin and taxifolin. From that we were able to obtain the relative amount of both taxifolin 
and silibinin present in the silyrnarin sample. 
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It is widely documented that in CZE analysis problems arise concerning the reproducibility 
of the measurements (Bachmann et al. 1994). This is thought to be due to sample 
preparation. separation such as variations in electroosmotic flow. analyte velocities and the 
discontinuous use of high voltage (Bachmann et at. 1994, Li et at. 2006). This was evident in 
our CZE output where the retention time for taxifolin (Fig. 8.3) changed from 22min to 
22.8min and the retention time for silibinin (Fig. 8.4) changed from 14.4min to 16.6min. 
This could have been caused in part, by the use of a pseudo-stationary phase and eliminated 
by the use of further internal standards. 
An additional contributing factor is the separation of polyphenolic compounds itself, as the 
polarity of the compound which is associated with the number of hydroxyl groups, can affect 
retention times (Wang et al. 2007). This is important as compounds such as taxifolin are 
made up of different isomers which have not yet been successfully isolated. The presence of 
isomers and other unknown impurities may have an impact on the number of hydroxyl 
groups present and whence may affect retention times. This requires strict and elaborate 
optimization of the sample preparation such as the method of extraction and the requirement 
to concentrate the sample prior to use. In addition, separation factors including buffer type, 
concentration and pH, the presence of various additives, voltage and temperature, as well as 
detection method are important factors to consider (Li et at. 2006). However, these were out-
with the scope and time frame of this thesis but should be determined prior to any further 
more detailed work using silibinin and taxifolin is carried out. 
Despite the limitations highlighted, the CZE analysis was sufficient for the relative amounts 
of silibinin and taxifolin to be determined prior to their preliminary comparison with 
silymarin. 
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CHAPTER NINE: Discussion 
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9.1. Discussion 
It is well established that diabetes mellitus is associated with an increase in oxidative stress 
(Baynes et al. 1999; Son et al. 2007) which is believed to playa key role in the pathogenesis 
of diabetic vascular dysfunction (Panus et al. 2003; Tesfamariam et al. 2007). The results 
presented in this thesis indicate that glucose and oxygen exhibit distinct yet potentially 
additive effects on endothelial cells which results in changes in cell proliferation and DNA 
damage. 
Literature reports on the effect of high glucose in endothelial cells show a reduction in cell 
proliferation (Lorenzi et al. 1986; Varma et al. 2005), abnormal cell cycling (Lorenzi et al. 
1987) and an increase in apoptosis over time (Baumgartnet-Parzer et al. 1995), whereas 
exposure of endothelial cells to hypoxia has been shown to accelerate cell proliferation as 
seen in tumour aetiology (Vender et al. 1992; Byrne et al. 2005). Although the exact 
mechanisms for the differing effects on cell proliferation remains unclear, ROS and ROS 
associated signalling pathways seem to playa key role. Sheu et al. (2005) have shown that 
high glucose causes ROS generation in HUVECs via a PI3K1Akt-dependent pathway. PI3K-
Akt dependent signalling plays a crucial role in cell survival, proliferation, microvascular 
permeability and angiogenesis (Varma et al. 2005), while hypoxia associated high flux of 
NO in contrast promotes cell death via the inhibition of cytochrome c oxidase mediated loss 
of mitochondrial membrane potential (Lee et al. 2002; Walford et al. 2004). 
Despite the observed acceleration in cell proliferation seen with high glucose concentration 
and/or low oxygen tension in HUVECs within the first 24h of exposure, our samples show 
no detectable change in cell viability. This suggests that the associated rise in DNA damage 
seen in these cells is not due to hyperglycaemia and/or hypoxia induced apoptosis but may 
indicate a pro-apoptotic state. Jiang et al. (2001) have shown that a threshold of DNA 
damage is necessary for the activation of DNA damage checkpoints and the initiation of 
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DNA repair. It is perceivable that the increase in proliferation rate observed leads to the 
potentiation of HUVEC DNA damage because the level of DNA damage incurred in 
response to high glucose concentration and/or low oxygen tension is too low to trigger DNA 
repair mechanisms prior to replication. This may eventually result in the HUVECs viability 
and proliferation being compromised, accounting for the frequently reported reduction in cell 
proliferation and apoptosis often observed with later time points (Lorenzi el al. 1986; Varma 
et al. 2005; Baumgartnet-Parzer et al. 1995). 
One ofthe most novel and interesting findings of this thesis is the potential additive effect of 
hypoxia and hyperglycaemia and its resultant impact on cell proliferation, DNA damage and 
mitochondrial ROS production. Although it is not possible to explain these effects, it is 
evident that although these stimuli trigger very different signalling cascades the different 
mediators must converge at some common point in the signalling pathway. Such possible 
signalling points include mitochondrial ROS production, expression and activation of the 
transcription factor HIF-la and the involvement of mitogen activated protein kinases 
(MAPK) such as p42/44 which links growth and differentiation signals. 
Mitochondrial ROS generation is a key factor in oxidative stress-mediated cell changes 
(Nishikawa et al. 2000). As described in Chapter One, mitochondria produce substantial 
amounts of ROS which will attack molecular targets such as membrane phospholipids, 
transporters, enzymes, transcription factors and DNA (Thannickal et al. 2000). 
Hyperglycaemia is thought to be synonymous with an increase in superoxide radical 
formation from the mitochondria of endothelial cells (Du et al. 2003), which possibly 
accounts for the sharp rise in mitochondrial ROS production observed in our data after 6h 
exposure to high glucose concentration and low oxygen tension. Du et al. (2003) have 
reported that superoxide production induces DNA strand breaks which in tum leads to the 
activation of PARP (poly (ADP-ribose) polymerase) a nuclear DNA repair enzyme. PARP 
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initiates the poly (ADP-ribosyl)ation of GAPDH (Glyceraldehyde-3-phosphate 
dehydrogenase) a catalytic enzyme involved in glycolysis and a mediator for the activation 
of biochemical stress pathways. Our results do, however, show a significant increase in 
mitochondrial ROS production in all four treatment samples, making it an unlikely event 
attributable specifically to high glucose concentration and/or low oxygen tension alone and 
is more likely to be the result of stress induced by incubation conditions. Direct measurement 
of superoxide radical production did also not produce any significant change, adding weight 
to the notion that superoxide radicals are not the sole cause for the observed rise in redox-
sensor red CC-l fluorescence intensity. Other reactive oxygen species must therefore play an 
important role in the observed changes. The most likely being nitric oxide (NO). 
NO is a highly diffusible gas which can regulate mitochondrial ROS generation on mUltiple 
levels (Cassina et al. 1996). It can remove O2'- from peroxynitrite and via cytochrome c by 
stabilizing the enzyme and preventing its leakage from the mitochondria (Zhang et al. 2007). 
By acting on cytochrome c, oxidase NO can regulate cellular oxygen consumption (Moncada 
et al. 2002) instigating an event known as "metabolic hypoxia" a condition in which cells 
and tissues are unable to use oxygen despite it being available (Moncada et al. 2002). The 
signalling consequences of this effect are reported to include the prevention of HIF-la 
stabilization and the activation of AMPK (Quintero et al. 2006), both of which are key 
mediators of cellular stress responses. 
Although the measurement of NO production and its related changes in endothelial cells 
were out with the scope of this thesis, the effect low oxygen tension and high glucose 
concentration have on HIF-Ia activity in endothelial cells was determined using antisense 
technology. Our results clearly show the contribution of HIF-Ia in hypoxia-mediated 
mitochondrial ROS production after 6h (Fig. 5.9) which is reflected in a subsequent increase 
in DNA damage under the same conditions after 24h (Fig. 5.6), suggesting the involvement 
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of HIF-Ia in the development of the observed hypoxia-mediated endothelial cell changes. 
Although no comparable reports exist which explore the direct effect HIF-Ia has on 
endothelial DNA damage, many studies are devoted to the elucidation of the mechanisms 
leading to the activation of HIF-Ia under oxygen dependent (Wenger et al. 2000) and 
independent (Semenza et al. 2002) pathways. It appears that the hypoxia-induced activation 
ofHIF-Ia is regulated by different mechanisms from its stabilisation and DNA binding (Hur 
et al. 2001). Many reports show that the activation ofp42/44 MAPK appears to be a critical 
step in the transcription HIF -I a (Richards et al. 1999, Hofer et al. 200 I, Hur et al. 200 I) 
while endogenous NO formation seems to induce HIF-Ia accumulation, HIF-t DNA 
binding and downstream target expression in normoxic conditions (Brune et al. 2003). High 
glucose concentration has also been shown to increase p42/44, activity resulting in eNOS 
expression in HUVECs (Vasquez et al. 2007). If the hypothesis that the observed DNA 
damage in HUVECs is linked to a p42/44 dependent effect on HIF-J a transcription is 
correct, then the use of the p42/44 MAPK inhibitor, PD98059, should result in the protection 
of HUVECs against DNA damage, similar to the effect seen with HIF-Ia antisense. Our 
results, however, show no significant effect of PD98059 on DNA damage (Fig. 6.2), 
although a slight reduction in DNA damage can be seen in samples cultured in both high 
glucose concentration and low oxygen tension simultaneously for 24h an effect which might 
be more pronounced with an increase in sample number. It is however unlikely that the 
p42/44 dependent effect on HIF-Ia is a suitable explanation for our observations. This is not 
necessarily surprising as mechanisms of oxygen sensing and signalling during hypoxia and 
normoxia involve different pathways in various cell types (Lopez-Bameo et al. 2001). In 
addition, the findings from Fig. 5.9 also show a significant rise in mitochondrial ROS 
production in the presence of HIF-Ia antisense under normoxic conditions (6h) making it 
altogether unlikely that we are looking at a HIF-Ia dependent effect on DNA damage in 
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normoxia, while the HIF-Ia. activation appears to be involved in hypoxia induced DNA 
damage. 
Interesting points have been highlighted in the course of these investigations, including the 
difference between high and low oxygen tension on endothelial cell responses and the 
immediate mitochondrial response present after 6h which is seemingly manifested as 
endothelial DNA damage after 24h. These changes in CC-l fluorescence are possibly due to 
the effect of incubating cells over-night in glucose free/serum free media and the subsequent 
"strain" of restoring glucose levels. As the ability to restore glucose concentration is not 
influenced by any of the subsequent culture conditions, the DNA damage seen in 20mM 
hypoxia must be independent of the fluorescence changes observed after 6h which suggests 
that ROS production is not involved to a significant extent. 
The use of flavonoid antioxidants provide further insight into events leading to DNA 
damage. These compounds have been explored extensively for their chemopreventative 
potential for many types of human cancers (Soobattree et al. 2006; Qin et al. 2007). Our 
results clearly show that silymarin has a strong protective effect on DNA damage of 
HUVECs cultured in hypoxia for 24h which results in a significant reduction in DNA 
damage in both low and high glucose concentrations (Fig. 7.3). At the same time, it has no 
effect on cells cultured in normoxia for 24h (Fig. 7.3), seemingly even leading to the 
induction of DNA damage between lh, 6h and 24h (Fig. 7.4). 
This distinct effect highlights once more that a change in cellular oxygen concentration 
triggers distinct signalling pathways, which may contribute to the development of 
endothelial DNA damage. The observed hypoxia-dependent DNA protective effect of 
silymarin is in agreement with its anti-carcinogenic properties, as tumour aetiology may be 
characterised by hypoxia due to the inadequate supply of oxygen triggered by cellular 
proliferation (Shannon et al. 2003). The expression of genes controlling tumour cell survival 
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such as hypoxia-responsive transcription factors (HIF-l a), which modulate the expression of 
genes that promote tumour growth and growth factors, such as VEGF, which govern the 
formation of new blood vessels known as angiogenesis, are regulated by hypoxia (Shannon 
et al. 2003). In 2000, Jiang et al. showed that silymarin led to a dose-dependent decrease in 
VEGF level in human prostate and breast-cancer epithelial cells (Jiang et al. 2000). Since 
VEGF expression is HIF-la dependent a reduction in VEGF expression could be association 
with a reduction in HIF-la activity. Furthermore, a reduction in VEGF expression would 
lead to a reduction of cell proliferation and angiogenesis. 
Looking at those parameters in our study, we were unable to observe an effect of silymarin 
on HUVEC proliferation (Fig. 7.2) after 24h, or any effect of HlF-la antisense in addition to 
silymarin on endothelial DNA damage (Fig. 7.6), suggesting that the mechanism of action 
through which silymarin protects endothelial DNA against hypoxia-dependent changes is 
possibly not VEGF dependent. However, no direct comparison can be established to the 
results of Jiang et al. (2000) or indeed any of the existing literature, as cancer cell lines 
behave very differently from healthy endothelial cells lines. In order to further elucidate the 
mechanisms through which silymarin acts, the effect of taxifolin and silibinin, two of the 
compounds found within the silymarin extract, on DNA damage was assessed. 
Taxifolin shows a very potent DNA protective effect in hypoxia, while the use of silibinin 
shows no effect on the level of DNA damage incurred by hypoxia after 24h (Fig. 8.5 & 8.6). 
This is somewhat surprising as silibinin is thought to be the most therapeutically active 
component of the silymarin compound, while taxifolin has not been attributed as an 
important therapeutic role (Flora et al. 1998; Gazak et al. 2007). Silibinin has been 
extensively researched in many areas and has been found to have an anti-tumourgenic effect, 
act as a neuro, nephro, and cardio-protector, interact with steroid hormone receptors to exert 
an antiandrogenic effect, have an anti-inflammatory and a gastro-protective effect as well as 
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being useful against the development of multidrug resistance through the accumulation of 
daunomycin in P-glycoprotein-positive cells (Kfen el af. 2005). It is therefore surprising that 
it does not appear to be the compound which is the most DNA protective. One possible 
explanation could be its reported action as an iron-chelating agent (Borsari el af. 200 I). 
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Iron chelators such as desferrioxamine, bind excess iron in the blood stream and lead to its 
excretion. It has been suggested that iron chelators may modulate certain inflammatory 
mediators as they seem to be able to induce the transcription of NO synthase and the 
subsequent release of interleukin-l ~ in human alveolar macrophages (O'Brien-Ladner el af. 
1998; Dalska et af. 1998). Woo et al. (2006) hypothesise that desferrioxamine increases HIF-
la protein stability through induction of COX-2 under hypoxic conditions in human colon 
cancer cells (Woo et al. 2006). If we work on the assumption that silibinin, as an iron 
chelator, enhances HIF-la stability (as hypoxia has been shown to induce COX-2 in 
HUVECs (Schmedtje et al. 1997» then the addition of silibinin in our experimental 
conditions would lead to an increase in HIF-la activity which we believe contributes to the 
development of endothelial DNA damage. This could explain why silibinin in contrast to 
taxifolin has no DNA protective effect after 24h. 
However, the addition of HIF-la antisense to silibinin treated cells has no effect on DNA 
damage levels (Fig. 8.Sb). If silibinin acted by stabilising HIF-Ia, then we would expect to 
see a rise in DNA damage levels. Since this is not the case, it is unlikely that silibininl 
silymarin acts by stabilising HIF-Ia. We do, however, have no evidence to corroborate this 
suggestion. 
The role of taxifolin within the silymarin compound is clearly very important as it seems to 
account for a significant proportion of its DNA protective effect. However, literature reports 
surrounding taxifolin do not provide much insight into any possible mechanisms of action as 
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it is mainly used in comparison studies alongside quercetin, its close structural relative, and 
other flavonoid antioxidants. No studies have, to our knowledge, been carried out looking at 
the mechanism of tax if olin as a potential therapeutic agent. It is perceivable that taxifolin, as 
the parent compound found in the milk thistle plant, is an important therapeutically active 
compound found in the silymarin extract and not just a mere impurity. 
9.2. Conclusion 
The mechanisms leading to endothelial DNA damage in response to oxidative stress are 
clearly very complex. Glucose and oxygen exhibit distinct yet potentially additive effects on 
endothelial cells which results in changes in cell proliferation and DNA damage within 24h 
of exposure. This DNA damage appears to be mediated via the mitochondria and there seems 
to be a close relationship between cellular ROS production and HIF-la activity. It appears 
that HIF-la is involved in the development of endothelial DNA damage. The flavonoid 
antioxidant silymarin protects glucose treated HUVECs under hypoxic conditions. Many of 
these effects appear to be due to the taxifolin component of the silymarin compound. 
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9.3. Limitations of thesis and directions for future work 
This study has identified a number of interesting findings that are dependent on changes in 
glucose and oxygen concentration which merit further investigation. 
1. To compare the effects seen in HUVECs with other micro- and macrovascular tissues in 
primary cell culture. 
The data collected in this thesis was observed in a well established model system for the 
study of endothelial function, using a reputable cell line. Although established cell lines are 
widely used models for preliminary studies, their significance is limited by the use of culture 
clones, a constraint avoided with the use of primary cells. 
As the results obtained indicate early and potentially additive cellular responses to changes 
in glucose concentration and oxygen tension, future research would benefit greatly from the 
investigation of these changes in primary cultures of micro- and macrovascular tissue(s). 
Such as the use of bovine- or human retinal endothelial cells (McBain et al. 2003, 
MacKinnon et al. 2004), cell culture of peripheral neurons and Schwann cells (Sango et al. 
2006) and primary culture of HUVECs (Piconi et al. 2006). 
Careful consideration will need to be given to the culture conditions used as the 
concentration of glucose and oxygen tension reported in the literature is widely varied. Other 
limitations of in vitro cell culture models compared to in vivo models of diabetes include the 
lack of interaction with other cell/tissue types and a lack of insulin release in response to the 
addition of glucose. Nevertheless the identification of the responses to changes in glucose 
and oxygen in those tissues will provide important information about potential early cellular 
changes which occur and possible mechanistic events which may contribute to the process of 
endothelial dysfunction. 
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2. To optimise the eZE analysis. carefully looking at sample preparation. method of 
extraction. buffer concentrations and pH, voltage. temperature and method of detection 
(HP Lei eZEJ. in order to separate all the individual components of silymarin. 
The composition of silymarin has been determined with various degrees of success. 
Literature reports detail a considerable number of isomers, flavonolignans and acids 
(Fromming et al. 1999, Carrier et al. 2004). This discrepancy is mainly due to the lack of 
standardised composition of commercially available silymarin and the different extraction 
methods used such as hot water (Barreto et at. 2003) and organic solvent extraction (Wallace 
et al. 2003). This poses considerable problems with respect to the interpretation of results 
and their comparison to other reported literature findings. As evident in the 
electropherograms presented in this thesis (Fig.8.2) compounds such as silibinin and 
taxifolin can be identified but are clearly made up of many unknown isomeric forms and 
compounds, the presence of which can affect retention times and reproducibility of the data. 
It would be of enormous benefit to this and other studies to completely separate and identify 
all the components found in the silymarin sample used. This requires detailed optimisation of 
the CZE analysis such as sample preparation and concentration, buffer- type, -concentration 
and pH, the discontinuous use of high voltage and the associated variations in electro-
osmotic flow, presence of additives and temperature changes. A comparison between CZE 
and HPLC separation would also be desirable. 
In order to clearly determine the therapeutic effects of any of these compounds, complete 
and detailed separation is necessary and would not only be beneficial for the interpretation of 
our data but also hugely contribute to the interpretation of other reported literature findings. 
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Other work which will further clarify cellular mechanisms involved include: 
3. The determination of apoptosis markers seen with changes in glucose concentration and 
oxygen tension to distinguish between reversible endothelial DNA damage and 
irreversible cell death which impacts on the cellular ability to cope with repeated 
exposure to abnormal glucose and oxygen levels. 
4. A detailed analysis of mitochondrial ROS production including superoxide and 
peroxynitrite to better understand the immediate cellular responses. 
5. The use of molecular cloning techniques to determine HIF-la. gene expression and 
stability in response to abnormal glucose and oxygen levels and its subsequent effect on 
endothelial DNA damage and pro-apoptotic pathways. 
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